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Abstract 
 
Many tumours have abundant macrophage populations. Tumour-associated 
macrophages (TAMs) frequently have tumour promoting roles and high tumour infiltrates 
are associated with poor clinical outcome. TAMs are highly plastic cells and their 
activation state is shaped by the integration of multiple stimuli in the context of specific 
tissue environments. Following chemotherapy TAMs can antagonise or promote 
therapeutic response; these opposite effects are largely determined by TAM activation 
state. 
 
To understand the impact of chemotherapy on TAMs in high-grade serous ovarian 
cancer (HGSOC) I assessed TAM populations in human biopsy samples pre and post-
chemotherapy as well as in murine HGSOC models harbouring a relevant mutational 
profile.  
 
I find chemotherapy results in a reorganisation of TAMs within the omental tumour 
microenvironment (TME) of human and murine HGSOC. TAMs expressing markers 
known to associate with disease progression decrease following chemotherapy. 
Additionally, TAMs upregulate inflammasome pathways and TLR signalling following 
chemotherapy. I show macrophages are killed by carboplatin in vitro and non-viable TAM 
increase in human and murine HGSOC following chemotherapy. Interestingly, 
macrophages cleave caspase-3 and gasdermin E following carboplatin treatment, this 
implicates chemotherapy in driving inflammatory cell death (pyroptosis) in TAMs. Using 
a novel murine model of HGSOC relapse after first-line chemotherapy, I demonstrate 
CSF-1Ri-mediated TAM depletion post-chemotherapy in mice worsened survival to 
relapse. Furthermore, in patient samples high TAM density post-chemotherapy 
associated with improved survival. 
 
Overall these results suggest chemotherapy promotes an anti-tumour TAM phenotype. 
TAM pyroptosis may be an important mechanism in chemotherapy-mediated 
enhancement of innate immunity. These results provide a rationale for treatments that 
re-program TAMs after chemotherapy in women with HGSOC. 
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1 
The aim of this thesis is to understand the effects of chemotherapy on tumour associated 
macrophages (TAMs) in high-grade serous ovarian cancer (HGSOC) metastases.  
 
 Epithelial ovarian cancer 
1.1.1 Epidemiology of ovarian cancer 
In 2012 there were 238,700 new diagnoses of ovarian cancer and 151,900 deaths 
worldwide from this disease1. In the United Kingdom it is estimated that there are 7,000 
newly diagnosed cases and 4,200 deaths per year2. Ovarian cancer is more common in 
Western countries were it represents the most lethal gynaecological malignancy and the 
fifth most common cancer in women1. The most recent figure for overall five year survival 
in the England was 42.9%3. This dismal figure is largely due to presentation at an 
advanced stage; over two thirds of patients present with disease disseminated within or 
beyond the abdominal cavity (FIGO stage III/VI). Survival is directly linked to stage at 
diagnosis: in early stage disease confined to the ovaries (FIGO stage I) the 5 year 
survival is 90%, compared to 4% for stage VI4. 
 
The most commonly reported symptoms of ovarian cancer include pelvic pain, weight 
gain, abdominal bloating and a change in bowel habit. The non-specific nature of these 
symptoms frequently results in a delay in diagnosis and highlights the importance of early 
investigation of such symptoms, particularly in post-menopausal women, to exclude 
gynaecological pathology5. 
 
1.1.2 Classification of epithelial ovarian cancer 
Historically, epithelial ovarian cancers (EOCs) were defined solely by morphological 
features and categorised into four main subtypes; serous, endometrioid, mucinous and 
clear cell cancers. Due the preponderance of HGSOC, EOC was generally regarded as 
a single disease with differences between other histological subtypes obscured6. 
Furthermore, as EOC generally presents clinically with a large pelvic mass involving the 
ovaries this was taken as evidence to suggest a common ovarian origin6. 
 
Molecular biology has revolutionised our understanding of EOC and has brought about 
a shift in classifying ovarian cancers based solely on histological features to an approach 
encompassing molecular and genetic differences. Significant progress has been made 
in identifying the genes that are commonly mutated in ovarian cancers; these include 
KRAS, PIK3CA, TP53, BRCA1 and BRCA22. It is now understood that these lesions are 
distributed unequally between the various histological subtypes of ovarian cancer. 
Microarray analyses have shown that EOC is a constellation of distinct diseases that are 
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frequently more similar to cancers arising in other organs than they are to one another7. 
For example, clear cell carcinoma of the ovary is more similar to renal cell carcinoma 
than to serous ovarian cancer8. When the common ovarian histological subtypes are 
compared, only high-grade serous and high-grade endometrioid tumours appear similar, 
and indeed these are indistinguishable by gene expression profiling, suggesting that 
high-grade endometrioid tumours may not be a separate entity9,10. 
 
1.1.3 Origin and pathogenesis of HGSOC 
In the absence of a precursor lesion seen within the ovary, previously held theories of 
the pathogenesis of HGSOC assumed the ovarian surface epithelium (OSE) was the site 
of origin of this disease. The OSE is composed of a single layer of epithelial cells and 
originates from the mesoderlike. It was considered that either ‘incessant ovulation’ 
causing continuous disruption to the OSE, or the invagination of the OSE within ovarian 
stroma, resulting in cortical inclusion cysts (CICs), initiated malignant transformation12. 
 
Recent histopathological observations have challenged this view, strongly suggesting 
that in many cases the cells of the distal fallopian tube epithelium (FTE) are the 
progenitors of this disease13,14. The FTE is a columnar epithelium composed of ciliated 
and secretory cells11. The secretory cells produce tubular fluid and the ciliated cells 
mediate oocyte transport towards the uterus15. Callahan et al. were the first to 
demonstrate the presence of serous tubal intraepithelial neoplasia (STIC) lesions as well 
as occult serous tumours arising in the fallopian tube in patients with germline BRCA 
mutations undergoing risk reducing surgery16. Leading on from this discovery, STIC 
lesions were identified in 50-60% of patients with HGSOC in non-BRCA patients17. 
Finding identical p53 mutations within STIC lesions and the concomitant HGSOC, 
strongly supports the FTE as an initiating site of this disease13. Furthermore, gene 
expression studies comparing HGSOC to OSE and FTE brushings from healthy tissues 
found that the expression profile of the FTE but not the OSE significantly correlated with 
that of HGSOC18. Foci of cells harbouring p53 mutations, termed ‘p53 signatures’, have 
been demonstrated in histologically normal fallopian tubes and currently represent the 
earliest detectable event associated with HGSOC precursor lesions7. Overall these data 
suggest that the distal fallopian tube is the initiating site for many HGSOCs and that p53 
mutation is the earliest event in the pathogenesis of this disease. Ectopic implantation of 
FTE (known as endosalpingiosis) or CIC formation followed by tubal-type differentiation 
are proposed as mechanisms to explain ‘non-tubal’ HGSOC, where there is no evidence 
of fallopian tube involvement19. 
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1.1.4 Mutational landscape of HGSOC 
Key genetic drivers of HGSOC progression have been identified. The high rate of TP53 
mutation in HGSOC suggests that this is an essential event in the pathogenesis of this 
disease7. BRCA mutations are also important in the pathogenesis of HGSOC. In the 
Cancer Genome Atlas Network HGSOC study 96% of the cases had a TP53 mutation 
and BRCA1 and BRCA2 were either mutated in the germline in 9% and 8% of cases 
respectively, somatic mutations accounted for 3% of cases20. 
 
BRCA genes regulate the homologous DNA repair (HDR) pathway, which is required to 
repair DNA double-strand breaks21. The presence of BRAC1 or BRAC2 germline 
mutation results in a 30% to 70% lifetime risk respectively of developing HGSOC by the 
age 707. Somatic mutations and inactivation of other components of the HDR pathway 
such as BRIP1, BARD1, RAD51B and RAD51C, are also found in HGSOC biopsies22–
25. The “BRCAness” phenotype is used to describe mutations affecting HDR26. The 
frequent deficiency in HDR pathway renders HGSOC susceptible to platinum-based 
chemotherapy, which induces DNA damage27. The treatment effect can be enhanced 
when combined with poly (adenosine diphosphate[ADP]-ribose) polymerase (PARP) 
inhibitors, which additionally inactivate the DNA repair capability of cancer cells28.  
 
Among HDR proficient HGSOCs, approximately 30% of patients have an amplification 
of Cyclin E1 (CCNE1), which regulates G1-S-phase transition during cell cycle 
progression29. Loss of neurofibromatosis type 1 (NF1), a negative regulator of the 
oncogene RAS30, occurs in 17%, loss of retinoblastoma protein (RB1), an inhibitor of 
cellular proliferation, in 15% and loss of PTEN in 6% of HGSOC patients29. PTEN is a 
phosphatase that inhibits cell proliferation through the PI3K pathway31. Additionally, loss 
of PTEN defines a subgroup of ovarian cancers with significantly worse prognosis31. 
 
A cardinal feature of HGSOC is genomic structural variations with amplifications and 
deletions of DNA. This chromosome instability results in inactivation of tumour 
suppressor genes, via deletions or through gene breakage. A proposed model for the 
molecular pathogenesis of HGSOC is the loss of p53 and BRCA function leading to 
defects in homologous recombination pathways resulting in chromosomal and 
widespread copy number variation7. These initial events drive tumour development and 
promote further genetic lesions in the evolving tumour (Figure 1.1). 
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Figure 1.1 Diagrammatic representation of the cellular and molecular pathogenesis of 
HGSOC. 
 
1.1.5 Molecular subtypes of HGSOC  
Tothill at al. defined four molecular subtypes of HGSOC based on gene expression: C1 
(mesenchymal), C2 (immunoreactive), C4 (differentiated) and C5 (proliferative)9. These 
subtypes associated with differences in clinical outcome. The mesenchymal subtype 
(C1) is characterised by an enhanced stromal gene signature. C1 tumours show 
extensive infiltration of activated fibroblasts, an epithelial-to-mesenchymal transition 
(EMT) gene signature and are associated with the worst survival amongst all of the 
subtypes9,32. The immunoreactive subtype (C2) is characterised by an extensive 
infiltration of intratumoural T cells, this was associated with enhanced overall survival9. 
C4 (differentiated) tumours have a low stromal response and share characteristics with 
serous borderline tumours, which have an intermediate prognosis9,32. Finally, the C5 
(proliferative) subtype shows low expression of differentiation markers and low immune 
cell counts9,32. Tumours of this subtype display upregulation of extracellular matrix 
(ECM)-related genes, developmental transcription factors, oncogenic stem cell-
associated genes associated with cell mobility9,32. The C5 subtype was associated with 
worse survival similar to the C1 subtype9,32. The four subtypes highlight the importance 
of the tumour microenvironment in the pathogenesis of HGSOC. These data 
demonstrate that transcriptional signatures of the immune infiltrate and stromal 
compartment of the tumour microenvironment can predict clinical outcome and 
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potentially dictate response to therapies33,34. 
 
 Treatment of HGSOC 
The majority of patients with ovarian cancer are treated with the combination of surgery 
and chemotherapy. Surgery provides the functions of diagnosis, staging, cytoreduction 
and palliation and includes total abdominal hysterectomy, bilateral salpingo-
oophorectomy, omentectomy, inspection of peritoneal surfaces with biopsy or removal 
of any areas suspicious of disease and consideration of para-aortic and pelvic lymph 
node dissection. Surgery should be performed by a trained gynaecological oncology 
surgeon with the goal of no residual disease. Surgery undertaken in specialist centres 
by gynaecological oncologists increases the proportion of cases achieving ‘optimal’ 
cytoreduction, defined as <2cm of residual disease35 and improved survival36. 
 
Primary debulking surgery (PDS) followed by adjuvant chemotherapy has been 
established as the standard of clinical care since the 1980s37. The aim of surgery is to 
achieve maximal disease clearance. Many studies have shown that the volume of 
residual disease following cytoreductive surgery predicts survival. The first of which was 
by Griffiths et al. in 1975 where cytoreduction to ≤1.5cm residual disease resulted in 
significantly improved survival38. The definition of what constitutes ‘ideal’ cytoreduction 
has evolved over time and is now taken to mean no macroscopically identifiable disease 
(R0). Aletti et al. showed that survival is significantly improved in patients with R0 disease 
resection compared to patients with any identifiable residual disease39. In contemporary 
clinical practice R0 resection after PDS is still the most important prognostic factor for 
survival40–46. There has been debate regarding the value of routine systematic pelvic and 
para-aortic lymphadenectomy in patients without obvious nodal involvement achieving 
R0 resection. Recently the LION trail showed that lymphadenectomy under these 
circumstances was not associated with improved survival and was associated with 
increased morbidity47. 
 
Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) was 
developed as an alternative treatment option in patients where it was deemed to be 
difficult to achieve complete tumour resection at PDS48. Two large randomized controlled 
trials have demonstrated non-inferiority of NACT-IDS to PDS in terms of patient 
survival45,49. Furthermore, lower operative morbidity has been reported in patients 
undergoing NACT-IDS compared to PDS49. However, both trials have attracted 
considerable criticism centred on the low R0 attainment rates and low survival in both 
trials37. To address these concerns the TRUST trial is currently recruiting which will 
randomise patients to either NACT-IDS or PDS from centres reporting greater then 50% 
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R0 resection rates. Patient selection to NACT-IDS vs PDS still remains an area of 
controversy. The EORTC 55971 trial showed a better overall survival in patients 
undergoing PDS with small volume stage 3 disease (<5cm metastases) in comparison 
NACT-IDS improved overall survival in stage 4 disease45. Based on these data strategies 
to select patients for IDS or PDS have been suggested50. Further research is needed to 
clarify the best way to select patients for IDS/PDS. Within the UK these decisions are 
made in the context of dedicated multi-disciplinary teams, MDTs. 
 
The intravenous administration of carboplatin (area under the curve [AUC] 5-6) and 
paclitaxel 175mg/m2 over 3 hours every three weeks is considered standard first-line 
chemotherapy for EOC37. The current standard recommendation is to give a total of six 
cycles of chemotherapy37. A Japanese study showed enhanced PFS when paclitaxel 
was administered weekly at a dose of 80mg/m2 51. However, this ‘dose-dense’ approach 
has not shown benefit in other studies predominately in Western patient populations, 
suggesting that pharmacogenomic influences may explain these differences. 
 
A number of trials have shown benefit of intraperitoneal (IP) administration of 
chemotherapy where cytoreduction to <1cm residual disease was achieved after PDS52–
54. However, these studies have been criticised due to differences in the overall 
chemotherapy dose patients received in the different arms of the study. Furthermore, 
GOG252 which randomised patients to IP chemotherapy and bevacizumab or 
intravenous (IV) chemotherapy and bevacizumab showed no benefit of IP over IV 
administration55. This has led to the suggestions that additional benefits of IP 
chemotherapy are due to higher overall doses of chemotherapy administered rather than 
the mode of delivery. However, further investigation is needed. 
 
A further development in the treatment of HGSOC is hyperthermic intraperitoneal 
chemotherapy (HIPEC)56,57. In 2017 two trials reported the outcome of HIPEC after 
NACT-IDS. The van Dreil et al. study showed a significant survival benefit of HIPEC 
whereas the Lim et al. study did not show survival benefit56,57. Therefore, further research 
is needed to understand if there is benefit from this approach. 
 
1.2.1 Mechanism of action of chemotherapy 
1.2.1.1 Carboplatin 
Carboplatin [cisdiammine(1,1-cyclobutane dicarboxylato)platinum(II)] is a second-
generation platinum drug developed to reduce the dose limiting toxicities (neuro and 
ototoxicity) associated with cisplatin58. Carboplatin enters the cell by diffusion; however 
a variety of membrane transporter proteins can also affect cellular accumulation of the 
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drug. One such protein is the copper transporter-1 (CTR1), which can facilitate the 
transport of carboplatin into cells. CTR1-/- murine fibroblasts were less sensitive to 
carboplatin treatment than wildtype cells59. Other transporter molecules (ATP7A and 
ATP7B) may be involved in sequestering cisplatin or enhancing drug efflux from the cell 
thus preventing cytotoxicity60. Indeed, downregulation of CTR1 and upregulation of 
ATP7A and ATP7B are mechanisms of acquired chemotherapy resistance58,61. Once 
inside cells, carboplatin is hydrolysed; this results in reactive carboplatin species that are 
able to bind DNA permitting the formation of inter-strand cross-links between guanine 
bases. Carboplatin mediated inter-strand cross linking results in significant distortion of 
the DNA double helix58. This DNA lesion is the principle cytotoxic effect of carboplatin, 
inhibiting DNA synthesis and mitosis and inducing apoptosis58,62. 
1.2.1.2 Paclitaxel 
Paclitaxel was originally extracted from the bark of the Western Yew, Taxes brevifolia63. 
Paclitaxel has a complex chemical structure and is extremely hydrophobic making it a 
difficult drug to formulate for human administration. The vehicle used in current medical 
practice is a mixture of ethanol and cremophor which is associated with sensitivity 
reactions, necessitating pre-medication with corticosteroids and antihistamines in some 
patients64. 
 
The most important cytotoxic effect of paclitaxel is the inhibition of tubulin 
depolymerisation, which results in stabilisation of the microtubular cytoskeleton65. These 
effects become manifest during mitosis and result in dysregulation of the cell cycle, 
mitotic failure and cell death. Cell death is mediated by a prolonged block in mitosis. 
Mitotic block is dependent on the formation of the spindle assembly checkpoint (SAC) a 
protein complex that forms to ensure correct attachment of chromosomes to the mitotic 
spindle before anaphase commences. Prolonged activation of the SAC triggers cell 
death65. It is suggested that altered microtubule dynamics caused by paclitaxel treatment 
result in tension defects that activate SAC66. The protein aroura B is important in this 
regard, as inhibiting aroura B abrogates paclitaxel mediated cell cycle arrest67. 
 
1.2.2 Targeted therapies 
1.2.2.1 Anti-angiogenic 
Anti-angiogenic therapy is now routinely used in the treatment of HGSOC in many 
countries. Bevacizumab, a humanised monoclonal antibody to VEGF-A, can prevent 
angiogenesis and therefore disrupt tumour growth68. The ICON 769 and GOG 21870 trials 
showed an increase in progression free survival, but not overall survival, with the addition 
of bevacizumab maintenance therapy to standard first-line chemotherapy with 
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carboplatin and paclitaxel69,70. This resulted in approval for this drug as a maintenance 
therapy in Europe68.  
 
Other antiangiogenic therapies aim to inhibit the VEGF receptor. A large range of other 
anti-angiogenic drugs are being tested, the most promising of which is cediranib68. 
Cediranib is an orally active small molecule tyrosine kinase inhibitor of the VEGF 
receptor68. Cediranib increases PFS in combination with chemotherapy or as 
maintenance therapy71. Furthermore, this drug has  antitumor activity as a single-agent 
in platinum sensitive and resistant recurrent disease72,73. 
1.2.2.2 PARP inhibitors 
PARP inhibitors (PARPi) represent an important new therapeutic approach in HGSOC. 
Approximately half of all HGSOC tumours have defects in DNA repair mechanisms, in 
particular the homologous recombination pathway which is essential for the repair of 
double stranded DNA breaks. BRCA1 or BRCA2 mutations are most frequently 
implicated in this process however, mutations in other HDR pathways or functional 
inactivation via methylation may also be responsible37. Homologous-recombination 
deficiency (HRD) results in an over-reliance of tumour cells on other DNA repair 
pathways, including base-excision repair which is dependent on the PARP proteins. 
Inhibition of PARP results in tumour cell death as the result of synthetic lethality68. 
 
Olaparib was the first PARPi used in HGSOC patients74. Phase I and II clinical trials have 
shown impressive clinical responses in patients with BRCA mutated and BRCA wild-type 
recurrent HGSOC68. In the context of platinum-sensitive HGSOC recurrence, objective 
response rates of 60% were seen in BRCA mutated tumours compared to 50% in BRCA 
wild-type tumours75. A phase 2 clinical trial assessing olaparib as maintenance therapy 
in patients with platinum-sensitive, relapsed disease showed an increase in progression 
free survival but with no changes in overall survival27.  In patients with BRCA1 and 
BRCA2 mutations, median PFS was significantly extended in the olaparib group 
compared to the placebo group (11.2 vs 4.3 months).  For BRCA wild-type patients the 
differences in survival were less pronounced, however there was still significantly 
improved PFS in olaparib compared to placebo treated patients (7.4 vs 5.5 months 
respectively)76. The SOLO2 trail confirmed the benefit of olaparib maintenance therapy 
in platinum-sensitive relapsed HGSOC77. These studies resulted in olaparib being 
approved for use as a maintenance therapy in platinum-sensitive recurrent disease with 
BRCA1 or BRCA2 mutations. Two other PARP inhibitors, rucaparib and niraparib, have 
also been granted regulatory approval for patients with relapsed ovarian cancer, 
irrespective of BRCA-mutation status or platinum-sensitivity68. The phase III NOVA study 
showed benefit of niraparib in women with a complete or partial response to platinum-
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based chemotherapy. In this study BRCA patients treated with niraparib had significantly 
increased PFS (21 vs 5.5 months) compared to (9.3 vs 3.9 months) in the non-BRCA 
wild type patients78. Similar benefits of rucaparib maintenance therapy in platinum-
sensitive recurrences were shown in the ARIEL3 study79. 
 
PARPi have been recently shown to have benefit as a front-line treatment of HGSOC. In 
December 2018 the FDA granted approval for olaprarib to be used as maintenance 
therapy in BRCA mutated platinum sensitive HGSOC37. This was on the basis of a phase 
III study, SOLO1, which showed a 70% lower risk of disease progression or death in 
patients treated with olaparib compared to placebo80. 
1.2.2.3 Immunotherapies 
To date there are no approved immune therapies for ovarian cancer81. 
Immunotherapeutic approaches, most notably inhibiting immune check point pathways, 
have resulted in dramatic and durable responses in a range of tumour types (melanoma, 
NSCLC and renal cancers)82. Compared to these cancer types, the response of ovarian 
cancer to checkpoint blockade has been modest81. The best response reported by 
Hamanishi et al. was 15% in a study of 20 heavily pre-treated platinum-resistant ovarian 
cancer patients83. In this study there was one complete response and two partial 
responses with an overall disease control rate was 45%83. Treatment of 124 patients with 
the anti-PD1 avelumab resulted in 12 partial responses (ORR, 9.7%) with 55 patients 
showing stable disease84. The KEYNOTE-028 phase 1b trial treated 26 recurrent EOC 
patients with pembrolizumab with one complete response and two partial responses and 
six patients with stable disease85. Despite overall modest responses in combined studies 
of EOC, data relating to clear cell ovarian cancers show more encouraging responses37. 
A portfolio of clinical trials assessing the value of checkpoint blockade in ovarian cancer 
alongside standard chemotherapies (Javelin Ovarian 100), as maintenance therapy in 
the context of platinum sensitive (ATALANTE), and platinum resistant relapse (Javelin 
Ovarian 200) and in combination with bevacizumab (NRG-GY009) are currently 
recruiting81,82. 
 
Other immunotherapeutic approaches include the use of adoptive T cell transfer. In this 
approach tumour reactive T cell subsets are expanded ex vivo and re-infused into 
patients. Furthermore, T cells can be genetically modified to express a ‘chimeric antigen 
receptor’ which encodes a tumour antigen binding domain linked to a costimulatory 
molecule81. These approaches have proved successful in the treatment of melanoma 
and B cell lymphoblastic leukaemia with response rates of 50-70%86. To date are few 
reported studies of adoptive T cell transfer in ovarian cancer. In a small study Fujita et 
al. showed that when TILs propagated from resected tumours were administered after 
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chemotherapy the three year-survival was 100% compared to 67% in patients who did 
not receive TILs87. Several trials in ovarian cancer patients are ongoing using TILs and 
engineered T cells targeting the tumour associated proteins MUC16, mesothelin and NY-
ESO-181,86. 
 
1.2.3 Recurrent HGSOC 
The majority of patients respond to primary chemotherapy but will, however, typically 
relapse and eventually go on to develop chemotherapy resistant disease37. 
Approximately 10% of patients do not respond to primary chemotherapy, suggesting 
intrinsic resistance also operates in a subset of patients88. The mechanisms of 
chemotherapy resistance are not completely understood but may include epithelial to 
mesenchymal transition, drug efflux mechanisms, cell cycle arrest, apoptosis block with 
up regulation of TGFβ, WNT and NOTCH signalling89. Significant effort has been 
expended to define a stem cell population that may be able to regenerate tumours after 
a complete response to chemotherapy. However, studies to date have demonstrated 
stemness markers to show variable expression in ovarian cancer90. 
 
Patch et al. performed whole genome sequencing in primary refractory/resistant, primary 
sensitive and matched acquired resistant HGSOC biopsies from ninety-two patients91. 
This study suggested that inactivation of RB1, NF1, RAD51B and PTEN genes was 
associated with acquired resistance as were reversions in germline BRCA1/2 
mutations91. Furthermore, overexpression of MDR1 was associated with acquired 
chemotherapy resistance91. Primary resistance was associated with CCNE1 
amplification91. More recently RNA-sequencing of sixty-six matched primary and 
relapsed HGSOC biopsies has demonstrated heterogeneity between primary and 
recurrent samples based on differential expression of a panel of genes involved in 
immune activation and matrix remodelling pathways92. This study classified tumours into 
‘immune active’ and ‘immune silent’ groups; at relapse some tumours shared the same 
immune status as the primary tumour, whereas other tumours switched immune status92. 
This demonstrates the complexity and heterogeneity of the tumour microenvironment 
between relapsed and primary tumours. 
 
Secondary cytoreductive surgery should be considered at relapse for appropriate 
patients37,93. The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) group 
developed the Descriptive Evaluation of preoperative Selection KriTeria for OPerability 
in recurrent OVARian cancer (DESKTOP OVAR) algorithm to predict patients that would 
benefit from secondary debulking surgery (SDS)94. Patients with a first recurrence of 
EOC with a platinum-free interval of greater then 6 months, in whom complete 
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cytoreduction was achieved in the first debulking procedure, ascites less the 500ml and 
a ECOG performance status of 0 represent of group of patients who will benefit from 
SDS and chemotherapy compared to chemotherapy alone37. Other clinical algorithms to 
predict complete SDS are the Tian Risk Model95 and the Slone Memorial Kettering 
criteria96. 
 
If surgical intervention is not an option, systemic chemotherapy is administered to control 
the disease for as long as possible. The various options for subsequent lines of 
chemotherapy will be based on the time to recurrence, patient characteristics and the 
disease biology.  
 
 The tumour microenvironment of HGSOC 
Malignant cells acquire mutations in oncogenes or tumour suppressor genes that serve 
to initiate tumour development. However, it is now established that malignant cells rely 
on resident and recruited populations of non-transformed host cells to promote tumour 
evolution97. This diverse ecology of cells includes endothelial cells, pericytes, fibroblasts, 
mesothelial cells and infiltrating immune cells which, with their soluble mediators and the 
extracellular matrix, form the tumour microenvironment (TME)97. Therefore, tumours can 
be considered ‘rogue organs’, where intracellular communication is mediated by 
networks of cytokines, chemokines and growth factors along with changes in the physical 
properties of the tissue98. 
 
A common feature of virtually all TMEs is a prominent immune cell infiltrate. As proposed 
by Dunn et al. early in the process of tumour development malignant cells may be ‘visible’ 
to the immune system and can be ‘eliminated’ by CD8+ cytotoxic T cells99. However, 
under the effects of continued immune pressure, malignant cell clones become ‘immuno-
edited’, this results in the selection of malignant cells that can ‘escape’ immune 
surveillance. Crucially neoplastic cells that escape immune detection also acquire 
capabilities to subvert the host immune response to promote tumour progression and 
metastasis100.  
 
The immune infiltrate is however pliable and this has been successfully leveraged 
therapeutically for example by checkpoint blockade, adoptive cell transfer and vaccine 
therapies101. Indeed, heavily immune infiltrated tumours, compared to immune excluded 
tumours, are more amenable to control by a range of therapies and associate with 
improved patient survival. Understanding the mechanisms and regulatory circuits that 
generate immunosuppression in the TME and how this can be mitigated therapeutically 
is therefore important. 
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1.3.1 Pre-chemotherapy 
1.3.1.1 Lymphocytes 
In HGSOC tumour infiltrating lymphocytes (TILs) robustly associate with improved 
survival, this reflects findings in other epithelial cancers. Critical to prognosis of TILs in 
HGSOC is the balance of effector to regulatory T cell subsets33.  
 
Zhang et al. were the first to show that high CD3+ T cell density within ovarian tumours 
correlated with increased progression free and overall survival34. In this study 186 stage 
III/IV EOC patients were studied. Within this cohort the major histological subtypes of 
EOC were represented. CD3 expression was assessed by IHC, in 55% of cases there 
were significant intratumoural CD3+ infiltrates and 39% of cases lacked CD3+ such 
infiltrates34. CD3+ infiltrates were seen both in the stroma and the malignant cell areas of 
the biopsy. The five year survival rate was 38% in patients whose tumours contained T 
cell infiltrates and only 4.5% in patients whose tumours contained few T cells34. 
Interestingly, T cell infiltrates were also positively correlated with optimal surgical 
cytoreduction. However in multi-variate analysis, both CD3+ T cell density and the extent 
of residual disease were independent predictors of overall and progression free 
survival34. Tumours richly infiltrated with T cells had higher expression of IFNg, IL2, 
CCL21 and CCL22. Conversely, VEGF was higher in tumours with fewer T cells 
suggesting that secreted factors determine TIL density which has a significant effects on 
patient prognsosis34. This finding was confirmed by Raspollini et al.102 and Tomsova et 
al.103.  
 
Woo et al. were the first to show that ovarian cancers contained CD4+CD25+ T regulatory 
cells (Tregs) which secrete the immunosuppressive cytokine transforming growth factor-
b (TGF-b)104. These cells additionally expressed the T regulatory markers; cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4), forkhead box P3 (FoxP3) and 
glucocorticoid-induced TNFR-related protein (GITR)104. In a multivariate analysis Curiel 
et al. showed that Tregs correlated with poor overall survival in EOC105. This finding was 
further substantiated by Wolf et al.106 who showed that a low FoxP3 expression 
associated with approximately a 60% reduced risk of death106. FoxP3 can also correlate 
with a positive outcome in EOC107,108. These findings may be explained by FoxP3 being 
an indicator of a strong CD8+ T cell response. Alternatively, subsets of FoxP3 T cells 
may have pro-inflammatory functions as demonstrated by the production of IL-1733. 
 
Sato et al. showed that the ratio of CD8+ T cells to Tregs was important in determining 
the prognosis in EOC109. In 117 Stage III disease patients a high CD8+ to FoxP3+CD25+ 
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T cell ratio within the malignant cell areas of biopsies correlated with longer survival 
compared to patients with a low intratumoural ratio. In this study and in contrast to Zhang 
et al.34 intraepithelial CD3+ T cells did not significantly correlate with survival109. 
Hamanishi et al. found that high intraepithelial CD8+ T cells were correlated with better 
overall prognosis whereas stromal CD8+ T cells did not110. High CD8+ T cell density was 
inversely correlated with programmed death ligand 1 (PDL1) expression on tumour 
cells110, providing evidence that checkpoint pathways are an important TIL-regulatory 
mechanism in EOC. 
 
Overall these studies suggest that enhanced patient survival is positively correlated with 
increased CD8+ T cell density. However, pathways inhibiting adaptive immunity are 
frequently active in the ovarian cancer TME. These include the PDL1 and other 
immunosuppressive pathways including, for example the expression of IDO-1 which is 
associated with T cell exhaustion111. Therefore, although there are cells capable of 
recognising and killing malignant cells, these functions are prevented33. 
 
Milne et al. showed that high CD20+ B lymphocyte densities are associated with a 
positive prognosis in optimally debulked HSOC patients107. Over 40% of the 198 patients 
showed intraepithelial expression of CD20107. Furthermore, CD20 staining was strongly 
associated with both CD4+ T cells and CD8+ T cells and markers of T cell activation and 
effector functionality107. In contrast to this finding, Phuc Dong et al. showed high B cell 
numbers in EOC ascites was associated with a worse outcome in EOC112. The 
mechanisms underlying these effects are not clearly understood. 
 
1.3.2 Post-chemotherapy 
Our laboratory and others have studied the effects of chemotherapy on the TME of 
HGSOC. Böhm et al. reported T cell activation in omental metastases after NACT; CD4+ 
T cells showed enhanced IFNg production and antitumor Th1 gene signatures were 
increased113. In patients with ‘good’ response to NACT, T-cell activation was more 
pronounced and these biopsies contained significantly fewer stromal FoxP3+ Treg 
cells113. This finding was supported by a reduction in a Treg cell gene signature in post 
versus pre-NACT samples that was also more pronounced in good responders113. A high 
proportion of T cells in biopsies expressed immune checkpoint molecules PD-1 and 
CTLA4. Indeed, PD-L1 levels were significantly increased after NACT113. Therefore, 
despite T cell activation following NACT, T cell response may be hampered by 
immunosuppressive circuits activated by chemotherapy. This suggests a rationale for 
chemo-immunotherapy combinational approaches in HGSOC. Furthermore, Montfort et 
al. showed NACT promoted B cells that were associated with an anti-tumour 
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response114. Collectively, these data suggest that NACT may promote an anti-tumoural 
TME.  
 
Pölcher et al. showed that NACT was associated with increased CD4+, CD8+ and 
granzyme B+ TILs, but that FoxP3+ cell density was unaffected by chemotherapy115. This 
study was conducted on a mixed cohort of epithelial ovarian cancer biopsies rather than 
exclusively studying HGSOC, furthermore there may not have been consistency of the 
site studied. However, although CD4+ and CD8+ TIL density did not affect prognosis 
before chemotherapy, after chemotherapy infiltration granzyme B+ cells showed a 
tendency to improved PFS115. Following chemotherapy low FoxP3+ T regulatory cell 
density was associated with significantly improved OS and PFS115. Additionally, post-
NACT a high granzyme B+:FoxP3+ cell ratio associated with enhanced progression free 
survival. This study also suggests that NACT can activate anti-tumoral effects within the 
TME. Peng et al. showed that CD8+ TILs increased in ovarian cancer patients 
undergoing NACT116. Wouters et al. also reported a similar tend117. Overall these data 
suggest that NACT enhances CD8+ cytotoxic TIL response and may diminish FoxP3+ 
Tregs.  
 
Recently, Lo et al. performed a detailed assessment of chemotherapy on immunologic 
changes in matched pre and post-chemotherapy HGSOC omental metastases. This 
study showed that NACT was associated with increased densities of CD3+, CD8+, PD1+ 
and CD20+ TIL with no significant changes in CD79a+CD138+ plasma cells or CD68+ 
macrophages. Furthermore, FoxP3+PD-1+ Tregs, indoleamine 2,3-dioxygenase (IDO)+ 
and PDL1+ cell density did not change. This group defined three response patterns to 
NACT by hierarchical clustering. Tumours containing both high and low TIL densities 
showed increases in multiple immune markers post-chemotherapy and their resulting 
immune profile were indistinguishable. This finding was in contrast to TIL-negative 
tumours which generally remained negative following NACT. Despite the changes 
observed in TIL markers overall, TIL densities following chemotherapy showed no 
association with survival. Therefore NACT appeared to enhanced a pre-existing TIL 
response, yet this failed to overcome immunosuppression118. 
 
Overall these studies suggest that chemotherapy alters the TME of HGSOC to promote 
antitumor adaptive immunity, yet immunosuppressive functions are still dominant. 
However, the effects of chemotherapy on TAMs is largely unexplored in HGSOC. TAMs 
are one of the most numerous immune cells within HGSOC. As I will describe below, 
TAMs have prominent roles in mediating immunosuppression within the TME of HGSOC. 
Therefore, it is important to study the effect of chemotherapy on this cell type. 
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 Tumour Associated Macrophages 
1.4.1 Macrophage activation states 
A characteristic hallmark of macrophages is diversity and plasticity of phenotype119. In 
1990’s terms ‘classical’ and ‘alternate’ activation were introduced to describe 
macrophage responses seen in vitro to IFNg and IL-4 stimulation respectively120. 
‘Classical’ and ‘alternate’ activation are two extremes of macrophage activation and 
clearly associated with differences in gene expression. Classical activation is now used 
interchangeably with IFNg or TLR stimulated macrophages. Classically activated 
macrophages are characterised by the expression of high levels of proinflammatory 
cytokines (e.g. IL-12, IL-23), reactive oxygen species and promotion of a Th1 
response119,121. These macrophages are able to kill tumour cells122. Alternately activated 
macrophages are characterised by the expression of scavenger receptor molecules, 
mannose and galactose receptor molecules123. These macrophages have trophic tissue 
functions promoting wound healing and fibrotic tissue responses but also tumour 
progression and spread119,121. 
 
In 2002 by Mills et al. proposed ‘M1’ and ‘M2’ macrophage activation states based upon 
differences in arginase metabolism seen in macrophages by C57BL/6 and BALB/c 
mice124. These states correlated with differences in Th1 and Th2 cell responses in the 
same strains. Based on this Mills et al. proposed M1 (inflammatory) and M2 (healing) 
states. Since this time these two nomenclatures have been used interchangeably in the 
literature to describe these two extremes of macrophage activation. Within tumour tissue 
macrophages are exposed to a range of stimuli that result in the attainment of distinct 
functional phenotypes. Conceptualising macrophage activation in this dichotomous 
manner is a restrictive and simplistic view of the complexity of macrophage polarisation 
and is an inaccurate description of macrophages residing in complex tissue 
enviroments125. That said, it is a useful concept as a descriptor of general skew of 
macrophage activation. In this thesis I will describe macrophages as resembling 
‘classically activated’ or ‘alternatively activated’ states to describe these two extremes of 
macrophage activation. 
 
1.4.2 TAMs within the tumour microenvironment 
Tumours develop in contact with resident or recruited populations of immune cells. The 
ability of malignant cells to evade immune detection is regarded as a hallmark of 
cancer126. Tumorigenesis relies on the subversion of immune cells at an early stage in 
tumour evolution; macrophages are highly implicated in this process. 
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Many cancers have abundant macrophage populations123,127,128; macrophages 
frequently represent the most common host cell type. As a non-malignant lesion makes 
the transition to malignancy, macrophages accumulate and become progressively 
polarised from inflammatory (classically activated) to immunosuppressive (alternatively 
activated) phenotypes128. Key chemokines driving this process are IL-4 derived from 
malignant cell and T cells, CSF-1, GMCSF and TGF-b. The hallmark of TAM is an 
immunosuppressive phenotype which impacts on multiple aspects of tumour biology, 
promoting tumour growth and metastasis123,127,128. The presence of TAMs is generally 
associated with a poor prognosis in many solid tumours. This has been shown using 
conventional IHC to quantify cellular density and by inferring the presence of 
macrophages based on gene expression profiles129. Depleting or antagonising 
macrophages can limit tumour growth and dissemination in experimental 
models119,129,130. This may be via direct effects on tumour cells however in vivo models 
indicate that this effect is often via enhanced recruitment and effector function of CD8+ 
cytotoxic T cells119,129,130. 
 
In the following sections I will describe the origins of TAM in the TME and the multiple 
mechanisms by which TAM drive tumour progression. I will then move on to describe the 
current literature on the effects of chemotherapy on TAMs followed by strategies that 
have been used to target TAMs therapeutically. 
 
1.4.3 Origins of TAMs 
In recent times it has become clear that in murine tissue under homeostasis 
macrophages can originate from two distinct sources: from CX3CR1+ cKit+ 
erythromyeloid progenitor cells that seed into tissues during embryonic development and 
from bone marrow (BM)-derived haemopoietic stem cell progenitors. Cells are seeded 
into tissues in two ‘waves’ during embryonic development, and derive from either the 
fetal yolk sac or the fetal liver (Figure 1.2). These cells are able to replicate in tissues to 
maintain macrophage populations. The relative contribution of cells from these two 
origins varies between tissues. In the brain for example microglial cells are derived 
exclusively from embryonic precursors with little contribution for BM-derived progenitors. 
In the colon the dominant population of macrophages dependent on continuous 
replacement from Ly6C+ inflammatory monocytes of bone marrow origin119,121. In 
perhaps the majority of tissues mixed populations of macrophages with divergent origins 
exist e.g. pancreas, breast and lung. The relevance of these divergent origins is still to 
be explored although it appears that tissue-specific stimuli are key in determining 
macrophage phenotype irrespective of origin131. The majority of these studies have been 
conducted in the mouse, in comparison studies of macrophage origin in human subjects 
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is far less explored, however recent reports suggest the existence of macrophage 
populations from divergent origins in humans as well132–134. 
 
Figure 1.2 Macrophage origins. Studies in mice show macrophages arise from two divergent 
origins: i) from erythromyeloid progenitor cells (EMP) during embryonic and fetal development 
and ii) in adult life from haematopoietic stem cell (HSC) precursors produced in the bone marrow. 
Under homeostatic conditions macrophage populations from both these origins contribute to the 
tissue macrophage population, the relative contribution of these populations varies by tissue. 
Within in neoplastic tissue TAMs may also arise from both these origins furthermore TAM are 
also derived from recruited monocytes. Adapted from Cassetta and Pollard 2018129 and Denardo 
and Ruffell135. 
 
Historically TAMs have been considered to derive principally from recruited BM-derived 
circulating monocytes that are recruited into malignant tissues. However, more recent 
data have called this assumption into question. In murine models of brain, lung and 
pancreatic cancer up to 50% of all TAMs were found to derive from tissue-resident 
populations134,136,137. Furthermore, these studies have suggested that embryonic-derived 
TAMs may have distinct phenotypes and functions compared to those derived from 
circulating monocytes. The relative contribution of macrophages of different origins to 
the TAM population is still debated and incompletely understood138. The majority of 
studies come from mouse cancer models, data relating to human TAMs are still rare. 
One recent paper addressing this deficit showed that 10-40% of TAMs in human PDAC 
expressed similar surface markers and transcriptional profiles to tissue resident TAM 
characterised in murine PDAC139. Furthermore, Cassetta et al. recently reported that 
TAM in endometrial and breast cancers were transcriptionally divergent compared to 
each other and compared to resident macrophages and monocyte precursors133. These 
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data suggest that cancer-specific microenvironments are responsible for driving myeloid 
cell pheneotype133. 
 
A myriad of cytokines, chemokines and chemotactic molecules may mediate the 
recruitment of monocytes from the blood into primary and metastatic tumours where they 
differentiate into TAMs140. Molecules that are important in this process in murine cancer 
models include CCL2, MIP1a, CCL4, CXCL12, IL1-b, IL6, VEGF, and CSF-1140. One of 
the most studied of these factors is the chemokine CCL2, which is expressed by tumour 
cells and macrophages in mouse and human cancers. CCL2 expression correlates with 
TAM number and poor prognosis. 
 
CSF-1 is a major regulator of myeloid cells irrespective of developmental origin and is a 
chemoattractant for macrophages128,141. High intratumoral CSF-1 concentrations 
correlated with high TAM density and poor prognosis133,142. In the context of endometrial 
cancer, CSF-1 protein concentration within the tumour was an independent predictor of 
survival143. In murine models multiple studies show that pharmacological and genetic 
inhibition of CSF-1 signalling resulted in reduced TAM density and delayed tumour 
initiation, reduced tumour growth and metastasis128,142. These findings could be 
explained by interruption of CSF-1 signalling locally within the tumour, or as the result of 
systemic effects on the BM128,129. Lin et al. showed clear evidence for CSF-1 mediating 
local recruitment of macrophages via inducing gain-of-function mutations in CSF-1 in the 
mouse mammary tumour virus-polyoma middle tumour-antigen (MMTV-PyMT) model of 
breast cancer144. Expression of CSF-1 in the mammary epithelium resulted in 
macrophage recruitment which enhanced tumorigenesis, additionally this rescued loss-
of function CSF-1 mutations, which were seen to delay tumour progression144,145. 
 
Chemotactic molecules activate signalling pathways that result in an inside-out 
conformational changes in integrins, including a4b1146,147. As a result of this process 
monocytes are able to interact with the endothelial cells and mediated extravasation from 
the blood into tissues. One important signalling pathway in myeloid cells activated by a 
range of chemotactic molecules is PI3kg140. Genetic or pharmacological inhibition of 
PI3kg, the signalling components in this pathway or a4b1 reduced TAM infiltration, 
tumour growth, and metastasis in a range of murine models148–151. As there is 
redundancy in the cytokine and chemokine networks recruiting TAM into tissues, 
targeting individual chemotactic molecules may not be as effective as targeting common 
down-stream signalling pathways140. 
 
Lineage tracing experiments in pancreatic ductal adenocarcinoma (PDAC) have shown 
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a proliferative TAM population of embryonic origin, distinct from BM derived cells134. 
Furthermore, cell proliferation within the TAM population has been shown in sarcoma 
and breast tumours152–154. This population of TAM derived from tissue resident cells is 
characterised by a unique set of markers in mice: these include CXCR3high, MERTK+, 
Siglec 1+, CD64+ F480high; whereas BM derived macrophages express integrin a4, L-
selectin, Ly6C, and Nr4a1140. Furthermore, TAM in different tissue environments express 
specific transcription factors, for example Gata-6 expression is characteristic of 
peritoneal macrophages140. Transcriptomic analysis of adult and embryonic-derived 
TAM populations sorted from murine PDAC showed embryonic TAM associated with a 
fibrotic signature and upregulated collagens and cyclins; whereas BM derived cells were 
characterised by a gene signature of antigen presentation134. Clear understanding of 
markers associated with these populations in human tumours is lacking. 
 
Feng et al. showed the differential contributions of resident and recruited TAM in a 
murine model of glioma. The glioma TAM population was a mixture of microglia, derived 
from embryonic precursors and macrophages recruited from BM-derived inflammatory 
Ly6Chigh monocytes. Depleting CX3CR1 resulted in ‘inflammatory’ Ly6Chigh monocyte 
recruitment which was associated with increased tumour incidence, decreased survival 
and decreased latency155. This suggested that recruited rather than resident myeloid 
cells may mediate protumoural functions in this model.  
 
1.4.4 Roles of tumour associated macrophages  
Within both the primary and metastatic sites of many tumours, TAMs promote tumour 
growth and development through multiple mechanisms including stimulation of 
angiogenesis, tumour cell invasion, cell mobility and extravasation at the metastatic site. 
This multiplicity of processes implicating TAM in the promotion of tumour development 
underscores the intense interest in therapeutic strategies to target TAMs128,138 (Figure 
1.3). 
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Figure 1.3 Diagrammatic representation of some of the known tumour promoting roles of 
TAMs. Macrophage production of IL-6 and TNF-a promote survival signalling in malignant cells. 
TAM mediate immunosuppression, directly or indirectly. TAMs promote angiogenesis via 
production of VEGF-A and WNT7b. TAM promote malignant cell invasion and metastasis via 
cytokine circuits and actions on the ECM. Adapted from Ruffell and Coussens 2015156.  
 
1.4.4.1 Angiogenesis 
The development of a vasculature is a hallmark of tumour development and has been 
referred to as the ‘angiogenic switch’126. TAMs regulated by CSF-1 are important in 
driving this process in a wide range of models; one of the most studied is the MMTV-
PyMT breast carcinoma model128. In this model tumour angiogenesis was dependant on 
WNT7b secretion by TAMs resulting in VEGF-A production in endothelial cells157,158. 
Genetic deletion of WNT7b in macrophages resulted in failure of angiogenesis and in 
reduced tumour growth, invasion and metastasis157. A specific population of TAMs 
expressing the surface glycoprotein TIE2 is implicated in angiogenesis in a number of 
cancer models as shown by genetic ablation studies159. These TIE2 positive cells are 
frequently found on the abluminal side of vessels as the result of the interaction of TIE2 
with its ligand ANG2 on endothelial cells128. Interestingly, these cells may also promote 
the invasion of cancer cells into the vasculature. Interfering with this vessel association 
through using an anti-ANG2 antibody or through conditional knockdown of TIE2 
prevented angiogenesis160. CSF-1R is important in generating TIE2+ macrophages161, 
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suggesting a link between these two molecules in driving angiogenesis128. 
 
1.4.4.2 Motility and intravasation 
TAMs promote cancer cell motility and haematogenous dissemination. Wychoff et al. 
found that TAMs can drive unidirectional motility of tumour cells through a paracrine 
signalling loop involving CSF-1 derived from tumour cells and EGF derived from 
macrophages162. This mechanism was sufficient to enable tumour cell invasion of 
collagen gels163. Furthermore, this process has been directly visualised in vivo in the 
MMTV-PyMT model using multiphoton microscopy. Here, TAMs and tumour cells were 
observed to rapidly co-migrate along collagen fibres towards blood vessels145. In the 
perivascular space TAMs can ‘open the gate’ to allow tumour cell entry to the 
circulation128. TAMs can further promote the invasive capabilities of tumour cells for 
example by the production of secreted protein acidic and rich in cysteine (SPARC) which 
increases tumour cell integrin mediated ECM interaction and motility164. Furthermore 
cathepsins produced by TAMs result in matrix remodelling promoting tumour cell 
invasion165,166 and TAM-derived TGFβ has been implicated in promoting EMT in tumour 
cells further facilitating mobility128,167. The trilogy of macrophages, malignant cells and 
endothelial cells has been termed the ‘tumour microenvironment of metastasis’ (TMEM) 
and can be identified as a histological marker for metastasis in human breast cancers168. 
 
Therefore, TAMs are implicated in promoting tumour growth via the induction of 
angiogenesis as well as promoting metastasis. Hence, targeting TAMs may facilitate 
both of these processes to be impacted simultaneously. 
 
1.4.4.3 Immunosuppression 
For tumours to evolve, evasion of the host immune response is essential. TAMs are 
important in this process, which is also mediated by Tregs and tumour cell driven immune 
evasion mechanisms169,170. Demonstrating this point, the ratio of Tregs and TAMs to 
CD8+ cells is an important predictor of survival in breast cancer171. 
 
TAMs secrete a broad range of chemokines, cytokines and enzymes that foster 
immunosuppression via the inhibition of CD4+ and CD8+ T cell function or by the 
induction of regulatory T cell phenotypes128. For example, Curiel et al. showed that in 
human ovarian cancer TAMs can recruit Treg cells via production of IL22105. Schlecker 
et al. using murine models of melanoma showed that myeloid cell production of CCL3, 
CCL4 and CCL5 recruited Treg via CCR5 signalling172. Furthermore, TAM produce 
molecules that can induce Tregs, important amongst these are IL-10 and TGFβ173. 
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Savage et al. showed that M2/alternatively activated (which expressed IL-10 at high 
levels) but not M1/classically activated human macrophages were able to induce Tregs, 
with a strong immunosuppressive phenotype174. Denning et al. show that macrophages 
in the lamina propria are able to induce Tregs via the production of IL-10 and TGFβ175. 
 
TAMs express a range of ‘inhibitory’ MHC molecules that are able to supress effector 
lymphocyte function. For example in mouse models HLA-G expression on tumour cells 
inhibits the activation of NK T cells via engagement of CD94176. In glioma this inhibitory 
signal can be provided by myeloid cells177. Likewise HLA-G expression on TAM can 
inhibit the activation of T cells178. Additionally, TAMs may inhibit intratumoural immune 
response via engagement of immune check point pathways. The most studied of these 
are mediated by PD1 and CTLA4 and are expressed on activated T-cells; stimulation of 
these receptors with their ligands, PDL-1/2 and CD80/CD86 respectively, inhibits T-cell 
responses. These pathways represent important mechanisms acting to limit immune 
responses and maintain homeostasis. Under the influence of HIF-1α signalling TAMs up 
regulate the expression of PDL-1179. It is difficult to define the importance of the TAM 
PDL-1 signal as this molecule is also expressed by tumour cells and other cells of the 
TME128.  
 
TAM can also mediate immunosuppression by influencing the metabolism of effector 
cells. TAM production of the enzyme arginase-1 results in the depletion of L-arginine 
from the TME of human and murine tumours. This can mediate immunosuppression by 
preventing the expression of the CD3g chain, rendering T-cells unable to respond to 
antigen180 in a murine lung cancer model. Furthermore, TAMs can produce the enzyme 
IDO which degrades L-tryptophan, this results in the production of immunosuppressive 
metabolites and the depletion of this amino acid from the TME which further contributes 
to T cell exhaustion181,182. 
1.4.4.4 Extravasation 
As described above, TAM have critical roles in mediating tumour growth, development 
and invasion. Macrophages are also able to facilitate tumour cell extravasation at sites 
of metastasis by priming the so-called ‘pre-metastatic niche’183. In lung cancer models, 
monocytes are recruited to the pre-metastatic niche by CCL2 gradients produced when 
micro-clots of tumour cells and platelets arrive in vessels128. The recruited monocytes 
differentiate into CCR2+, VEGFR1+ Ly6C- F4/80+ macrophages (defined as metastasis 
associated macrophages, MAMs in this model). MAMs facilitate tumour cell 
extravasation into the tissue via the production of vascular permeability factors such as 
VEGF. Ablation of MAMs prevented tumour cell seeding and decreased metastasis 
growth128,184.  
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1.4.5 TAM density and clinical outcome 
The prognostic significance of TAMs has been studied in a wide range of human 
tumours138. High TAM density predicts poor patient prognosis185, suggesting 
immunosuppressive actions of TAM, within many solid tumours. Indeed, an overall 
negative association of TAM density across a range of solid tumour types has been 
demonstrated in a large meta-analysis by Zhang et al.186. However, in colorectal, 
prostate and non-small cell lung cancer, high TAM density correlates with a favourable 
patient outcome138. 
 
In these studies, general myeloid markers or markers representative of specific 
macrophage polarisation states have been correlated with survival. CD68 is the most 
common pan-macrophage marker employed. Markers such as CD163, CD206 and 
CD204, which are regarded as markers of an alternatively activated phenotype have 
been assessed with similar results to CD68187,188. As will be discussed below, when 
interpreting these data it is important to consider the effects of chemotherapy on the TAM 
infiltrate. It is likely that the positive effects of TAMs on patient survival in CRC result 
from the effects of TAM on response to chemotherapy138. 
 
1.4.6 Tumour associated macrophages in ovarian cancer 
In ovarian cancer multiple soluble mediators have been demonstrated as important in 
TAM polarisation and patient outcome. These include IL-6, IL-10, TGFβ and aracadonic 
acid88,189. Initial studies have shown ovarian TAMs to express markers suggesting an 
immunosuppressive alternatively activated phenotype, including CD163, CD204, CD206 
and IL-10190–192. Although density of total macrophage populations quantified by CD68 
have not been shown to predict patient outcome193, clear evidence does exist that 
specific subsets of TAMs affect clinical outcome. For instance, Lan et al. showed that 
patients with tumours richly infiltrated with CD163+ TAMs to have significantly reduced 
progression-free and overall survival194. TAM CD206/CD68 ratio predicts worse PFS193, 
and, correspondingly, a high M1 (classically activated)/M2 (alternatively activated) ratio 
associated with improved survival195. Furthermore, Zhang et al. showed a high intra-
tumoural, as opposed to stromal or whole tissue, M1 (classically activated)/M2 
(alternatively activated) phenotypic ratio was associated with improved survival196 
suggesting localisation as well as phenotype to be clinically relevant. However, it should 
be noted that these studies are predominantly in mixed cohorts of ovarian cancer 
subtypes and the effects of chemotherapy on macrophage phenotype was not 
considered. A recent meta-analysis confirmed the association of poor prognosis with 
CD163+ TAMs and improved prognosis with a high M1 (classically activated)/M2 
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(alternatively activated) ratio197, further strengthening these data. 
 
Transcriptomic assessment of TAMs from HGSOC ascites demonstrated a ‘mixed’ 
polarisation phenotype198. In this study TAM expression of CD163 was associated with 
early disease relapse, suggesting the importance of this population of TAM in promoting 
the tumours. Furthermore, transcriptomic assessment of TAMs and resident peritoneal 
macrophages has demonstrated a surprising similarity between these two populations. 
Interestingly, the most striking difference between these populations was an up 
regulation of ECM related genes in ovarian cancer ascites TAMs199. 
 
 The effects of chemotherapy on TAM 
Both clinical and experimental evidence show that chemotherapy can modify TAM 
phenotype and function within the TME of many tumours.  
 
1.5.1 Clinical studies 
Studying patient cohorts pre and post-chemotherapy shows that chemotherapy can 
modify the association of TAM density and patient outcome. This effect is exemplified in 
follicular lymphoma where CD68+TAM density associated with favorable or unfavorable 
outcome in patients depending on the multi-agent chemotherapy administered200,201. In 
the post-treatment setting, following the rituximab, cyclophosphamide, doxorubicin, 
vincristine and prednisone regimen (R-CHOP) a high TAM density was associated with 
a favorable prognosis202. This effect was not seen however in patients treated with 
another chemotherapy regime which excludes doxorubicin: rituximab, 
cyclophosphamide, vincristine and prednisone (R-CPV)203. Hence, specifically 
doxorubicin treatment may engage antitumoral immune responses. Interestingly, 
doxorubicin can activate ‘immunogenic’ forms of cell death (see next section) which may 
provide a mechanism to explain these findings. 
 
Di Caro et al. were the first to show the prognostic association of TAM density is impacted 
by chemotherapy exposure in solid tumours188. They studied PDAC patients with locally 
advanced cancers, who, following surgical resection, were either treated with adjuvant 
chemotherapy or did not receive additional treatment. High TAM density was associated 
with an extended disease free survival in patients treated with adjuvant gemcitabine, 
which negated the negative prognosis associated with high TAM density in patients who 
did not receive adjuvant chemotherapy188. Furthermore, Malesci et al. also showed that 
a high TAM density post-adjuvant 5-fluorouracil treatment was associated with favorable 
outcomes, however, this was not seen in untreated patients181.  
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These data highlight that the prognostic significance of TAMs can be modified by 
exposure to chemotherapeutic agents and suggest that post-chemotherapy TAMs may 
adopt anti-tumour roles. This underscores the importance of considering the association 
of TAM density with clinical outcome in the context of chemotherapy. Moreover, most 
studies to date that have assessed the prognostic value of TAMs do not report the 
chemotherapy regimens used204–206. 
 
1.5.2 Experimental studies 
Chemotherapy may affect macrophage function directly or indirectly138. For the last thirty 
years it has been known that tumour response to chemotherapy is at least in part 
dependent on myeloid cells. Mantovani et al. showed that tumour cell lines exposed to 
actinomycin D became susceptible to killing by monocytes; this phenomenon was 
termed drug dependant cellular cytotoxicity207. Building on this early work, the concept 
of ‘immunogenic cell death’ (ICD) was developed and suggests that in response to 
chemotherapy, tumour cells express alarm signals that then trigger immune 
responses208. For example, Ma et al. showed that doxorubicin exposure of tumour cells 
resulted in the release of ATP which recruited macrophage precursors that differentiated 
into antigen presenting cells capable of effective immune responses209. Indeed, ICD has 
been demonstrated in response to a range and suggests and immunological 
mechanisms may underlie the effects of many chemotherapies208. 
 
Trabectedin, a chemotherapy agent that binds DNA and causes cell cycle arrest acts, at 
least in part, via its effects on macrophages. Germano et al. showed that trabectedin, 
through interactions with DNA binding proteins, caused changes in genes encoding pro-
inflammatory cytokines and chemokines in sarcoma xenografts and cell lines210,211. In a 
murine sarcoma model Germano et al. show that trabectedin activated caspase-8 
mediated apoptosis selectively in monocytes/macrophages212. TAM depletion was 
demonstrated to be a mechanism underlying the effects of trabectedin in murine models. 
Furthermore, reduced TAM infiltration and decreased angiogenesis are observed in pre 
vs post-trabectedin treatment samples211,212. These data suggest TAM depletion may 
underlie the delayed yet prolonged effects of this drug on human tumours212.  
 
Further evidence showing the capability of TAM to mediate positive responsiveness to 
chemotherapy are made in the context of studies assessing the effects of the microbiome 
on TAM function. Lida et al. showed that priming of myeloid cells by microbiota 
components promoted the anti-tumoural effects of platinum chemotherapy in mouse 
tumour models213. Mice with formyl peptide receptor 1 (FPR1) dysfunction, a protein 
expressed in myeloid cells that functions as a DAMP sensor, have impaired responses 
 Chapter 1: Introduction 
 47 
to anthracyclines214. The presence of loss-of-function mutations within the FPR1 allele 
in human breast cancer is tied to an unfavourable response in patients with both breast 
and CRC following chemotherapy214. The above studies show that chemotherapy can 
alter the pro-tumoural phenotype of TAM in many tumour types to instead promote anti-
tumoural immunity. However, under other conditions, TAMs can limit the effects of 
chemotherapy on tumour response. This dualistic effect of chemotherapy on TAM is 
perhaps not surprising given the plasticity of macrophages.  
 
Enhancement of alternatively activated TAM phenotypes by chemotherapy reduces 
cytotoxic effects on malignant cells. In preclinical models this has been shown in the 
context of treatment with platinum compounds, paclitaxel and doxorubicin215–221. 
DeNardo et al. demonstrated that macrophages were recruited into murine breast 
tumours following paclitaxel treatment222. In this model abrogation of TAM recruitment 
using CSF-1R-antagonists enhanced response to chemotherapy, an effect that was 
dependent on CD8+ T-cells222. Nakasone et al. also demonstrated that CCR2-dependent 
macrophage recruitment following chemotherapy in breast cancer models impaired 
response220. Hughes et al. showed that in a mouse tumour transplantation model M2 
macrophages accumulated around vessels post-chemotherapy and promoted 
revascularization and relapse223. This was dependent on the CXCR4-CXCL12 axis223. 
Alberto Mantovani in his recent review138 suggests two possible general mechanisms to 
explain negative impact of TAMs on chemotherapy response: in murine models 
chemotherapy induced tissue damage can trigger recruitment of immunosuppressive 
myeloid cells, or elicit a pro-tumorigenic type 17 T-helper-cell (Th17) skewed immune 
response promoted by IL1138,218. Alternatively, TAM may protect cancer stem cells from 
the cytotoxic effects of chemotherapy138,216. 
 
In conclusion, macrophage plasticity provides a platform to promote or limit the effects 
of chemotherapy, that is dependent on tumour type, chemotherapy and other host 
immune cells. Understanding how different chemotherapeutics interact with myeloid cells 
in different TMEs will enable rational approaches to targeting TAM in combination with 
chemotherapy be developed.  
 
 Targeting TAMs 
Strategies to target macrophages in tumours fall into two broad categories, those 
blocking TAM recruitment and localisation within tumours and those that aim to 
functionally alter macrophages from a pro-tumour to anti-tumour phenotype138. I will 
provide an overview of both strategies and focus in more detail on CSF-1R pathway and 
its pharmacological blockade. 
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Figure 1.4 Macrophage-targeting treatment strategies in oncology. A range of therapeutic 
strategies have been explored that either deplete TAM or re-educate TAM towards anti-tumoural 
classically activated/M1-like functional programs (as described in the main text). Adapted from 
Mantovani 2017138. 
 
1.6.1 Targeting TAM recruitment 
Multiple molecules are involved in the recruitment of TAM into tumours. Chemokines 
frequently act on multiple receptors and on different cell types and these features are a 
potential limitation to translating chemokine-targeting strategies in the clinic138,224. 
Targeting TAM via CCL2 reduces tumour growth and metastasis in a number of murine 
experimental models225–229. Concerns regarding this approach have been flagged with 
the observation of a rebound effect of monocyte/macrophage re-accumulation after drug 
withdrawal which enhanced metastasis development in murine breast cancer230. Despite 
this CCL2 antibodies have entered Phase 1 and 2 clinical testing231–233. A Phase 1 trial 
of carlumab, a fully human anti-CCL2 antibody, showed that the antibody was well 
tolerated, however there were no objective responses to treatment and only four of the 
thirty-three evaluable patients achieved durable disease stabilisation by RECIST 
criteria233. Furthermore, no objective responses were seen in a phase 2 study of 
carlumab in prostate cancer231 and in a Phase 1b trial of carlumab in combination with 
chemotherapy no objective responses were observed232. In these studies only a transient 
suppression of CCL2 was followed with paradoxical increases in free CCL2 plasma 
 Chapter 1: Introduction 
 49 
concentrations, which may underscore the lack of a clinical effect. This was in contrast 
with effects of an oral CCR2 antagonist PF-04136309, which engages the CCL2-CCR2 
axis. This was evidenced by decreases in CCR2+ blood monocytes and increases in 
CCR2+ bone marrow monocytes in matched human samples234, in keeping with the 
known role of this pathway in mediating monocytes egress from the bone marrow 
compartment. In a phase 1b human study, PF-04136309 has been used in patients with 
locally advanced PDAC who were not suitable candidates for surgery, alone and in 
combination with FOLFIRINOX (5-fluorouracil, folinic acid, irinotecan, and oxaliplatin) 
chemotherapy234. In this study, good safety profiles were observed and partial responses 
were seen in sixteen of thirty-three (49%) patients, compared with no objective 
responses in five patients treated with chemotherapy alone234. Therefore, targeting CCL2 
may be a useful strategy. 
1.6.1.1 Targeting TAM via CSF-1-Ri 
Colony-stimulating factor 1 receptor (CSF-1R), is a cell-surface receptor for the cytokines 
CSF-1 and IL-34235,236. CSF-1R is predominately expressed by cells of the 
monocyte/macrophage lineage. Binding of ligand results in receptor dimerization and 
tyrosine kinase-mediated autophosphorylation of cytoplasmic tyrosine residues which 
creates binding sites for cytoplasmic proteins that activate phosphatidylinositol 3-kinase 
(PI3K) and extracellular regulated protein kinase 1/2 (ERK1/2) signalling pathways141. 
CSF-1 is the major growth and differentiation factor for the monocyte-macrophage 
lineage and is abundantly expressed by several tumour types237. IL-34, a second ligand 
for CSF-1R, also regulates macrophage recruitment to tissues141. CSF-1R is exclusively 
expressed by cells of the monocytic lineage and therefore represents a logical target to 
interfere with TAMs and their precursor cells138. As a tyrosine kinase CSF-1R represents 
an attractive therapeutic target. A number of small molecule CSF-1R inhibitors have 
been developed and tested in preclinical models, as well antibody antagonists163,222,238–
240. 
 
CSF-1 and CSF-1R density in tissue is positively correlated with poor prognosis in a 
number of cancer types (breast, classical Hodgkin lymphoma, hepatocellular 
carcinoma)138,241,242. Inhibiting the CSF-1-CSF-1R axis has been investigated in a 
number of preclinical settings, both alone and in combination with conventional 
therapies163,216,222,238,239,243. The therapeutic antibody emactuzumab (RG7155) binds to 
the CSF-1R and prevents receptor dimerization, thereby preventing signalling239. 
Patients with diffuse type giant cell tumours (dt-GCTs) have shown objective responses 
to CSF-1R blockage with RG7155 and with PLX3397 (pexidartinib),  a tyrosine kinase 
inhibitor of CSF-1R239,244,245. This disease is characterised by overexpression of CSF-1 
and therefore serves as a ‘model disease’ for agents targeting the CSF-1-CSF-1R 
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axis237. In human dt-GCTs Ries et al. showed that RG7155 decreased TAM density and 
the circulating monocyte concentraion239. These effects were associated with an 
increase in the CD8:CD4 ratio within dt-GCT tumour tissues in five out of seven 
patients239. 
 
PLX3397, which is able to penetrate the blood brain barrier, has been tested in preclinical 
glioma models and was found to reduce glioma progression, tumour cell proliferation and 
tumour grade246. In patients with recurrent glioblastoma, PLX3397 decreased circulating 
monocyte populations, however no objective clinical responses were observed247. 
BLZ945, another small molecule inhibitor of CSF-1R, has also been studied in preclinical 
models of glioblastoma. In this setting BLZ945 treatment did not result in TAM depletion 
but caused a change in phenotype of TAM towards an anti-tumoural/classically activated 
phenotype215. In ovarian cancer, there have been few pre-clinical studies targeting TAM. 
Moughon et al. used GW2580, a small molecule inhibitor of CSF-1, to treat mice bearing 
ID8 tumours, which readily disseminate throughout the peritoneum248. GW2580 
treatment decreased alternatively activated macrophage density in ascites and reduced 
ascites volume secondary to normalisation of the peritoneal vasculature248. However, a 
criticism of this study is the use of the ID8 model, which does not accurately recapitulate 
the genetic landscape of HGSOC (see also below). Lyons et al. used CSF-1Ri in 
combination with anti-VEGF and taxane chemotherapy, using HGSOC PDX models they 
found CSF-1Ri reduced VEGF resistance and enhanced anti-tumour effects249. These 
studies provide preliminary evidence to suggest that CSF-1Ri could be a valuable 
therapeutic approach in the context of ovarian cancer. 
 
GW2580-mediated TAM depletion in a genetic model of gemcitabine-resistant PDAC 
enhanced activity of gemcitabine treatment250. TAM appeared to mediate resistance in 
tumour cells by upregulating cytidine deaminase, an enzyme that degrades the active 
form of gemcitabine250. In work carried out in our lab, Candido et al. used the CSF-1Ri 
AZD7507 to target TAM in a genetic model of PDAC251. AZD7507 treatment resulted in 
shrinkage of established tumours and increased survival in this model251.  Malignant cell 
proliferation diminished, with increased cell death and an enhanced T cell immune 
response. TAM depletion rewired other features of the TME, for instance, there were 
significant decreases in several pro-tumor cytokines including IL-6 and IL-10 and 
chemokines such as CCL2 and CCL12 in AZD treated tumours251. 
 
Overall these data suggested that targeting the CSF-1-CSF-1R axis could be important 
in improving the therapeutic responses of conventional treatments. Based on these pre-
clinical data, multiple clinical trials are currently in progress testing TAM-targeting agents 
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in combination with conventional treatment modalities and immunotherapies135,138,237. 
 
1.6.2 Activation of TAMs 
Using bacterial products to promote immune responses to cancer represents the 
founding principle of immunotherapy, as pioneered by William Coley252. Indeed, 
microbial preparations (e.g. muramyl-dipeptide) prime macrophages for anti-tumour 
activity253. The clinical use of intravesical Bacillus Calmette-Guerin (BCG), in patients 
with recurrent urothelial malignancy, represents a clinical intervention inspired by this 
era of immunotherapy138. In addition to LPS, IFNg is an inducer of classical macrophage 
polarization to a phenotype capable of tumour cell killing138. The therapeutic use of this 
cytokine has been tested in women with ovarian cancer both with advanced disease and 
after surgery in women with minimal residual disease254,255. Although in a very small 
study, Colombo et al. showed that in the context of small volume residual disease 
following cytoreductive surgery, IFNg treatment resulted in tumour cell cytotoxicity and 
clinical responses254. These studies provide preliminary data to suggest that IFNg-based 
immunotherapy and by extension M1/classically-activated macrophages may be useful 
in ovarian cancer. 
 
CCL5 is a chemokine associated with functional reprogramming towards an M2 
phenotype138. Halama et al. show in patients with advanced CRC, that targeting the 
CCL5-CCR5 axis resulted in objective clinical responses (60% partial responses, 80% 
disease control), although this was a very small cohort of patients256. This may represent 
another therapeutic strategy to alter macrophage phenotype256. 
 
CD40 agonists can reprogram alternatively activated TAM towards a classically activated 
phenotype. In a murine model of PDAC, treatment using an agonistic anti-CD40 mAb 
resulted in reprogramming of TAM toward classically-activated functions with reductions 
in tumour volumes257. On the basis of these findings a Phase 1 trial was undertaken 
which showed improved overall survival when CP-870,893 (a fully human CD40 agonist 
antibody) was administered in combination with gemcitabine and partial responses in 
four of twenty-two patients258. Interestingly, a recent study by Hoves et al. showed that 
CSF-1Ri treatment sensitises TAM to treatment with a CD40 agonist259. This resulted in 
a short-lived state of TAM activation which produced a proinflammatory cytokine milieu 
which enhanced T cell dependent immunity259. Therefore, multiple targeting approaches 
may be required to efficiently re-wire TAM immunosuppressive programs. This approach 
is being tested in an early phase clinical trial138,259.  
 
CD47 in an important negative regulator of phagocytosis, this molecule is broadly 
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expressed and has been regarded as a ‘don’t eat me’ signal260. CD47 interacts with 
signal regulatory protein-a (SIRP-a) on macrophages and this prevents macrophage 
phagocytosis260. c-MYC drives the expression of this molecule which is expressed by 
virtually all cancers261. Inhibition of the CD47-SIRP-a interaction represents a 
mechanism of engaging anti-tumoral functions of TAMs. Advani et al. showed in a phase 
1b clinical trial that blocking CD47-SIRP-a interaction using a humanized anti-CD47 
antibody (Hu5F9-G4) along with anti-CD20 treatment had significant anti-tumor activity 
in lymphoma patients262.  
 
Reprogramming from an alternatively activated to a classically activated macrophage 
phenotype has been achieved using histidine-rich glycoprotein (HRG)263. This effect was 
associated with down regulation of placental growth factor (PlGF)263. EF-022, a modified 
form of the vitamin D binding receptor, is undergoing early clinical trials, based on 
evidence that it promotes classically activated repolarization264. Other agents that have 
shown potential to re-polarise TAM to a classically activated phenotype include PI3Kg 
and BTK inhibitors149,150. In a preclinical model, PDAC treatment with a PI3Kg inhibitor or 
a BTK inhibitor reset macrophages toward a classically activated phenotype that 
promoted CD8+ T-cell cytotoxicity and resulted in reduced tumour growth150. 
 
 Murine models of HGSOC 
In order to develop improved treatments in ovarian cancer, pre-clinical murine models 
that accurately reflect the genetic, pathological and response to treatment characteristics 
are required. A diverse range of models have been developed to model ovarian cancer.  
 
Human tumour xenograft models offer advantages of being able to study the effects of 
mutations or gene expression on human tumour progression, furthermore they allow the 
validation of therapeutic strategies. A crucial disadvantage is that these models use 
immunocompromised mice and therefore do not model the effects of immunity within the 
tumour265. Patient derived xenografts (PDX) models faithfully recapitulate the tumour 
mutational landscape and can be used to study the effects of therapeutic approaches on 
individual tumours. Again, these models are conducted in immunocompromised mice 
and therefore the effects of immunity and the full complement of the TME cannot be 
studied effectively in these models.  
 
The ID8 model is widely used as a syngeneic model of HGSOC266. This model was 
generated by the multiple passage of mouse ovarian surface epithelial cells which 
underwent malignant transformation in culture. This model offers advantages in 
producing tumours in mice with an intact immune system. However, whole exome 
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sequencing has demonstrated that this models lacks any of the mutations implicated in 
driving HGSOC267. ID8 cells are p53 and brca-1/2 wildtype and are competent in double 
stranded DNA break repair267. Recently, clustered regularly interspaced short 
palindromic repeats (CRISPR) editing has been used to engineer ID8 cells that are p53-
/-Brca1/2-/-; these cells displayed greater sensitivity to both platinum chemotherapy and 
PARPi267,268. 
 
More recently genetic engineered murine models (GEMM) have been developed to 
better reflect the genetic landscape of ovarian cancer. Furthermore, these models offer 
a number of additional advantages. First, they allow study of early events in tumour 
development and second, they are fully immunocompetent models and therefore allow 
study of the effects of the immune system within tumours, essential for studying the 
TME265.  
 
As discussed previously, HGSOC is characterised by a complex mutational landscape 
including frequent mutations in TP53, BRCA1/2 and RB1 and PTEN. Simian virus 40 
(SV40) large T antigen binds and inactivates both p53 and pRb and this was used as an 
early method for inhibiting both of these genes265. Expressing SV40 under the control of 
the promoter for a Müllarian specific gene (MISIIR) produced mice that developed poorly 
differentiated ovarian carcinomas269. This represented the first transgenic model of 
epithelial ovarian cancer. The major disadvantage of this model was that the mice were 
infertile and tumours sometimes occurred in new born mice265.  
 
Flesken-Nikitin et al. used cre conditional alleles in combinations with intrabursal 
injections of a cre-expressing adenovirus to target the mouse ovarian surface epithelium 
(MOSE)270. This approach was used to inactivate Tp53 and Rb1 within the MOSE which 
resulted in poorly differentiated ovarian tumours which metastasised to the lung, liver 
and contralateral ovary270. Mice with both Rb and p53 knockout where much more 
efficient at producing tumours than single knockouts, although p53 knockout alone was 
sufficient to induce tumour formation265. Szabova et al. further refined these approaches 
to generate a genetic model of HGSOC271. This was achieved by inhibition of Rb in 
concert with Tp53 aberration (missense mutation or deletion) and inactivation of either 
Brca-1 or 2. This study demonstrated that loss of Rb was sufficient for tumourigenesis 
but additional inactivation of p53 facilitated peritoneal dissemination and metastasis. 
Ovarian tumours from these models had a gene expression profile that recapitulates 
HGSOC271. This GEMM model was then used to generate orthotropic immunocompetent 
transplantable models, demonstrating the ability of this model to generate synchronised 
cohorts of mice suitable for preclinical study272. Using this model these tumours showed 
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response to single agent and combination treatment with cisplatin and olaparib based 
on Brca status272.  
 
In view of the finding of STICs as the likely precursor lesion of HGSOC, Perets et al. 
developed a HGSOC GEMM model that specifically targeted the fallopian tube secretory 
epithelial (FTE) cells by expression of cre recombinase from a Pax8 promotor273. Using 
this system Brca1 or Brca2 were deleted in combination with p53 and Pten273. This 
approach resulted in the development of fimbrial STIC lesions followed by HGSOC that 
progressed to an advanced stage with ovarian and peritoneal metastasis273. More 
recently Zhai et al. have used the Ovgp1 promoter to control cre recombinase in the 
oviductal epithelium, the mouse equivalent to the fallopian tube epithelim274. Using this 
approach inactivation of combinations of Brca1, Tp53, Rb1 and Nf1 resulted in STIC 
formation and progression to HGSOC274. These models closely recapitulate the 
histological, genetic and biological features of HGSOC and as such are useful tools in 
understanding the pathogenesis as well as testing new strategies for prevention, 
detection and treatment of HGSOC274. However they have a mixed genetic background 
and the complex breeding protocols mean they are not suitable for extensive pre-clinical 
testing of immuno- and other biological therapies that target the TME275. 
 
 Hypothesis and aims 
The effect of chemotherapy on TAMs in HGSOC is incompletely understood. Previous 
work has shown that chemotherapy may enhance adaptive immune responses within 
the HGSOC TME, yet effector function may be limited by immunosuppression. TAMs are 
a major immunosuppressive force in the TME of HGSOC. Therefore, research into the 
effect chemotherapy has on TAMs in HGSOC may be important in understanding how 
chemotherapy modifies tumour immunity in this disease. This knowledge may facilitate 
the development of rational immunotherapies for HGSOC. 
 
I hypothesise that targeting the recruitment, polarisation and effector function of TAMs 
may improve HGSOC response to chemotherapy as well as having independent anti-
cancer activity.  
 
This hypothesis will be investigated with the following objectives: 
 
1. Explore macrophage phenotypes in metastases of human HGSOC and the 
influence of NACT on their activity, density and location (Chapters 3-5). 
2. Explore macrophage phenotypes in mouse models of HGSOC and the influence 
of chemotherapy on their activity, density and location (Chapters 6, 7). 
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3. Determine the effects of macrophage-targeting agents on mouse models of 
HGSOC alone and in combination with chemotherapy (Chapter 8). 
4. Explore the links between immunogenic cell death and macrophages after 
chemotherapy in HGSOC (Chapter 9). 
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 Buffers, solutions and reagents  
Phosphate-buffered saline (PBS) (1x) 
KCl 0.2 g/L, KH2PO4 0.2 g/L, NaCl 8.0 g/L, Na2HPO4-7H2O 2.16 g/L from Gibco (cat. no. 
141-90-094, Gibco). 
 
PBS-tween (PBST) 
PBS 1x with the addition of 0.1% v/v Tween20 (cat. no. P7949, Sigma-Aldrich). 
 
Blocking buffer (immunohistochemistry) 
2.5% bovine serum albumin (BSA) (cat. no. A4503, Sigma-Aldrich) and 2.5% Goat 
serum (cat. no. B15-035, PAA) in PBS 1x. 
 
Tris-buffered saline (TBS) (10x) 
1.5M NaCl (cat. no. 71380, Sigma-Aldrich) and 200mM Trizma base (cat. no. T1503, 
Sigma-Aldrich) in deionised H2O, pH 7.6. 
 
TBS-tween (1x) 
1:10 dilution of TBS (10x) in deionised H2O with 0.1% v/v Tween20 (cat. no. P7949, 
Sigma-Aldrich). 
 
Complete radioimmunoprecipitation assay (RIPA) lysis buffer 
RIPA buffer (cat. no. R0278, Sigma-Aldrich) supplemented with one tablet of protease 
inhibitor cocktail I (cat. no. 11836153001, Roche) per 10ml, and 1:100 phosphatase 
inhibitor cocktail II (cat. no. P5726, Sigma-Aldrich). 
 
Bicinchoninic acid (BCA) assay reagent 
4% (w/v) copper (II) sulphate (cat. no. C2284, Sigma-Aldrich) diluted 1:50 in BCA (cat. 
no. B9643, Sigma-Aldrich). 
 
3-(N-morpholino)propanesulfonic acid (MOPS) running buffer 
50ml NuPAGE® MOPS sodium dodecyl sulphate (SDS) running buffer (20x) (cat. no. 
NP0001, Thermo Fisher Scientific) in 950ml of deionised H2O. 
 
Transfer buffer 
50ml NuPAGE® transfer buffer (20x) (cat. no. NP0006, Thermo Fisher Scientific) and 
200 ml methanol (cat. no. 11976961, Thermo Fisher Scientific) in 750ml of deionised 
H2O. 
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Blocking buffer (western blotting) 
5% (w/v) non-fat dry milk (Marvel), in 1x TBST. 
 
Fluorescence-activated cell sorting (FACS) buffer 
Dulbecco’s phosphate buffered saline (PBS) (cat. no. 141-90-094, Gibco), pH 7.2, 2.5% 
BSA (cat. no. A4503, Sigma-Aldrich) and 2 mM EDTA (cat. no. AM9262, Ambion). 
 
Methyl green counterstain 
0.5% (w/v) methyl green (cat. no. 67060, Sigma-Aldrich) dissolved in 0.1M sodium 
acetate trihydrate (cat. no. S8625, Sigma-Aldrich) in deionised H2O, pH 4.6. 
 
2.1.1 Antibodies 
Antibody Clone Dilution Company Cat. No. 
CD3 FITC HIT3a 1:100 Biolegend 300306 
CD19 FITC SJ25C1 1:100 Biolegend 363008 
CD20 FITC 2H7 1:100 Biolegend 302304 
CD56 FITC MEM-188 1:100 Biolegend 304604 
CD66b FITC G10F5 1:100 Biolegend 305104 
Siglec8 FITC 7C9 1:100 Miltinyi Biotec 130-098-
715 
HLA-DR BV650 L243 1:100 Biolegend 307650 
CD45 PerCP 2D1 1:100 Biolegend 368606 
CD14 BV510 M5E2 1:100 Biolegend 301842 
CD16 APC-Cy7 B73.1 1:100 Biolegend 360710 
CD11c PE-Cy7 3.9 1:100 Biolegend 301608 
CD1c A700 L161 1:100 Biolegend 331530 
CD123 PE-CF594 7G3 1:100 BD 
Biosciences 
562391 
CD141 APC M80 1:100 Biolegend 344106 
CD163 PE GHI/61 1:100 BD 
Biosciences 
556018 
CXCR1 PE 528728 1:100 R&D Systems FAB5204P 
CD206 PE 19.2 1:100 BD 
Biosciences 
555954 
CD209 PE 9E9A8 1:100 Biolegend 330106 
Table 2.1 Antibodies used for flow cytometry in human samples. 
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Antibody Clone Dilution Company Cat. No. 
CD45 BV785 30-F11 1:100 Biolegend 103149 
CD3 PE-Cy7 145-2C11 1:50 Biolegend 100320 
CD4 PE RM4-4 1:200 Biolegend 116006 
CD8 APC 53-6.7 1:200 eBioscience 17-0081-83 
CD44 BV650 IM7 1:100 Biolegend 103049 
CD62L BV605 MEL-14 1:100 Biolegend 104438 
CD69 FITC H1.2F3 1:100 Biolegend 104506 
PD1 e450 RMP1-30 1:40 eBioscience 48-9981-82 
CD11b A780 M1/70 1:100 eBioscience 47-0112-82 
CD19 Percp5.5 eBio1D3 1:200 eBioscience 45-0193-82 
CD11b BV650 M1/70 1:100 Biolegend 101239 
Ly6G A700 RB6-8C5 1:200 eBioscience 56-5931-82 
Ly6C Percp5.5 HK1.4 1:200 Biolegend 128012 
F4/80 PE BM8 1:100 Biolegend 123110 
PDL1 BV421 10F.9G2 1:80 Biolegend 124315 
MHCII APC/CY7 M5/114.15.2 1:200 Biolegend 107628 
CD206 FITC C068C2 1:100 Biolegend 141704 
CD80 APC 16-10A1 1:100 eBioscience 17-0801-82 
CD86 BV605 GL-1 1:100 Biolegend 105037 
Table 2.2 Antibodies used for flow cytometry in mouse samples. 
 
 
Antibody Clone Dilution Company Cat. No. 
CD3 FITC HIT3a 1:100 Biolegend 300306 
CD19 FITC SJ25C1 1:100 Biolegend 363008 
CD20 FITC 2H7 1:100 Biolegend 302304 
CD56 FITC MEM-188 1:100 Biolegend 304604 
CD66b FITC G10F5 1:100 Biolegend 305104 
Siglec8 FITC 7C9 1:100 Miltinyi Biotec 130-098-
715 
HLA-DR BV650 L243 1:100 Biolegend 307650 
CD45 PerCP 2D1 1:100 Biolegend 368606 
CD14 BV510 M5E2 1:100 Biolegend 301842 
Table 2.3 Antibodies used for flow sorting of human samples. 
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Protein Dilution Species  Cat. no. Company 
CD68 1:8000 Mouse M0814 Dako 
TREML4 1:1100 Rabbit ab204798 Abcam 
PAX-8 1:400 Rabbit NBP1-32440 Novus 
Cleaved caspase-3 1:100 Rabbit 9664S Cell 
Signalling 
F4/80 1:100 Rat MCA497 BioRad 
CD206 1:100 Rat MCA2235 BioRad 
Rabbit IgG1 isotype 
control 
Primary antibody 
dependent 
Rabbit AB-105-C 
 
R&D 
Systems 
Mouse IgG1 isotype 
control 
Primary antibody 
dependent 
Mouse X0931 Dako 
Rat IgG1 isotype 
control 
Primary antibody 
dependent 
Rat 14-4031-81 eBioscience 
Table 2.4 Antibodies used for immunohistochemistry. 
 
Antibody Dilution Species Cat. no. Company 
NLRP3 1:100 Rabbit bs-10021R Bioss Antibodies 
CD68 1:1000 Mouse M0814 Dako 
Anti-rabbit Alexa 
Fluor 488 
1:1000 Goat A11008 Life 
Technologies 
Anti-mouse 
Alexa Fluor 568 
1:1000 Goat  A21050 Life 
Technologies 
Table 2.5 Antibodies used for immunofluorescence. 
 
Antibody Expected 
size [kDa] 
Dilution Species Cat. no. Company 
b-actin 46 1:2000 Mouse A1978 Sigma-
Aldrich 
Cleaved 
caspase-3 
17, 19 1:1000 Rabbit 9664S Cell 
Signalling 
DFNA5 55 1:1000 Rabbit ab215191 Abcam 
Secondary 
anti-mouse 
- 1:2000 Sheep NXA931 GE 
Healthcare 
Secondary 
anti-rabbit 
- 1:2000 Donkey NA9340V GE 
Healthcare 
Table 2.6 Antibodies used for western blotting. 
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Antibody Dilution Species Cat. no. Company 
NLRP3 1:50 Mouse AG-20B-0014-
C100 
AdipoGen 
ASC 1:50 Rabbit AG-25B-0006-
C100 
AdipoGen 
Table 2.7 Antibodies used for proximity ligation assay. 
 
 Patients and samples 
Institutional review board approval was granted for the Barts Gynae Tissue Bank to 
collect and store biological material and clinical information. Patients were treated at St. 
Bartholomew's Cancer Centre and St. George’s Hospital (London, UK) between 2010 
and 2019 and gave written informed consent (REC reference: 15/EE/0151). 
 
 Histology and Immunostaining 
2.3.1 Single stain immunohistochemistry (IHC) 
For immunohistochemical analysis, human tissue samples were fixed in 10% formalin 
solution (cat. no. HT501128, Sigma-Aldrich) for 24 - 72 hours in PBS at room 
temperature, dehydrated in 70% ethanol (cat. no. E/0650DF/17, Fisher Scientific) in 
H2O, embedded in paraffin wax and sectioned by the Pathology Department, Barts 
Cancer Institute. 
 
Paraffin embedded sections were cleared in two changes of xylene (cat. no. X/0100/17, 
Fisher Scientific) for 5 minutes, rehydrated through decreasing series of ethanol 
solutions (100%, 90%, 70% and 50% ethanol in H2O) for 2 minutes each and rehydrated 
in H2O for 3 minutes. Citrate-based Antigen unmasking solution (cat. no. H-3300, Vector 
Laboratories) was preheated to 100°C in a microwave and the slides were placed into 
the antigen retrieval buffer. The temperature of the antigen retrieval buffer was 
maintained at 100°C for 20 minutes using the microwave on a ‘medium’ power setting. 
Afterwards the slides were cooled down for 5 minutes with tap water and washed by 
submersion in 1x PBS. Sections were blocked for endogenous horseradish peroxidase 
(HRP) activity using 0.3% hydrogen peroxide (cat. no. H/1800/15, Fisher Scientific) in 
methanol (cat. no. M/4000/PB17, Fisher Scientific) for 10 minutes. Following submersion 
in 1x PBST for 5 minutes. Tissue sections were delimited using a hydrophobic pen (PAP 
pen, cat. no. H-4000, Vector Laboratories). Tissue sections were blocked with blocking 
buffer for 60 minutes at room temperature. The blocking buffer was then removed and 
primary antibody was applied diluted in blocking buffer (volume 100-250 µl depending 
on the size of the section). Primary antibodies were applied 60 minutes at room 
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temperature. 
 
After three washes for 3 minutes each in 1x PBST, sections were incubated with an 
appropriate HRP conjugated secondary antibody Vector Impact Kit (H-4343, MP-63636, 
Vector Laboratories). Sections were then was three times for 3 minutes each in 1x PBST 
before addition of DAB chromogen followed by washing with tap water to stop further 
DAB development. Counterstaining was performed with haematoxylin (cat. no. GHS116, 
Sigma-Aldrich) for 20 seconds to obtain clear blue nuclear staining. Subsequently the 
sections were dehydrated briefly (7 dips) in 70% ethanol followed by 90% and 100% 
ethanol incubations for 1 minute followed by two xylene incubations for two minutes 
each. Sections were mounted in DPX resin (cat. no. 06522, Sigma-Aldrich) using 100 x 
50 mm coverslips and left to dry over-night at room temperature prior to microscopic 
examination. 
 
2.3.2 Staining of TMAs 
HGSOC biopsy sections obtained from patients following neo-adjuvant chemotherapy 
and contained within a tissue microarray (TMA) were stained with anti-CD68 antibody 
(clone KP1, cat. no. M0814, Dako). Briefly, 4 μm sections were de-paraffinised and 
rehydrated, antigen retrieval was performed in a pressure cooker using citrate-based 
antigen unmasking solution (cat. no: H-3300, Vector Laboratories) followed by staining 
using an autostainer (Dako) using an ultrasensitive HRP Polymer Kit (Biogenex). 
 
2.3.3 Pax-8/CD68 dual colour IHC 
Paraffin embedded sections were cleared in two changes of xylene (cat. no. X/0100/17, 
Fisher Scientific) for 5 minutes, rehydrated through decreasing series of ethanol 
solutions (100%, 90%, 70% and 50% ethanol in H2O) for 2 minutes each and rehydrated 
in H2O for 3 minutes. Antigen unmasking solution (cat. no. H-3300, Vector Laboratories) 
was preheated to 100°C in a microwave and the slides were placed into the antigen 
retrieval buffer. The temperature of the antigen retrieval buffer was maintained at 100°C 
for 20 minutes using the microwave on a ‘medium’ power setting. Afterwards the slides 
were cooled down for 5 minutes with tap water and washed by submersion in 1x PBS. 
Sections were blocked for endogenous horseradish peroxidase (HRP) activity using 
0.3% hydrogen peroxide (cat. no. H/1800/15, Fisher Scientific) in methanol (cat. no. 
M/4000/PB17, Fisher Scientific) for 10 minutes. Following submersion in 1x PBST for 5 
minutes. Tissue sections were delimited using a hydrophobic pen (PAPpen, cat. no. H-
4000, Vector Laboratories). Tissue sections were incubated with IHC blocking buffer for 
60 minutes at room temperature. The blocking buffer was then removed and anti-CD68 
antibody (Table 2.4) was applied diluted in IHC blocking buffer (volume 100-250 µl 
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depending on the size of the section) for 60 minutes at room temperature. 
 
After three washes for 3 minutes each in 1x PBST, sections were incubated with 
ImmPRESS® HRP Anti-Mouse IgG (Peroxidase) Polymer Detection Kit (cat. no. MP-
7402, Vector Laboratories) for 30 minutes at room temperature in accordance with the 
manufacture’s instructions. Sections were then was three times for 5 minutes each in 1x 
PBST. Staining was revealed using the Liquid Dab+ Substrate Chromogen system (cat. 
no. K3468, Dako). Slides were the washed with tap water to stop colour development. 
 
Slides were was washed by submersion in 1x PBS. Sections were blocked for 
horseradish peroxidase (HRP) activity using 0.3% hydrogen peroxide (cat. no. 
H/1800/15, Fisher Scientific) in methanol (cat. no. M/4000/PB17, Fisher Scientific) for 10 
minutes. Following submersion in 1x PBST for 5 minutes. Tissue sections were 
incubated with IHC blocking buffer for 40 minutes at room temperature. The blocking 
buffer was then removed and anti-PAX-8 antibody (Table 2.4) was applied diluted in IHC 
blocking buffer (volume 100-250 µl depending on the size of the section) for 60 minutes 
at room temperature. After three washes for 3 minutes each in 1x PBST, sections were 
incubated with ImmPRESS® HRP Anti-Rabbit IgG (Peroxidase) Polymer Detection Kit 
(cat. no. MP-7415, Vector Laboratories) for 30 minutes at room temperature in 
accordance with the manufacture’s instructions. Sections were then was three times for 
5 minutes each in 1x PBST. Staining was revealed using the VIP Peroxidase (HRP) 
Substrate Kit (cat. no. SK-4600, Vector Laboratories). Slides were the washed with tap 
water to stop colour development. 
 
Counterstaining was performed with methyl green applied for 10 minutes at 60°C. 
Subsequently the sections were dehydrated briefly (7 dips) in 70% ethanol followed by 
90% and 100% ethanol incubations for 1 minute followed by two xylene incubations for 
two minutes each. Sections were mounted in DPX resin (cat. no. 06522, Sigma-Aldrich) 
using 100 x 50 mm coverslips and left to dry over-night at room temperature prior to 
microscopic examination. 
 
2.3.4 Mouse Immunohistochemistry 
Omental biopsy sections were fixed for 24 – 72 hours in 4% PFA and transferred to 70% 
ethanol prior to paraffin embedding. 4μm sections were cut by microtome in the Bart’s 
Cancer Institute Pathology Department. Briefly, sections were de-paraffinised and 
rehydrated through an alcohol series, proteinase K (cat. no. P2308 Sigma-Aldrich) 
antigen retrieval was performed in CaCl2 buffer at 37°C for 20 minutes. Endogenous 
peroxidase blocking was performed in 0.3% hydrogen peroxide in methanol for 20 
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minutes. Slides were incubated in IHC blocking buffer for 60 minutes at room 
temperature. Slides were then incubated with primary antbody (Table 2.4) followed by 
incubation with Impress anti-Rat IgG kit (cat. no: MP-7444, Vector Laboratories). 
Staining was revealed using the Liquid Dab+ Substrate Chromogen system (cat. no. 
K3468, Dako) followed by washing with tap water to stop further DAB development. 
Counterstaining was performed with haematoxylin (cat. no. GHS116, Sigma-Aldrich) for 
20 seconds to obtain clear blue nuclear staining. Subsequently the sections were 
dehydrated briefly (7 dips) in 70% ethanol followed by 90% and 100% ethanol 
incubations for 1 minute followed by two xylene (cat. no. X/0100/17, Fisher Scientific) 
incubations for two minutes each. Sections were mounted in DPX resin (cat. no. 06522, 
Sigma-Aldrich) using 100 x 50 mm coverslips and left to dry over-night at room 
temperature prior to microscopic examination. 
 
2.3.5 Haematoxylin and eosin (H&E)  
Sections were stained with H&E by the Pathology department of the Barts Cancer 
Institute.  
 
2.3.6 Digital quantification of IHC and H&E staining 
Immunohistochemistry and H&E sections were imaged using the Panoramic digital slide 
scanner (3DHISTECH). Definiens® digital image analysis was used to quantify staining 
and determine location within tumour islands and stromal areas. Scanned images were 
imported into a Definiens® workspace. The entire tissue area sample or TMA core was 
selected manually. Within the tissue area ‘regions of interest’ (tumour and stroma areas) 
were selected using the built-in automated algorithms within the Definiens® software. 
The software-determined tumour and stromal separation for the entire tissue sample was 
reviewed (with the oversight of Consultant Gynaecological Pathologist, Dr. Jacqueline 
McDermott) prior to proceeding to analysis of the straining characteristics within the 
tumour and stromal areas of the biopsy. 
 
 Mouse models 
FVB-NCrl and C57BL/6 wild type mice (aged 8-9 weeks) were purchased from Charles 
River Laboratories and were acclimatised for 1 week prior to the initiation of the studies. 
Mice were housed under sterile conditions in individually ventilated cages, a maximum 
of five per cage, fed with standard chow diet and water ad libitum, and maintained on an 
automatic 12 hour light cycle at 22–24°C. All studies were conducted using sterile 
techniques in accordance with the guidelines of the Animal Care Committee and the 
Procedures Project License (70/7411 and PBE3719B3). 
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60577, 30200 or HGS2 cells were grown in mouse cell line media (as below) 271,272. At 
the commencement of the experiment mice received 1x107 cells injected i.p. in 300μL 
PBS.  
 
2.4.1 Chemotherapy treatment 
Carboplatin (Hospira) and paclitaxel (Hospira) were obtained from the pharmacy at St. 
Bartholomew’s Hospital, London, were dissolved in 0.9% NaCl, and were administered 
to mice i.p. in 300μL volume. Mice were treated with carboplatin 20mg/kg, paclitaxel 
10mg/kg or the combination of carboplatin 20mg/kg + paclitaxel 10mg/kg, based on 
average weight of all mice in the experiment. Vehicle-treated controls were treated in an 
identical manner to chemotherapy treated mice and received either 0.9%Nacl or 
cremophor (cat. no. C5135, Sigma-Aldrich) / ethanol (cat. no. 51976, Sigma-Aldrich) 
(1:1) dissolved in 0.9%NaCl. 
 
2.4.2 CSF-1Ri treatment 
AZD7507 was obtained from AstraZeneca. AZD was dissolved in 0.5% (w/v) methyl 
cellulose (cat. no. M7027, Sigma-Aldrich) and 0.1% (v/v) Tween-80 (cat. no. P4780, 
Sigma-Aldrich) in deionised H2O and administered to mice at 100mg/kg twice daily by 
oral gavage, based on an average weight of all mice in the experiment. Treatment was 
administered to mice on weekdays, on weekends no treatment was given. BLZ945 (cat. 
no. HY-12768, MedChemTronica) was dissolved in 10% sulfobutylether-b-cyclodextrin 
(cat. no. HY-17031, MedChemTronica) in deionised H2O and administered to mice at 
200mg/kg once daily by oral gavage. Treatment was administered to mice on weekdays, 
on weekends no treatment was given. 
 
2.4.3 Survival end point determination 
Mice were assessed daily and weighed twice weekly. Assessment of survival endpoint 
was based on ‘moderate’ severity as per the project license. The survival endpoint for 
mice was defined as a change in general health, specifically 15% body weight loss over 
72 hours or 20% over any time period, or inability to ambulate, or hunched posture, or 
difficulty breathing or signs of hypothermia as well as signs of ascites or palpable 
tumours exceeding an estimated size of 1cm diameter. In survival experiments 
assessment of mice was made twice daily by the same individual to limit interobserver 
variability. Furthermore, in the majority of cases survival determinations were made by a 
trained animal technician who was not directly involved in the experimental design. 
 
Chapter 2: Materials and Methods 
 66 
 Flow cytometry 
2.5.1 Human stromal vascular fraction extraction 
Human omental biopsy specimens were received directly from the operating theatre from 
patients undergoing primary surgery or interval debulking surgery for confirmed or 
presumed HGSOC. Samples were processed as rapidly as possible and generally 
processing was completed within 5-7 hours from sample resection. Omental samples 
were treated enzymatically and mechanically to obtain a stromal vascular fraction (SVF). 
Samples were dissected into small pieces using a scalpel, incubated with collagenase D 
from Clostridium histolyticum 1mg/mL (cat. no. 11088866001, Roche) and DNAse I from 
bovine pancreas 25mg/mL (cat. no. D4513, Sigma-Aldrich) in 5% FBS RPMI (cat. no. 
R8758, Sigma-Aldrich) media for 30 minutes under agitation. The solution was then 
filtered through a 70μm strainer (cat. no. 352350, Falcon), followed by red blood cell lysis 
(cat. no. 555899, BD Biosciences) diluted 1:10 in water for 5 minutes, followed by 
washing with 5% FBS RPMI. The resulting cell suspension was stained with a panel of 
antibodies for flow cytometry analysis. 
 
2.5.2 Human immunostaining for flow cytometry 
SVF obtained from human samples were stained in FACS buffer for 30 minutes at 4°C 
in a V-bottomed 96-well plate (cat. no. 2605, Thermo Fisher). Cells were stained using 
the antibodies at the concentrations listed in Table 2.1. Cells were washed three times 
with 100µl PBS 1x and subsequently stained with FVD450nm or DAPI (cat. no. 65-0863-
14, eBioscience) at a dilution of 1:2000 (stock concentration: 5 mg/ml) in 50 µl PBS for 
25 minutes at 4°C. After three washing steps with FACS buffer, the cells were fixed by 
adding 2% formalin (cat. no. HT501128, Sigma-Aldrich) in 1.25% BSA and 1mM EDTA 
in 1x PBS for 10 minutes at 4°C. After the fixation the cells were washed three times, 
centrifuged and transferred in a total volume of 100µl FACS buffer and analysed with on 
a LSR Fortessa II flow cytometer (BD Biosciences). Compensation was performed on 
DIVA software using One Comp eBeads (cat. no. 01-1111-42, eBiosciences) with the 
exception for FVD450nm, which was compensated using the ArCTM Amine Reactive 
Compensation Bead kit (cat. no. A10346, ThermoFisher Scientific). The results were 
analysed using FlowJo v10.2 (Treestar Inc.) with tSNE plugins installed. 
 
2.5.3 Cell sorting of human samples 
SVF obtained from human samples or human stained in FACS buffer for 30 minutes at 
4°C. Cells were stained using the antibodies at the concentrations listed in Table 2.3. 
Cells were then stained with DAPI (cat. no. 422801, Biolegend) 1:2000 (stock 
concentration: 5 mg/ml) immediately prior to sorting. FITC-HLA-DR+CD14+ cells were 
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then sorted using a FACSAria II cell sorter (BD Bioscience). Cells were sorted into 5% 
FBS RPMI 1640 media (cat. no. 21875-034, Gibco) maintained at 4°C. 0.25-2x106 cells 
were sorted per sample. A purity check was performed following sorting completion. Cell 
purities of >96% were obtained. Cells were them centrifuged at 1500rpm for 10 minutes 
at 4°C. Cells were then lysed in RLT buffer (cat. no. 1015750, Qiagen) supplemented 
with 1% β-mecaptoethanol (cat. no. M-6250, Sigma-Aldrich). The cell lysate was snap 
frozen on dry ice and stored at -80°C prior to RNA extraction. 
 
2.5.4 Mouse stromal vascular fraction extraction 
Mice were culled by cervical dislocation. A laparotomy was performed and the mouse 
greater omentum was dissected in its entirety from surrounding structures and placed in 
PBS at 4°C. Omenta were weighed using a AM100 analytical balance (Mettler). A 2-
3mm biopsy of each resected omentum was taken at the centre and fixed in 4% PFA. 
The sample for digestion was then re-weighed. This sample was cut into pieces 
approximately 1 mm2 and digested in Hanks Balanced Salt Solution (cat no. 9374543, 
Gibco) supplemented with Collagenase from Clostridium histolyticum (Sigma, cat. no. 
C9263) and DNAase I from bovine pancreas for 20 minutes on an rotational platform at 
140rpm at 37°C. The resulting digest was then passed through a 70μm cell strainer and 
flushed with FACS buffer. The resulting cell suspension was centrifuged at 1500rpm for 
10 minutes. Cells were then resuspended in FACS buffer and concentration and viability 
assayed using a Vi-CELL Analyser (Beckman Coulter). 
 
2.5.5 Mouse immunostaining for flow cytometry 
SVF obtained from murine omenta were stained in FACS buffer for 30 minutes at 4°C. 
Cells were stained using the antibodies at the concentrations listed in Table 2.2. Cells 
were then washed 3 times in PBS 1x and stained separately with FVD506nm (cat. no. 65-
0866-14, eBiosciences,) for 20 minutes in 100μL PBS at 4°C. Cells were then washed 
once in FACS buffer and were then fixed in 2% PFA in PBS containing 1.25% BSA and 
1nM EDTA for 10 minutes at 4°C. After the fixation the cells were washed three times, 
centrifuged and transferred in a total volume of 100µl FACS buffer and analysed with on 
a LSR Fortessa II flow cytometer (BD Biosciences). Appropriate fluorescence minus one 
controls were used. Data analysis was performed in FlowJo v10.2 (Treestar Inc.) with 
tSNE plugins installed. 
 
2.5.6 Cell sorting of murine samples 
SVF obtained from murine tumour samples were stained in FACS buffer for 30 minutes 
at 4°C. Cells were stained using the antibodies at the concentrations listed in Table 2.2. 
Cells were then stained with DAPI (cat. no. 422801, Biolegend) 1:2000 (stock 
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concentration: 5 mg/ml) immediately prior to sorting. FITC-HLA-DR+CD14+ cells were 
then sorted using a FACSAria II cell sorter (BD Bioscience). Cells were sorted into 5% 
FBS RPMI 1640 media (cat. no. 21875-034, Gibco) maintained at 4°C. 0.25-2x106 cells 
were sorted per sample. A purity check was performed following sorting completion. Cell 
purities of >96% were obtained. Cells were them centrifuged at 1500rpm for 10 minutes 
at 4°C. Cells were then lysed in RLT buffer (cat. no. 1015750, Qiagen) supplemented 
with 1% β-mecaptoethanol (cat. no: M-6250, Sigma-Aldrich). The cell lysate was snap 
frozen on dry ice and stored at -80°C prior to RNA extraction. 
 
2.5.7 t-distributed stochastic neighbour embedding (tSNE) analysis 
tSNE analysis was performed using FlowJo v10.2 (Treestar Inc.). 2,500 CD45+ events 
for each sample were selected using the FlowJo downsample plugin. FACS data relating 
to an entire murine experiment were concatenated into a single .fcs data file. Within a 
FlowJo workspace dimensionality reduction was performed using the tSNE algorithm. 
The resulting tSNE plots were analysed using FlowJo v10.2 (Treestar Inc.). 
 
 RNA extraction 
RNA was extracted from the FACS-sorted TAM population using the micro RNAEasy kit 
(cat. no. 74004, Qiagen) utilizing the on column DNAse digestion step as per the 
manufactures recommended protocol. RNA was eluted in 12μl volume. Purity and 
integrity was assessed using Nanodrop and RNA NanoChip (cat. no. 5067-1511, Agilent) 
and RIN (RNA integrity number) values were ≥8.60. 
 
 RNA sequencing 
RNA Sequencing was carried out at the Wellcome Trust Centre for Human Genetics. 
Library preparation was with RNA-Seq Ribozero and sequencing was performed with 
HiSeq4000, 150bp read-length, paired-end, strand specific and a coverage of 
approximately 40 million reads per sample. Raw reads were aligned to the reference 
genome GRCh37 (hg19). The number of reads aligned to the exonic region of each gene 
were counted using htseq-count based on the Ensembl annotation. Only genes that 
achieved at least one read count per million reads (CPM) in at least 25% of the samples 
were kept. This led to 17,184 filtered genes in total, 13,259 of which were protein-coding 
genes. Conditional quantile normalisation (cqn) was performed counting for gene length 
and GC content and a log2 transformed RPKM expression matrix was generated. 
Differential expression analysis was performed using the edgeR R package. The 
generalized linear model (GLM) approach was used for the differential analysis. All 
bioinformatics and graphical analysis of the data was performed by Dr. Eleni Maniati in 
the statistical programming language R (version 3.1.3). 
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 Cell lines and culture conditions  
 
2.8.1 Human cell line culture 
Human cell lines  
G164 
G33 
AOCS1 
Table 2.8 Human cell lines 
 
Table 2.8 shows the human cell lines used in this project.  Cells were grown in 
DMEM/F12 with Glutamax (cat.no 31331-093, Gibco) supplemented with 4% human 
serum (cat. no. H4522, Sigma-Aldrich) and 100ug/ml pen/strep (cat. no. 15140-122, 
Gibco) (G164) or 10% FBS (cat. no. SV30160.03, lot. no. RXL35906, HyClone) and 
100ug/ml pen/strep (cat. no. 15140-122, Gibco) and ITS (cat. no. 51300-044, Gibco) 
(G33, AOCS1) on non-precoated tissue culture plastic. When splitting cells 0.5% trypsin-
EDTA (cat. no. 15400-054, Gibco) diluted 1:10 in PBS was used. 
 
2.8.2 Murine cell line culture 
Mouse cell lines  
30200 
60577 
HGS2 
Table 2.9 Murine cell lines. 
Two mouse HGSOC cell lines (30200 and 60577) were obtained in collaboration with 
the National Cancer Institute, USA271,272. Both mouse cell lines are Rb, p53 and Brca-1 
deficient and therefore accurately recapitulate the genetic lesions of HGSOC271,272. 
HGS2 cell line was derived from the fallopian tube and ovary of a doxycycline-induced 
mouse from a GEMM276 where Pax8-Cre drives inducible inactivation of Brca2, Trp53, 
and Pten (Brca2-/-;Trp53-/-;Pten-/-) in the fallopian tube. Mouse cell lines were cultured in 
DMEM/F12 with Glutamax (cat. no. 31331-028, Gibco) supplemented with insulin, 
transferrin, sodium selenite, sodium pyruvate, hydrocortisone, EGF from murine 
submaxillary gland, FBS, penicillin, streptomycin and amphotericin B at the 
concentrations outlines in Table 2.10. Cells were grown at 37°C 5% CO2 on non-
precoated tissue culture plastic. When splitting cells 0.5% trypsin-EDTA (cat. no. 15400-
054, Gibco) diluted 1:10 in PBS was used and inactivated with DMEM/F12 with Glutamax 
(cat. no. 31331-028, Gibco).  
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Supplement Concentration Catalogue number Company 
Fetal bovine serum 4% (v/v) SV30160.03 
Lot No: RXL35906 
HyClone 
Insulin 10ug/ml 51300-044 Gibco 
transferrin 5.5ug/ml 51300-044 Gibco 
sodium selenite 6.7ng/ml 51300-044 Gibco 
sodium pyruvate 110ug/ml 51300-044 Gibco 
hydrocortisone 0.5ug/ml H0135 Sigma 
Murine epidermal growth 
factor 
0.2µg/ml E4127 Sigma 
Penicillin 200units/ml 15240-062, P4333 Gibco, Sigma 
Streptomycin 200µg/ml 15240-062, P4333 Gibco, Sigma 
Amphotericin B 0.25µg/ml 15240-062, P4333 Gibco, Sigma 
Table 2.10 Supplements required for mouse cell line culture 
Routine testing for mycoplasma contamination using the MycoAlert PLUS Mycoplasma 
Detection Kit (cat. no. LT07-710, Lonza) has been consistently negative. 
 
2.8.3 Freezing and recovery of cell lines 
Cells were frozen in 1ml 10% of dimethyl sulfoxide (DMSO) (cat. no. D2650, Sigma-
Aldrich) in fetal bovine serum (cat. no. SV30160.03, lot. no. RXL35906, HyClone). Cells 
were stored at -80°C over-night prior to long-term storage in liquid nitrogen at -196°C. 
Cells were recovered from liquid nitrogen by thawing at 37°C prior to addition to 10ml 
DMEM/F12 medium with appropriate supplements. Cells were collected by 
centrifugation at 1400rpm for five minutes, re-suspended in DMEM/F12 medium with 
appropriate and added to a T75 culture flask (cat. no. CLS430641, Corning, Sigma-
Aldrich).  
 
 In vitro cell viability assay 
Cells were plated into 6 well plates at a density of 1x105 cells/well. Media was replaced 
with media alone or media containing variable concentrations of carboplatin (Hospira) or 
paclitaxel (Hospira) obtained from St. Bartholomew’s Hospital pharmacy. Cells were 
incubated with media supplemented with chemotherapeutic agent for 48 hours. The 
media was then aspirated and cells were fixed and stained in 70% ethanol (cat. no. 
51976, Sigma-Aldrich) + 0.5% crystal violet (cat. no. C0775, Sigma-Aldrich). Plates were 
washed and air-dried. The resulting crystal violet staining was dissolved in 10% acetic 
acid (cat. no. W200603, Sigma-Aldrich) and transferred to an optically clear 96 well plate 
(cat. no. 3690, Costar). The optical density at 595nm (OD595) was quantified using a plate 
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reader (Dynex Technologies). 
 
OD595 measurements for each concertation of chemotherapeutic agent were normalised 
to the media only control and plotter in Prism v7.0 and curves were fitted using the 
‘log(agonist) vs response - variable slope’ equation. 
 
 Terminal deoxynucleotide transferase dUTP nick end labelling (TUNEL) 
Assay 
The Novus Biologicals APO-BRDU-IHC reagent kit (cat no. NBP2-31164, Novus 
Biologicals) was used in accordance with the manufacturer’s instructions following the 
staining protocol for paraffin embedded tissue. 4μm sections of FFPE tissue were cut by 
the Bart’s Cancer Institute Pathology Department. Kit positive control in addition to a 
tissue positive control section, produced by incubation of sections for 30 mins with 1ug/ml 
DNAse in 1xPBS + 1mM MgSO4, were stained within the experiment. Sections were de-
paraffinised in xylene (cat. no. X/0100/17, Fisher Scientific) and rehydrated through an 
ethanol (cat. no. E/0650DF/17, Fisher Scientific) series (100%, 90%, 80%, 70%) and 
washed in PBS. Slides were then incubated with proteinase K solution for 20mins at RT. 
Slides were then washed in PBS followed by endogenous peroxidase blocking by 
incubating slides with 3% hydrogen peroxide in methanol for 5 minutes at toom 
temperature followed by washing in PBS. Slides where then equilibrated in reaction 
buffer followed by addition of labelling reaction (reaction buffer, TdT enzyme, Br-dUTP 
and distilled water), the sections were then incubated in a humidified chamber for 1.5 
hours at 37˚C. The slides were then washed in 1x PBS followed by incubation with 
Blocking buffer for 10mins at room temperature. Following this, slides were incubated 
with biotinylated BrDU antibody for 1.5 hours at room temperature. The slides were 
washed in PBS followed by incubation with 1x conjugate solution for 30 minutes at room 
temperature. After washing in PBS the slides were incubated with DAB for 15 minutes, 
slides were washed in water followed by counterstaining with methyl green. Slides were 
then cover slipped using permanent mountant (cat. no. 06522, Sigma-Aldrich). Sections 
were then imaged on an Axiophot microscope (Zeiss). 
 
 Cytokines MSD V PLEX Assay 
Lysates were analysed on a V-PLEX Proinflammatory panel 1 (human) kit (cat. no. 
K15049, Mesoscale), according to manufacturer’s instructions. Briefly, the plate was 
washed three times with Wash buffer, 50 µl of sample and the calibration curve were 
added and incubated for two hours. The plate washed again three times with Wash 
buffer, then the detection antibody was added and incubated for two hours. Following 
three washes with Wash buffer, 150 µl of 2X Read buffer were added, and the plate was 
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analysed on MDS QuickPlex SQ 120 (Mesoscale). 
 
 Proximity ligation assay (PLA) 
The PLA assay was performed using the Duolink PLA Fluorescence kit (cat. nos. 
DUO92002, DUO92004, DUO92014, Sigma-Aldrich) Cells were grown on 13mm glass 
coverslips (VWR). Prior to starting the PLA assay cells were fixed in 10% formal saline 
(cat. no. HT501128, Sigma-Aldrich) for 10 minutes at toom temperature. The cells were 
then washed three times in PBS at room temperature and stored in PBS at 4C. Cells 
were permeabilised in 0.5% Triton-X100 (cat. no. T8787, Sigma-Aldrich.) in PBS (cat. 
no. D8537, Sigma-Aldrich) for 10 minutes at room temperature. Cells were then washed 
blocked in 5% BSA (A4503, Sigma-Aldrich) in PBS for 60 minutes at room temperature. 
Following this, cells were incubated with primary antibodies (see table 2.7) overnight at 
4°C. Cells were then washed three time in 0.1% Triton-X100 in PBS for 10 minutes each 
wash. The cells were then incubated with PLA probes (DUO92002, DUO92004, Sigma-
Aldrich) for 60 minutes at room temperature. The cells were then washed three times 
with 0.1% triton x-100 for five minutes each. The ligation reaction was then applied to 
the cell and the cells were incubated at 37°C in a humidity chamber for 30 minutes. 
Following this the cells were washed twice in 0.1% triton X100 for 3 minutes each. The 
polymerisation reaction was then applied to the cells and the cells were incubated at 
37°C in a humidity chamber for 100 minutes in the dark. The cells were then washed 
three times in 0.1% Triton X-100 for 5 minutes each wash. Cells were then stained with 
1µg/ml DAPI (cat. no. 40043, Biotium) applied to cells for 3 minutes followed by three 
five-minute washes in PBS. The coverslips were then mounted on Polysine glass slides 
(cat. no. 631-0107, VWR) using FluorSave reagent (cat. no. 345789, Calbiochem). 
Slides were stored at 4°C in the dark. Cells were imaged the next day on a LSM 710 
confocal microscope. Approximately 30 cells were images using 63x objective under oil 
immersion. LSM files were exported and analysed in Fiji v1.2 software. 
 
2.12.1 Quantification of PLA signals 
LSM files were opened in Fiji v1.2. Regions of interest were drawn manually around each 
cell based on the position of the nucleus and the green fluoresces within the cell. Within 
the green channel of the image the “find maxima” process was used to isolate the green 
specs individual points. For each ROI the number of maxima points was counted by the 
software and manually recorded. The sample settings were used across all samples in 
the analysis.  
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 Leucocyte cone monocyte isolation 
Human blood from anonymous healthy donors were obtained from leucocyte cones from 
the NHS Blood and Transplant service. Leucocyte cones contain leukocytes that are 
collected as a by-product from individuals donating platelets via apheresis. To isolate 
peripheral blood mononucleated cells (PBMCs), blood was diluted 1:10 with PBS (cat. 
no. D8537, Sigma Aldrich) and a total volume of 25ml of diluted blood was overlaid onto 
15ml Ficoll-Paque PLUS (cat. no. 17-1440-03 AG, GE Healthcare) at room temperature. 
The samples were centrifuged at 2600rpm for 20 minutes at room temperature without 
braking. PBMCs located at the interface of the Ficoll and the plasma were collected and 
centrifuged at 300g for 10 minutes with interim washes with PBS for three times. The 
cells were counted and an appropriate volume (20µl beads per 107 cells) of CD14+ beads 
(cat. no. 130-050-201, Miltenyi) was added to the cells and incubated for 15 minutes at 
4°C. According to the manufacturer’s instructions, CD14+ monocytes were isolated from 
PBMCs by labelling with CD14 microbeads (cat. no. 130-050-201, Miltenyi) and 
magnetic isolation on LS columns (cat. no. 130-042-401, Miltenyi). Subsequently the 
cells were seeded onto 6-well plates at a seeding density of 1.5 million per well in RPMI-
1640 (cat. no. 31870-074, Invitrogen) supplemented with 10% foetal calf serum (FCS) 
cat. no. SV30160.03, lot. no. RXL35906, HyClone), 100 µg/ml penicillin/streptomycin 
(pen/strep) (cat. no. 15140-122, Gibco) and 100 ng/ml recombinant human (rh) 
macrophage colony stimulating factor (MCSF) 1 (cat. no. 574806, Biolegend). 
Monocytes were differentiated to macrophages for seven days and cell surface marker 
expression was assessed by flow cytometry to check for CD14+ cell purity. For 
macrophage re-plating, the cells were washed with PBS and incubated with cell 
dissociation buffer (cat. no. 13151014, Gibco) for 15 minutes at 37°C. For complete 
detachment the cells were scraped of the tissue culture plastic using a cell scraper (cat. 
no. 353085, Falcon) and washed twice with PBS before reseeding at the desired cell 
concentration or staining for flow cytometry analysis.  
 
2.13.1 Monocyte differentiation and polarisation  
Differentiated macrophages (monocytes incubated for seven days in 100 ng/ml rhMCSF 
[cat. no. 574806, Biolegend]), were treated with various recombinant human cytokines 
to polarise them towards a pro- or anti-inflammatory phenotype. The cytokine 
concentrations used are listed in Table 2.11.  
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Cytokine Concentration Cat. no. Company 
IL-4 20ng/ml 200-04 Peprotech 
IL-10 20ng/ml 200-10 Peprotech 
IFNγ 10ng/ml 300-02 Peprotech 
LPS  100ng/ml L2630 Sigma Aldrich  
Table 2.11 Recombinant human cytokines used for macrophage polarisation. 
 
During all culture conditions 100ng/ml rhMCSF was added to the medium. The cells were 
stimulated for 72 hours. Cells were then detached for flow cytometric analysis or for 
protein lysates and medium was kept for MSD analysis (stored at -20°C).  
 
 Protein detection 
2.14.1 Protein extraction 
Cells were washed with cold PBS (cat. no. D8537, Sigma-Aldrich) and lysed with a RIPA 
cell lysis buffer (cat. no. R0278, Sigma-Alrich) containing 1:10 complete mini EDTA 
protease inhibitor (cat. no. 11836153001, Roche) and 1:100 phosphatase inhibitor 
cocktail (cat. no. P5726, Sigma-Alrich). Adherent cells were detached using a cell 
scraper (cat. no. 353085, Falcon) and the cell lysate was centrifuged at 4°C for 10 
minutes at 13200 rpm. The protein supernatant was collected and the concentration was 
calculated using the BCA assay (see paragraph 2.14.2).  
 
2.14.2 Bicinchroninic acid (BCA) assay  
Protein standard concentrations were prepared using BSA (cat. no. A4503, Sigma-
Aldrich) at a concentration of 0, 0.2, 0.4, 0.6, 0.8 and 1.0µg/µl. 10µl of each standard is 
measured in duplicates in a 96-well plate (cat. no.3599, Costar). The protein samples 
were diluted 1:5 and were measured in triplicates. 4% (w/v) copper (II) sulphate solution 
(cat. no. C2284, Sigma-Aldrich) was added to bicinchroninic acid (cat. no. B9643, Sigma-
Aldrich) at a ratio of 1:50 and 200µl was added to each condition. The plate was 
incubated for 30 minutes at 37°C. Subsequently the absorbance was measured at 
595nm using the Opsys MR plate reader (Dynex technology) and the Revelation 
Quicklink software. 
 
2.14.3 Western blotting 
Western blotting was performed using 10-well or 15-well 4-12% NuPAGE Bis-Tris pre-
cast gels (cat. no. NP0335BOX (10-well), NP0336BOX (15-well), Invitrogen). 4x 
Chapter 2: Materials and Methods 
 75 
NuPAGE LDS sample buffer (cat. no. NP0007, Invitrogen) and 10x NuPAGE sample 
reducing agent (cat. no. NP0009, Invitrogen) were added to 20-35µg protein to achieve 
a 1x dilution. Protein samples were heated to 70°C for 10 minutes and centrifuged prior 
to loading. Gel electrophoresis was performed using an XCell SureLock mini-cell (cat. 
no. EI0001, ThermoFisher Scientific) system. The gel was run at 150V for 1.5 hours (first 
30 minutes at 90V) in 1x MOPS SDS running buffer (cat. no. NP0001, Invitrogen). The 
running buffer of the inner chamber was supplemented with NuPAGE anti-oxidant 
solution (cat. no. NP0005, Invitrogen) at a dilution 1:400. 7µl of ColorPlus pre-stained 
protein ladder (cat. no. P7711S, New England Biolabs) were used to visualise the protein 
weight [kDa]. After running the gel, the resolved proteins were transferred onto a 
PolyScreen® polyvinyl fluoride hybridisation transfer membrane (cat. no. 
NEF1002001PK, Perkin Elmer). The mini Trans-Blot cell (Biorad) transfer cassette was 
built of a sandwich of the gel placed next to a methanol (cat. no. 11976961, Thermo 
Fisher Scientific) activated PVDF membrane, lined by two Whatman chromatography 
papers (cat. no. 3030-6189, Whatman) on each side and surrounded by Scotch-Brite 
pads. The tray holding the sandwich was placed into the transfer tank, cooled by an ice 
pack, and the chamber was filled with 1x NuPAGE transfer buffer (cat. no. NP0006-1, 
Invitrogen). The protein transfer was performed at 100V for 1.5 hours. 
 
2.14.4 Immunodetection  
Non-specific antibody binding was inhibited using 5% skimmed milk powder (Marvel) in 
1x TBST. The membrane was blocked for one hour at room temperature on a shaker. 
The primary antibody (see) was diluted in blocking buffer and the membrane was 
incubated over-night at 4°C. After three times five-minute washing steps in 1x TBST the 
membrane was incubated with a secondary antibody conjugated to HRP (see Table 
2.12) for one hour at room temperature. Following additional three times five-minute 
washes in 1x TBST the HRP activity was visualised with Amersham enhanced 
chemiluminescence (ECL) Western Blotting Detection Reagent (cat. no. RPN2232, GE 
Healthcare) or the Luminata Forte Western HRP substrate (cat. no. WBLUF0500, 
Millipore) and the Amersham Imager 600 (GE Healthcare).   
 
2.14.5 Immunofluorescence staining 
Cells grown on glass slides were washed with PBS, fixed in 10% formalin (cat. no. 
HT501128, Sigma-Aldrich) for 10 minutes and stored in PBS (cat. no. D8537, Sigma-
Aldrich) at 4°C prior to staining. Cells were permeabilised for 15 minutes in PBS solution 
containing 0.2% (v/v) Triton-X100 (cat. no. T8787, Sigma Aldrich) and blocked in PBS 
solution supplemented with 2% BSA (cat. no. A4503, Sigma-Aldrich) for one hour at 
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room temperature. Samples were incubated with primary antibody (see Table 2.5) in 
PBS containing 2% BSA at room temperature for one hour. Glass slides were then rinsed 
three times with PBS for five minutes and the secondary detection antibody (see Table 
2.5) at a 1:1000 dilution was incubated for one hour at room temperature. Cells were 
counterstained with 1µg/ml DAPI (cat. no. 40043, Biotium) and washed three times in 
PBS for 10 minutes in order to remove excess dye. Glass slides were mounted using 
FluorSave Reagent (cat. no. 34589, Calbiochem) and, once dried, analysed using a 
Zeiss 710 confocal microscope (Zeiss). 
 
 Statistical Analysis  
Graphic representation of data and statistical analysis was performed in the programme 
Prism Version 7.0. Data was tested for normality using the Kolmogorov-Smirnov test. If 
the data was normally distributed an unpaired Student's t-test was used for analysis of 
differences between two groups. Non-parametric data was tested using a Mann-Whitney 
test. For multivariate data analysis, one or two-way analysis of variance (ANOVA) was 
used for assessment of group differences with Turkey’s post-test applied. Kaplan Meier 
curves were used to show survival and Log-rank Mantel-Cox test applied to assess for 
differences. A p-value below 0.05 was used to define significance. 
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3t The effects of chemotherapy on TAM density and localisation in HGSOC patients 
 Background 
The aim of this thesis is to investigate the effects of chemotherapy on myeloid cells in 
the tumour microenvironment of HGSOC. As described in detail in Chapter 1, there are 
conflicting reports on the effects of chemotherapy on TAM density. For instance, 
DeNardo et al. showed recruitment of macrophages into breast tumours following 
paclitaxel treatment222 and Nakasone et al. demonstrated that CCR2-dependent 
macrophage recruitment following chemotherapy220. However, other studies have shown 
either depletion or no change in TAM density following chemotherapy188,277–279.  
 
The omentum is the disease site studied throughout this thesis. This was chosen as it 
represents the most common metastatic site of HGSOC and is the principle site of 
disease studied in the lab113,114,280. Furthermore, omentum is routinely used for 
percutaneous diagnostic biopsy and its surgical accessibility means it can be resected 
separately from the pelvic mass, allowing rapid tissue processing following surgical 
devascularisation. 
 
 Patient cohorts 
The gold standard treatment for advanced ovarian cancer has been primary 
cytoreductive surgery followed by adjuvant chemotherapy281. More recently clinical 
evidence supports NACT followed by interval cytoreductive surgery49. In this thesis I 
have studied matched omental biopsies from patients with FIGO stage IIIC and stage IV 
HGSOC, before and after NACT using a tissue resource collected by Dr. Steffen Böhm113 
(Table 3.1). This fully annotated set of human samples allows for correlations between 
clinical data, myeloid cell density and phenotype. Additionally, I have used a cohort of 
unmatched omental samples obtained from treatment naïve patients or from patients 
who received NACT (Table 3.2). These samples were provided under ethical approval 
from Barts Cancer Institute Tissue Bank and St. George’s Hospital, London. 
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Table 3.1 Clinical characteristics of patients from whom matched biopsies are used in this 
thesis. Patient ID, description of histological diagnosis, FIGO stage, chemotherapy regime and 
pre/post-chemotherapy status are listed for each patient. 
  
Patient ID Histology Stage Chemotherapy regime Pre/Post
G4 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G17 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G29 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G57 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G61 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G64 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel+ Bevacizumab Matched Pre and Post
G67 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G68 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Matched Pre and Post
G75 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G77 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G95 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G98 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G100 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G102 High-grade serous primary peritoneal carcinoma 3C Carboplatin + Paclitaxel Matched Pre and Post
G105 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G109 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Matched Pre and Post
G117 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G118 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G119 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G120 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
G127 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel+ Bevacizumab Matched Pre and Post
G128 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel+ Bevacizumab Matched Pre and Post
G132 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel+ Bevacizumab Matched Pre and Post
G135 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel+ Bevacizumab Matched Pre and Post
G139 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Matched Pre and Post
G143 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Matched Pre and Post
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Table 3.2 Clinical characteristics of patients from whom non-matched biopsies are used in 
this thesis. Patient ID, description of histological diagnosis, FIGO stage, chemotherapy regime 
and pre/post-chemotherapy status are listed for each patient. 
 
 Quantification of macrophage density pre- and post-chemotherapy in human 
HGSOC metastases 
The effect of chemotherapy on TAM density in HGSOC has not been determined. 
Therefore, I set out to measure the effects of NACT on TAM density and location within 
human HGSOC omental metastases. Expecting significant heterogeneity between 
patient samples I used a cohort of twenty-six matched pre and post-NACT biopsy 
samples to control for inter-patient variability, as described above. Post-chemotherapy 
samples were contained in a tissue microarray (TMA) whereas pre-chemotherapy 
samples were sections of the diagnostic percutaneous core biopsy from the omentum. 
The TMA cores were 1.2 mm in diameter and multiple cores were taken from each tissue 
sample (three-six per patient) from different areas of the tumour (e.g. invasive margin, 
tumour core). 
 
Patient ID Histology Stage Chemotherapy regime Pre/Post ChemoRx
G159 High-grade serous ovarian/tubal carcinoma 3C Carboplatin + Paclitaxel Post
G161 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel + Bevacizumab Post
G163 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Pre
G164 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Post
G165 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Post
G166 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Post
G168 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Pre
G172 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel + Bevacizumab Post
G173 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel + Bevacizumab Post
G178 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel + Bevacizumab Post
G181 High-grade serous carcinoma of the ovary 3B Carboplatin + Paclitaxel Pre
G184 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Pre
G192 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Pre
G195 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Post
G196 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Post
G197 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel + Bevacizumab Post
G204 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Pre
G208 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel + Bevacizumab Post
G209 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel + Bevacizumab Post
G214 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Post
G220 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel + Bevacizumab Post
G221 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel + Bevacizumab Post
G275 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel + Bevacizumab Pre
G276 High-grade serous carcinoma of the ovary 4 Carboplatin Post
G278 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Post
G301 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Post
G302 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Post
G338 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Post
G343 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Pre
G347 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Pre
G351 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Post
SG0001 Mucinous cystadenoma of instinal type n/a n/a n/a
SG0004 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel + Bevacizumab Post
SG0005 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel + Bevacizumab Post
SG0008 Endometrioid adenocarcinoma of the endometrium 1 n/a n/a
SG0011 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel + Bevacizumab Post
SG0012 High-grade serous carcinoma of the ovary 3C Referred ouside SGH Pre
SG0013 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Pre
SG0014 Mucinous cystadenoma of instinal type n/a n/a n/a
SG0017 High-grade serous carcinoma of the endometrium 1 n/a n/a
SG0018 High-grade serous carcinoma of the ovary 2 n/a n/a
SG0020 High-grade serous carcinoma of the ovary 3C Referred ouside SGH Post
SG0021 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Pre
SG0024 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel Pre
SG0026 High-grade serous carcinoma of the ovary 3C Carboplatin + Paclitaxel + Bevacizumab Pre
SG0027 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Pre
SG0028 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Post
SG0029 High-grade serous carcinoma of the ovary 4 Carboplatin + Paclitaxel Post
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I stained these sections for CD68, as a pan-macrophage marker171 and used Definiens® 
digital analysis software to quantify CD68 staining within malignant cell islands and 
stromal areas of the biopsies. Definiens® was used to perform automated tumour-stromal 
separation. The results of the software tumour-stroma separation were reviewed and 
manually corrected were necessary. Assessment of CD68 staining was then performed 
within the tumour and stromal areas of the biopsy. During optimisation of the Definiens® 
analysis I found that quantification as CD68+ cells/mm2 would not be accurate due to the 
CD68 staining pattern. CD68+ cells were large with cytoplasmic extensions, this resulted 
in multiple bleb-like structures seen in cross-section which were counted as individual 
cells by the software. Therefore, I quantified the CD68+ staining as a percentage of the 
malignant cell area, the stromal area or the entire TMA core/tissue area. Figure 3.1 
shows Definiens® digital analysis of a single TMA core from a patient biopsy showing 
tumour and stroma separation and detection of CD68+ staining.  
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Figure 3.1 Definiens® digital analysis of human HGSOC omental metastases stained with 
an anti-CD68 antibody. A TMA core from a single HGSOC biopsy sample from a patient who 
received NACT is shown. A Original stained section, A' area of TMA core as marked by rectangle 
depicted at x20 magnification. B Core overlaid with areas assigned as malignant cell islands (red) 
and as adjacent stroma (green). C Core overlaid with areas assigned as positive CD68 staining 
(yellow), analysed within both tumour and stromal areas and darkly counterstained nuclei (blue). 
C' area of TMA core as marked by rectangle depicted at x20 magnification. Scale bars, A-C: 
200μm; A', C': 50μm. 
 
Figure 3.2 shows the result for the Definiens® analysis. Counting within the entire tissue 
sample, there was no difference in CD68+ area in treatment naïve compared with 
samples post-NACT. However, there were differences when the malignant cell and 
stromal areas of the biopsy were considered separately. Values for CD68+ area did not 
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change after NACT in the stromal areas. In contrast, within malignant cell islands there 
was a significant reduction in the mean CD68+ area following NACT compared to pre-
treatment samples (7.88 vs 1.01% p<0.0001). These changes resulted a higher TAM 
density in the stroma compared to the malignant cell areas following NACT (3.94 vs 
1.01% p=0.02).  
 
Figure 3.2 Quantification of CD68 density within tumour, stromal and whole biopsy areas 
in matched pre- and post-NACT human HGSOC omental metastases. A Mean percentage 
area of CD68 staining within stromal areas (green circles; pre-chemotherapy filled circles, post-
chemotherapy unfilled circles), malignant cell islands (red triangle; pre-chemotherapy filled 
triangles, post-chemotherapy unfilled triangles), and the biopsy overall (grey diamonds; pre-
chemotherapy filled diamonds, post-chemotherapy unfilled diamonds) was quantified by 
Definiens® digital analysis in matched pre and post-chemotherapy human HGSOC biopsy 
samples from the omentum. Data presented from twenty-six matched pre and post-NACT biopsy 
samples, error bars represent SEM and individual data points are overlaid. Wilcoxon matched-
pairs signed rank test p-values for matched analyses and Mann-Whitney U test p-values for 
unmatched analyses are shown. B Data presented showing matched sample pairs. Significant p-
values shown; ****<0.0001, *<0.05. 
 
 Tissue features in pre and post-chemotherapy human HGSOC biopsy 
sections 
As seen in Figure 3.2 the stromal CD68+ area was greatly increased in four of the 
patients. A core from one of these patients is shown in Figure 3.1. The striking increase 
in stromal CD68+ area in this subset of patients suggested that macrophages may not 
be uniformly distributed through the tissue and that macrophage density may not have 
been fully captured as a result of limited sampling of the tissue in the post-NACT TMAs.  
 
In order to explore this further, I studied the effects of chemotherapy in HGSOC omental 
metastases using unmatched larger tissue sections from a different patient cohort. I 
Chapter 3: Results 
 84 
performed dual colour immunohistochemistry, staining malignant cells with an anti-PAX8 
antibody and TAMs with an anti-CD68 antibody. I observed large clusters of 
macrophages frequently surrounding or in close proximity to viable-appearing malignant 
cells. This pattern of staining was frequently seen post-NACT but rarely in pre-treatment 
samples. I used the term stromal macrophage ‘lakes’ to describe these areas (Figure 
3.3).  
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Figure 3.3 Dual colour immunohistochemistry of human HGSOC metastases. Representative images of dual colour immunohistochemistry staining malignant 
cells with an anti-PAX8 antibody (purple) and myeloid cells with an anti-CD68 antibody (brown) from A four patients pre and B four patients post-chemotherapy. 
Images shown at x20 and x63 magnification. Scale bars; 400μm; 50μm.  
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I then quantified the macrophage lakes in a total of thirty-two unmatched HGSOC 
omental metastases; nine patients were pre-treatment and twenty-three patients had 
received chemotherapy. I defined macrophage lakes as areas of continuous CD68+ 
staining >4000µm2, 10,000µm2 or >50,000µm2 and quantified these in an unbiased 
manner across the entire tissue section. There were significantly more macrophage 
lakes within post-NACT tissues sections compared to pre-chemotherapy (Figure 3.4). 
Furthermore, no macrophage lake areas >50,000µm2 were observed in pre-
chemotherapy samples (Figure 3.4).  
 
 
Figure 3.4 Quantification of ‘macrophage lakes’ within human HGSOC omental 
metastases. Macrophages lakes were quantified in human HGSOC omental metastases pre and 
post-chemotherapy. Macrophage lakes were defined as areas of continuous CD68+ staining 
greater than A 4,000µm2, B 10,000µm2 and C 50,000µm2. Data represent quantification of 
unmatched biopsies from nine patients pre and twenty-three patients post-chemotherapy. 
Fisher’s exact test p-values are shown. 
 
Taken together these data suggest widescale changes in the overall tissue architecture 
as the result of chemotherapy with non-homogenous localisation of macrophages within 
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the post-NACT microenvironment, in contrast to pre-chemotherapy biopsies. 
 
 CIBERSORT assessment of immune populations in pre and post-
chemotherapy HGSOC omental metastases 
CIBERSORT is an analytical tool developed by Newman et al. to provide an estimation 
of cells types in mixed populations of cells using gene expression data282. Using this 
approach Dr. Eleni Maniati (BCI Core Bioinformatics Service) compared the cellular 
composition of unmatched pre and post-chemotherapy HGSOC omental metastasis 
samples on which RNA-sequencing had been previously performed for a previous 
project in the lab. Treated samples were further sub-categorised into those having a 
good response and those have a bad response to NACT, as assessed by the 
chemotherapy response score (CRS)280. According to the CIBERSORT analysis, all 
tumours contained significant populations of naïve B cells, memory CD4+ T cells, 
monocytes, M0 and M2 macrophages (Figure 3.5). Genes associated with CD8+ T cells, 
resting dendritic cells, neutrophils and NK cells were variably expressed.  
 
 
Figure 3.5 Proportions of immune cell populations estimated from human omental 
metastasis pre and post-NACT using CIBERSORT. Analysis performed on RNA-sequencing 
data derived from whole tumour preparations. Median values are shown representing four 
patients treated with upfront surgery, five patients post-NACT with a good response and seven 
patients post-NACT with a bad response. 
 
In agreement with the IHC data there were no obvious changes in the global frequency 
of myeloid cell gene expression between untreated and post-NACT samples. 
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Interestingly, it appeared that bad responders had less macrophages and good 
responders had more macrophages compared to untreated samples. Furthermore, 
CIBERSORT provided information on macrophage phenotypes which will be described 
in more detail in Chapter 5. Bad responders to NACT appeared to have more 
M1/classically activated macrophages and less M0 macrophages compared to untreated 
samples. Conversely, good responses to NACT had less M1/classically activated 
macrophages and more M0 macrophages. There appeared to be overall little change in 
M2/alternatively activated macrophages between untreated and post-NACT patients and 
these cells represented the dominant myeloid phenotype. CIBERSORT additionally 
provided an analysis of the human HGSOC lymphocyte compartment, which has not 
been assessed in any other aspect of this thesis. Within the group of bad responders to 
NACT there was an increase in CD8+ and naïve B cell gene expression. 
 
CIBERSORT analysis supports the concept of little change in TAM frequency overall. 
Interestingly, clustering patients into good and bad responders to NACT suggests 
macrophages may promote beneficial response post-chemotherapy as overall, the 
expression of the macrophage signatures was higher in the good prognosis group. 
 
 Effects of TAM density on patient survival 
Studies in mixed cohorts of ovarian cancer patients have not shown any clear prognostic 
implications of overall TAM density186,197. However, these studies have not accounted for 
the effects of chemotherapy on TAM. To investigate if TAM density affected overall 
survival I categorised patients with high or low CD68+ TAM area and compared the pre- 
and post-NACT values with their overall survival.  Figure 3.6 and Figure 3.7  show Kaplan 
Meier curves for patient survival stratified by overall, stromal or malignant cell area TAM 
density pre (Figure 3.6) and post-chemotherapy (Figure 3.7) using a cohort of thirty-three 
patient biopsy samples contained on the post-treatment TMAs. 
 
Stratifying patient overall survival by TAM density above and below the median value 
showed no significant difference in survival outcome either before or after chemotherapy. 
To determine if there was any association of high compared to low TAM density on 
overall survival, I also compared survival in the upper quartile versus the lower quartile 
for CD68+ TAM density. As can be seen in Figure 3.7 there was a significantly increased 
overall survival in patients with high compared to low CD68+ TAM area following 
chemotherapy (log-rank p=0.05) and a near-significant trend (p=0.08) to improved 
survival within the stroma before chemotherapy. Interestingly, within the malignant cell 
areas there was a trend to reduced survival before NACT with no obvious difference after 
NACT. Overall these data, albeit on a small cohort of patients, suggest that high stromal 
Chapter 3: Results 
 89 
TAM density may confer positive influence on overall survival and furthermore, that TAM 
within the stromal and malignant cell areas of the HGSOC TME may have different 
associations with survival. 
 
Figure 3.6 Overall survival of patients stratified by pre-chemotherapy TAM infiltrate. A,C,E 
Overall survival of HGSOC seventeen patients stratified by high (>median) or low (<median) 
CD68+ percentage area. B,D,F Overall survival of nine HGSOC patients stratified by high (upper 
quartile) or low (lower quartile) CD68+ percentage area A,B shows overall TAM density C,D 
shows stromal TAM density and E,F shows malignant cell density. Selected log-rank test p-values 
are shown. 
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Figure 3.7 Overall survival of patients stratified by post-chemotherapy TAM infiltrate. A,C,E 
Overall survival of HGSOC thirty-three patients stratified by high (>median) or low (<median) 
CD68+ percentage area. B,D,F Overall survival of sixteen HGSOC patients stratified by high 
(upper quartile) or low (lower quartile) CD68+ percentage area A,B shows overall TAM density 
C,D shows stromal TAM density and E,F shows malignant cell density. Selected log-rank test p-
values are shown. 
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 Discussion 
To date the role of TAMs in HGSOC has not been extensively studied192. No studies 
have addressed the effects of chemotherapy on ovarian cancer TAM density, phenotype 
or function in vivo, however, work in other cancer types suggests this could be a 
promising area to explore156,220–222,283. 
 
I observed striking differences in the microscopic appearance of HGSOC sections three 
weeks following NACT compared to untreated samples. In chemotherapy treated 
samples I frequently observed extensive immune infiltrates associated with extracellular 
matrix deposition extending through large areas of the biopsies. These areas measured 
up to 4mm2 and were often in close proximity to or surrounding islands of apparently 
viable malignant cells. This was in contrast to pre-chemotherapy samples, where 
although there was evidence of an extensive immune infiltrate this was typically 
observed as scattered cells interspersed within the stroma or malignant cell islands. 
Assessment of cell morphology within these extensive immune infiltrates post-
chemotherapy was suggestive of many of the cells being macrophages. This was 
confirmed by IHC using an anti-CD68 antibody.  
 
I rereferred to these large clusters of macrophages as macrophage ‘lakes’. Macrophage 
lakes were significantly more numerous in the stroma following NACT. A fibro-
inflammatory response including infiltrating macrophages and ‘foam’ cells has been 
described as a tissue response to chemotherapy within omental HGSOC metastases280. 
Indeed, assessment of these infiltrates form a part of the chemotherapy response score 
(CRS) and are associated with a favourable response to chemotherapy (CRS3) when 
associated with a concomitant tumour cell response280. 
 
To minimise the effect of sample heterogeneity I used a cohort of matched untreated and 
post-NACT biopsies to study the effect chemotherapy on TAM density within HGSOC 
metastases. Digital quantification demonstrated a significant decrease in the CD68+ area 
following NACT within the malignant cell islands compared to pre-treatment samples. 
Assessment of stromal areas demonstrated no significant differences in mean CD68+ 
area following chemotherapy compared to pre-treatment samples. However, in four 
patients there was a marked increase in TAM density within the stroma which was 
reflected in the quantification of TAM density in the biopsy overall (Figure 3.2). A core 
relating to one of these patients is shown in Figure 3.1; the appearance of the stromal 
CD68 staining in this core is characteristic of a macrophage lake. It is likely therefore that 
TMA cores for these four patients sampled macrophage lakes. As the result of the 
relatively limited sampling of the TME combined with the non-uniform CD68 staining 
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pattern, the TMA analysis may not have completely captured the stromal response in all 
patients. 
 
In other cancer types, studies have addressed the effects of chemotherapy on overall 
TAM density, although they have not compared malignant and stromal biopsy areas. 
These studies show conflicting results, in pancreatic ductal adenocarcinoma (PDAC) Di 
Caro et al. show trends toward reduction in CD68+ TAM density at the tumour-stroma 
interface after chemotherapy188. In a murine sarcoma model Germano et al. show that 
trabectedin activated caspase-8 mediated apoptosis selectively in 
monocytes/macrophages212. TAM depletion was a mechanism underlying the effects of 
trabectedin in murine models. Also in mouse models, gemcitabine and 5-fluorouracil are 
able to deplete suppressive populations of myeloid cells277–279. In contrast to these 
studies showing either no change or a depletion of myeloid cells after chemotherapy, 
TAM recruitment following paclitaxel treatment was reported in mouse breast cancer 
models220,222. It is possible that different chemotherapeutic agents may effect TAM 
density differently277.  
 
To investigate if TAM density before or after chemotherapy affects patient survival I 
compared overall survival in cohorts of patients stratified by TAM density within the 
stroma, malignant cell islands and within the biopsy overall. Although comparing patients 
above and below the median did not show differences in survival, comparing high TAM 
infiltrate (upper quartile) with low TAM infiltrate (lower quartile) in the biopsy overall was 
associated with a significant increase in patient survival in this small cohort (Figure 3.7). 
It appeared that chemotherapy treatment potentiated this effect, suggesting the 
possibility of chemotherapy driving an anti-tumorigenic TAM phenotype within stromal 
TAM. In agreement with these findings, in patients with haematological malignancies202, 
PDAC188 and CRC181, high TAM density after chemotherapy predicts enhanced survival.  
 
The data presented here relate to a small number of patients and need to be confirmed 
in a larger cohort before robust conclusions can be drawn. However, in a study of 326 
pre-treatment primary HGSOC biopsies by others in the lab, high levels of stromal CD68+ 
cells significantly associated with increased overall survival (Montfort et al. manuscript 
under preparation). These data do not show that TAM are mechanistically involved in 
promoting a positive response to chemotherapy. TAM tissue density may be acting as a 
surrogate marker of patient response to therapy. Further experiments will be required to 
confirm these results and search for the molecular and cellular circuits within the TME 
underpinning these observations. Additionally, the TME is affected by the underlying 
genetic landscape of the tumour. Tothill at al. defined four molecular subtypes of HGSOC 
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based on gene expression: C1 (mesenchymal), C2 (immunoreactive), C4 (differentiated) 
and C5 (proliferative)9. These subtypes associated with differences in clinical outcome 
as well as differences in the TME. I have not sought to classify tumour based on gene 
expression, and it is likely that more samples would be needed to capture the genetic 
diversity of HGSOC then analysed in this study.  
 
As noted above, published studies to date in ovarian cancer do not  show total 
macrophage density to predict patient outcome193; however, specific TAM subsets 
differentiated phenotypically and spatially in tumours, do have associations with patient 
surival193–195,197. Zhang et al. showed that a high intra-tumoural, as opposed to stromal 
or whole tissue, M1 (classically activated)/M2 (alternatively activated) phenotype ratio 
was associated with improved survival196 suggesting localisation as well as phenotype 
to be clinically relevant. However, it should be noted that these studies are in 
predominantly in mixed cohorts of ovarian cancer subtypes and crucially that the effects 
of chemotherapy on macrophage phenotype were not considered.  
 
In conclusion these data demonstrate that at a time point on average three-four weeks 
following NACT, there are significant differences in the macrophage infiltrate, as 
measured by CD68+ area, within the malignant cell and stromal areas of the biopsy 
compared to pre-treatment samples. There are preliminary data that high TAM density 
post-NACT in the omental biopsies may associate with greater overall survival. In the 
following two chapters I will examine the effects of chemotherapy on TAM phenotype by 
flow cytometry (Chapter 4) and on TAM pathways and processes using RNA-sequencing 
(Chapter 5).
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Chapter 4  
The effects of chemotherapy on myeloid cell 
phenotype within HGSOC omental metastases 
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4The transcriptome of human HGSOC TAMs pre and post-chemotherapy 
 Background 
The aim of this chapter is to phenotype macrophages and dendritic cells (DCs) in pre 
and post-NACT samples by cell surface protein expression of canonical activation 
markers. In this chapter I have used flow cytometry (FC) to assess the phenotype of 
TAMs before and after chemotherapy. 
 
It is established that TAM in ovarian cancer adopt an immunosuppressive (alternatively 
activated) phenotype, and express markers including CD163, CD204, CD206 and IL-
10190–192.  Densities of alternatively activated TAMs associate with a reduced patient 
survival, in keeping with their roles in limiting anti-tumour immunity. For example, patients 
with tumours richly infiltrated with CD163+ TAMs have significantly reduced progression 
free and overall survival194 and the CD206/CD68 TAM ratio predicted worse PFS193. 
Further confirming the importance of macrophage phenotype, a high M1 (classically 
activated)/M2 (alternatively activated) ratio associated with improved survival195,196. This 
suggests that macrophages in ovarian cancer may enhance or limit tumorigenesis 
depending on activation state. However, these studies were predominantly in mixed 
cohorts of ovarian cancer subtypes and the effects of chemotherapy on macrophage 
phenotype was not considered. A recent meta-analysis confirmed the association of poor 
prognosis with CD163+ TAMs and improved prognosis with a high M1 (classically 
activated)/M2 (alternatively activated) ratio197 in ovarian cancer, further strengthening 
these data. 
 
In this chapter, immunostaining for FC analysis using a ‘myeloid panel’ of antibodies (see 
Materials and Methods) included assessment of DCs in addition to TAMs. FC 
assessment of the DC population was included to provide additional descriptions of 
these myeloid cells and allow for the study of the effects of chemotherapy on this cell 
type. DC are bone-marrow derived cells that have essential roles in antigen sensing and 
presentation and as such lie at the interface between innate and adaptive immunity284. 
Therefore, assessment of the effects of chemotherapy on DC subsets could be 
important. 
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 Flow cytometry analysis of macrophages in human HGSOC omental 
metastases 
I used multicolour FC to define myeloid cell populations and to phenotype TAM in omenta 
that were undiseased, and HGSOC omenta pre-treatment and following NACT. Figure 
4.1 shows the gating strategy employed to define myeloid populations from human 
biopsy samples. To gate for TAMs, lineage markers (CD3, CD19, CD20, CD56, CD66b, 
Siglec8) were all stained with FITC conjugated antibodies, allowing exclusion of cells 
expressing these markers, by gating for the FITC− population. TAMs were defined as 
CD45+FITC−HLA-DR+ cells. Given the possibility of other myeloid cells residing within 
the gate, most notably DCs, a further population of CD14+TAMs was defined. Analysis 
of canonical surface makers were assessed within the TAM and CD14+TAM populations. 
 
Figure 4.1 Multicolour flow cytometry gating strategy to characterise myeloid populations. 
Density plots shown from a representative patient sample showing the immunostained stromal 
vascular fraction from a human omental HGSOC metastasis. A Gating to exclude cellular debris, 
B, C sequential gating to exclude doublet cells, D sequential gating to exclude non-viable cells, 
E sequential gating for CD45 positive cells, F sequential gating for FITC−HLA-DR+ cells. Insert 
showing FMO for HLA-DR. G sequential gating for CD14 by CD16, insert showing FMO for CD14. 
H sequential gating for CD11c by CD123, insert showing FMO for CD123. I sequential gating for 
CD1c by CD141, inserts showing FMOs for CD1c and CD141. FMO: florescence minus one 
control, FVD: fixable viability dye, SSC-A: side scatter area, SSC-W: side scatter width, FSC-A: 
forward scatter area, FSC-H: forward scatter height. 
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 A total of twenty-eight patient samples were analysed; nine patients treated by upfront 
surgery pre-chemotherapy and fourteen patients undergoing interval cytoreduction after 
three to six cycles of NACT. Additionally, omental samples from five patients with no 
omental disease or benign pathology were included (Table 4.2). There was a non-
significant decrease in TAMs as a percentage of the CD45+ infiltrate (23.60% vs 16.02% 
p=0.37) in patients undergoing interval cytoreductive surgery following chemotherapy 
compared to patients being treated with upfront surgery (Figure 4.2A). When the analysis 
was restricted to CD14+TAMs, I again observed a non-significant reduction (21.19% vs 
11.58% p=0.16) of this cell population relative the total CD45+ population at interval 
cytoreductive surgery compared to upfront surgery (Figure 4.2B).  
 
Figure 4.2 Effect of chemotherapy on the TAM infiltrate of human HGSOC omental 
metastases. Flow cytometry data demonstrating frequency of A TAMs (FITC−HLA-DR+) and B 
CD14+ TAMs as a percentage of CD45+ cells in fourteen patients having received NACT (red), 
nine patients treated with upfront surgery (green) and five patients with undiseased omenta 
(grey). Error bars represent SEM. One-way ANOVA with Turkey post hoc test was applied. ns 
denotes a non-significant p-value. 
 
To study TAM phenotype pre and post-chemotherapy I assessed the surface expression 
of a panel of markers (CD163, CD206, CD209, CX3CR1). There was a significant 
reduction in CD163+ (55% vs 32% p=0.006) and CX3CR1+ (68% vs 25% p=0.003) TAMs 
in patients receiving chemotherapy compared to those treated with primary surgery 
(Figure 4.3A,B). Furthermore, there were trends to reduced expression of CD206+ and 
CD209+ TAMs following chemotherapy (Figure 4.3C,D). 
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Figure 4.3 Effect of chemotherapy on TAM surface marker expression in human HGSOC 
omental metastases. Flow cytometry data demonstrating TAM (FITC−HLA-DR+) expression of 
A CD163, B CX3CR1 C CD206, D CD209, as a percentage of the TAM population in fourteen 
patients having received NACT (red), nine patients treated with upfront surgery (green) and five 
patients with undiseased omenta (grey). Error bars represent SEM. One-way ANOVA with 
Turkey’s post-hoc test p-values are shown; ns = non-significant, ** <0.01. 
 
Given that in Chapter 5 I will perform RNA-sequencing on CD14+TAM I wished to explore 
any differences in activation marker expression within the CD14+TAM population. These 
data show the same trends as seen within the TAM population (Figure 4.4). Again, I 
observed significant reductions of CD163 (62% vs 38% p = 0.02) and CX3CR1 (77% vs 
42% p = 0.03) expression as a percentage of the CD14+TAM population. 
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Figure 4.4 Effect of chemotherapy on CD14+TAM surface marker expression in human 
HGSOC omental metastases. Flow cytometry data demonstrating TAM (FITC−HLA-DR+) 
expression of A CD163, B CX3CR1, C CD206, D CD209 as a percentage of the TAM population 
in fourteen patients having received NACT (red), nine patients treated with upfront surgery (green) 
and five patients with undiseased omenta (grey). Error bars represent SEM. One-way ANOVA 
with Turkey’s post-hoc test p values are shown; ns = non-significant, *<0.05. 
 
To gain an understanding if these changes held at the level of the entire immune infiltrate, 
I quantified marker positive TAMs as a percentage of the CD45+ cell infiltrate. This 
demonstrated significant reductions CX3CR1+TAM (18% vs 5% p=0.016) (Figure 4.5) 
and near significant reductions of CD163+ (p=0.06) and CD206+ (p=0.09) TAMs as a 
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percentage of the total CD45+ population. This suggests robust changes in TAM 
phenotype following chemotherapy discernible at the level of the entire immune infiltrate. 
The comparison to undiseased tissue suggests that TAM density and marker-positive 
TAM density was very similar to that seen after NACT. However, the data were not 
statistically significant between untreated and undiseased samples, due to the small 
number of patients in the undiseased group. However, based on the mean values with a 
larger sample size these differences are also likely to be significant. Taken together the 
data show that chemotherapy is acting to ‘normalise’ the TAM population towards that 
of undiseased tissue. 
 
Figure 4.5 Effect of chemotherapy on TAM surface marker expression in human HGSOC 
omental metastases. Flow cytometry data demonstrating TAM (FITC−HLA-DR+) expression of 
A CD163, B CX3CR1 C CD206, D CD209, as a percentage of the CD45+ cell population in 
fourteen patients having received NACT (red), nine patients treated with upfront surgery (green) 
and five patients with undiseased omenta (grey). Error bars represent SEM. One-way ANOVA 
with Turkey’s post-hoc test p-values are shown; ns = non-significant, *<0.05. 
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Given the changes in the percentage of positive cells I wished to quantify the mean 
fluorescence intensity (MFI) values for these markers within the TAM population (Figure 
4.6). I normalised MFI values to the fluorescent minus one control acquired at the same 
time to account for variation in cytometer laser calibration over time. These data 
recapitulated the percentage positive cell analysis and demonstrated significant 
reductions of CX3CR1 (8.22 a.u. vs 3.05 a.u. p=0.0008) and CD163 MFI (8.53 a.u vs 
2.45 a.u. p=0.027). In view of the significant decrease in CD163, a marker of alternatively 
activated macrophages, I looked for reciprocal changes in markers of classical 
macrophage activation. However, I observed no significant difference in MFI value for 
the MHC Class II molecule HLA-DR (Figure 4.6A).  
 
Taken together, these data show that chemotherapy alters the surface expression of 
canonical macrophage activation markers in omental metastases of HGSOC suggesting 
a change in macrophage phenotype. 
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Figure 4.6 Effect of chemotherapy on TAM surface marker expression in human HGSOC 
omental metastases. Flow cytometry data demonstrating TAM (FITC−HLA-DR+) MFI of A HLA-
DR, B CD163, C CX3CR1 D CD206, E CD209 in fourteen patients having received NACT (red), 
nine patients treated with upfront surgery (green) and five patients with undiseased omenta 
(grey). Error bars represent SEM. One-way ANOVA with Turkey’s post-hoc test p-values are 
shown; ns = non-significant, *<0.05, ***<0.001. 
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4.2.1 Chemotherapy increases macrophage cell death 
In Chapter 3 I found extensive stromal lakes of CD68+ macrophages. However, as 
assessed by FC, viable TAMs showed a trend to a decrease in post-NACT samples 
compared to untreated samples (Figure 4.2). This discrepancy in my observations led 
me to consider that chemotherapy may increase cell death within the TAM population or 
render TAMs more susceptible to destruction during tissue processing. To investigate 
this possibility, I determined the number of non-viable TAMs for each patient sample. As 
shown in Figure 4.7 there was a significant increase in non-viable TAMs as a percentage 
of all TAMs in chemotherapy treated samples compared to untreated and undiseased 
samples. These data rely on gating dead cells which may non-specifically bind antibody 
and this is an acknowledged potential source of error. However, the differences between 
the groups suggests that there are more dead or dying TAMs post-NACT than in 
untreated samples which could potentially reside within stromal ‘lakes’. 
 
 
Figure 4.7 Assessment of non-viable TAMs in human HGSOC pre and post-chemotherapy 
and in uninvolved omentum. Flow cytometry data demonstrating non-viable (FVD positive) 
TAM (FITC−HLA-DR+) as a percentage of all TAMs in nine patients having received NACT (red), 
eight patients treated with upfront surgery (green) and five patients with undiseased omenta 
(grey). Error bars represent SEM. One-way ANOVA with Turkey’s post-hoc test p-values are 
shown; *<0.05, **<0.01. 
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 Effect of chemotherapy on CD14/CD16 myeloid subsets in HGSOC omental 
metastases 
Subsets of human blood monocytes have been defined on the basis of CD14 and CD16 
(FcgRIII) surface co-expression. ‘Classical’ monocytes are defined as CD14++CD16- and 
these account for the majority (~90%) of circulating monocytes. Two CD16+ monocyte 
subsets have been defined based on relative expression of CD16, these are 
CD14+CD16+ termed ‘intermediate’ monocytes and CD14+CD16++ termed ‘non-classical’ 
monocytes285. Non-classical monocytes are frequently expanded in pathological 
inflammatory states and Cassetta et al. show that non-classical monocytes are 
expanded in the patients with breast and endometrial cancer133. It is not completely 
understood if specific monocyte subsets give rise to different populations of 
macrophages within tissues. Clear differentiation of macrophage phenotypes based on 
CD14/CD16 expression has not been described, however, CD16 has been regarded as 
a marker of an inflammatory (classically activated) phenotype286 and has been shown to 
be important in myeloid ADCC287 and may be associated with improved outcome in CRC 
patients288. 
 
To gain an appreciation of how CD14 and CD16 markers changed between undiseased 
and pre- and post-chemotherapy diseased samples, I compared CD14 and CD16 co-
expression within the TAM population in these three groups (Figure 4.8A). CD14 was 
expressed on a majority of HGOSC TAM, with less than five percent of the CD45+ 
population being CD14-negative. CD14+CD16+ cells were expanded in pre-
chemotherapy diseased samples compared to undiseased controls. In chemotherapy-
treated samples there were no significant changes in CD14+CD16+ and CD14+CD16- 
subsets compared to pre-treatment samples. However, there was a significant increase 
in CD14-CD16- myeloid cells in post-treatment compared to pre-treatment samples. This 
suggests an expansion of DCs within the myeloid population post-chemotherapy. 
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Figure 4.8 CD14/CD16 myeloid subsets with the HGSOC samples pre and post-
chemotherapy and uninvolved tissues. Flow cytometry data on CD14/CD16 subsets as a 
percentage of A myeloid cells and B CD45+ cells in fourteen patients having received NACT (red), 
nine patients treated with upfront surgery (green) and five patients with undiseased omenta 
(grey). Error bars represent SEM. Two-way ANOVA with Turkey’s post-hoc test p-values are 
shown; ns = non-significant, *<0.05, **<0.01, ***<0.001. 
 
 
 Effect of chemotherapy on DCs in HGSOC omental metastases 
I next divided the CD14-CD16- population into conventional DC (cDC) and plasmocytoid 
DC (pDCs) populations on the basis of CD123 and CD11c expression (Figure 4.1). 
These results show that cDC represent the greater population of DC in both untreated 
and treated samples. Interestingly with chemotherapy exposure there was a significant 
increase in cDCs compared to untreated and undiseased samples (Figure 4.9). 
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Figure 4.9 Dendritic cell phenotypes of HGSOC samples pre and post-chemotherapy and 
in uninvolved tissues. Flow cytometry data cDC (CD14-CD16-CD123-CD11c+) and pDC (CD14-
CD16-CD123+CD11c-) as a percentage of A CD45+ cells and B cells in the ‘TAM gate’ in fourteen 
patients having received NACT (red), nine patients treated with upfront surgery (green) and five 
patients with undiseased omenta (grey). Error bars represent SEM. Two-way ANOVA with 
Turkey’s post-hoc test p-values are shown; ns = non-significant, *<0.05, **<0.01  
 
Further characterisation within the cDC gate by CD141 and CD1c demonstrated the 
majority of the cDC gate to be CD141-CD1c- (double negative, DN) cells and furthermore 
this population was significantly increased in chemotherapy treated compared to 
untreated samples (Figure 4.10).  
 
 
Figure 4.10 cDC phenotypes of HGSOC samples pre and post-chemotherapy and in 
uninvolved tissues. Flow cytometry data showing DN cells (CD14-CD16-CD123-CD11c+CD141-
CD1c-), cDC1 (CD14-CD16-CD123-CD11c+CD141+CD1c-) and cDC2 (CD14-CD16-CD123-
CD11c+CD141-CD1c+) as a percentage of cDC cells in fourteen patients having received NACT 
(red), nine patients treated with upfront surgery (green) and five patients with undiseased omenta 
(grey). Error bars represent SEM. Two-way ANOVA with Turkey’s post-hoc test p-values are 
shown; *<0.05, ***<0.001. 
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In conclusion these data support an increase in dendritic cells post chemotherapy.  
CD141-CD1c- cDCs appear to be the dominant DC phenotype within HGSOC and are 
significantly increased following chemotherapy exposure. 
 
 Discussion 
In this chapter I first assessed TAM phenotype in HGSOC before and after chemotherapy 
and in undiseased omental tissue. I found a significant reduction in the surface protein 
expression of CD163+ and CX3CR1+ TAMs after chemotherapy compared to pre-
chemotherapy samples (Figure 4.3A,B; Figure 4.4A,B). I also observed a decrease, 
although not statistically significant with this number of patients, in CD206 expression. 
This suggests that chemotherapy may alter TAM phenotype. As the last dose of 
chemotherapy was an average of three-four weeks preceding interval surgery, these 
data suggest durable changes of TAM phenotype. 
 
Reduction of CD163 and CD206 surface expression suggests a change in TAM 
activation from an alternatively activated towards a classically activated phenotype. 
Interestingly, and consistent with these data, in human PDAC, CD206+ TAMs 
significantly decreased following chemotherapy compared to untreated samples, 
suggesting that chemotherapy curbs the immunosuppressive microenvironment of this 
disease188. In HGSOC, CD163-high TAM were enriched for matrix pathways whereas 
CD163-low TAM were enriched for interferon signalling pathways289. CD163 expression 
is associated with decreased survival and a shorter time to relapse197,198,289. In contrast 
to my data, an in vitro study by Dijkgraaf et al. showed that platinum-based 
chemotherapy treatment of ovarian cancer cells lines co-cultured with monocytes 
enhanced M2 polarisation217. Furthermore, in murine models of breast cancer and in 
patient samples chemotherapy increased tumour promoting macrophages220,222.  
 
To assess for reciprocal changes in a marker of classical macrophage activation, I 
quantified MHC Class II expression. There was no significant difference in MHC Class II 
expression on TAM between pre and post-chemotherapy samples (Figure 4.6A). This 
suggests a change of macrophage phenotype distinct from the simplistic M1 (classically 
activated)-M2 (alternatively activated) model. Mirroring my data, Reinartz et al. showed 
that CD163 is highly expressed on HGSOC TAM, but did not associate clearly with other 
canonical M1 (classically activated)/M2 (alternatively activated) markers198. Therefore, 
selective reductions in CD163 expressing TAMs may be independent of an M1 
(classically activated)/M2 (alternatively activated) phenotype change, yet reflect an anti-
tumoural myeloid phenotype associated with improved patient outcome. 
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As discussed in Chapter 1 high CX3CR1 surface expression is a marker for self-
renewing populations of macrophages in healthy tissue290 and in tumour 
microenviroments139 in mice. I observed CX3CR1 expression at higher levels in 
undiseased tissue than the other macrophage surface markers (~50% vs ~25% of the 
TAM population) (Figure 4.3B), which suggests this marker is associated with the tissue-
resident population in the human omentum. In murine models of PDAC CX3CR1+ tissue-
resident macrophages were significantly enriched for matrix secretion and remodelling 
pathways, whereas recruited bone-marrow derived cells upregulated genes relating to 
antigen presentation139. I show chemotherapy causes a reduction in CD163+ and 
CX3CR1+ macrophages which have both been linked to roles in matrix remodelling and 
fibrosis. Collectively, these data suggest TAM phenotype following chemotherapy may 
be associated with improved clinical outcome in HGSOC; furthermore, chemotherapy 
may selectively deplete a tissue-resident macrophage-derived TAM population. 
 
In Chapter 3 I observed chemotherapy-associated macrophage lakes, however, I 
observed no significant changes in TAM density by flow cytometry (Figure 4.2). This 
suggested that TAMs may be either dying as a result of chemotherapy exposure or being 
rendered more sensitive by tissue processing during FC. This finding fits with others that 
have shown increases in TAM death in inflammatory states291. M1/classically activated 
macrophages may be killed by their own NO production or via Fas-mediated 
processes291; this has led to the suggestion that classically activated macrophages may 
represent a terminal differentiation phenotype, with the natural endpoint of most of these 
cells being death within tissues291. 
 
CD14-CD16- cells were significantly expanded with chemotherapy treatment compared 
to untreated and undiseased samples (Figure 4.8). This suggests chemotherapy resulted 
in an increase in DCs. Given the role of DCs as antigen presenting cells, DCs may 
expand in response to increased tumour antigen load following chemotherapy. 
Plasmacytoid DCs (pDCs) are characterised by expression of the surface marker CD123 
in humans284. These cells have well-described roles in viral immunity and are rapid and 
potent producers of type I and type III IFNs284. Conventional DCs (cDCs) can be 
subdivided in to cCD1 and cDC2 cells on the basis of surface expression of CD141 and 
CD1c respectively284. cDC1 cells have particular roles of antigen cross presentation via 
MHC class I to CD8+ T-cells cells whereas cDC2 cells are regarded as migratory and 
express TLRs, NOD and RIG-I-like receptors suggesting roles in response to diverse 
stimuli. They can secrete broad range of cytokines (IL1, IL8, IL-10, IL-12 and IL-23) but 
are low in the secretion of IFN. 
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In this analysis, cDC1 and cDC2 cells were very minor populations. The major dendritic 
cell population appeared to be double negative (DNcDC) for CD141 and CD1c. In 
support of this finding, in a recent study in head and neck cancer, DNcDC was the 
population most significantly expanded in malignant compared to benign tonsil292. 
Furthermore, transcriptomic profiling of these cells showed enrichment for IFN, IL6 and 
PGE2 signalling pathways compared to this population in non-malignant tissue292. Given 
the importance of DCs in activating adaptive immune responses, coupled with their 
expansion seen after chemotherapy, my results suggest that chemotherapy creates the 
potential for enhancement of adaptive immunity in HGSOC. This finding expands 
previous work in our lab which has shown that NACT enhances adaptive anti-tumour 
immunity in HGSOC in studies of T and B cell populations 113,114.  
 
In conclusion these results show significant downregulation of CD163 and CX3CR1 on 
the cell surface of TAMs in chemotherapy treated compared to chemotherapy naïve 
patients. Both these markers have been associated with extracellular matrix remodelling 
and are linked to poor prognosis in cancer TMEs. DC increased significantly after 
chemotherapy exposure. CD141-CD1c-cDC appear to be a dominant population of DC 
in the TME of HGSOC and expansion of this population accounted for the increases 
seen in this cell type overall.  
 
In the next chapter I will build on these data and assess the HGSOC TAM transcriptome 
by RNA-sequencing before and after chemotherapy. 
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Chapter 5  
The transcriptome of human HGSOC TAMs pre 
and post-chemotherapy 
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5The effects of chemotherapy on myeloid cell phenotype within HGSOC omental metastases 
 Background 
RNA-sequencing allows for sensitive and accurate measurement of gene expression 
across the entire transcriptome. This approach offers advantages over gene microarrays 
by allowing global coverage of the transcriptome and is not limited by prior knowledge of 
gene function. TAMs are characterised by diversity and plasticity of function and 
phenotype; therefore RNA-sequencing offers the best approach to the assessment of 
TAM pathways and processes in a global and unbiased manner. 
 
As discussed in Chapter 1, few studies have examined the transcriptome of TAMs in 
HGSOC198,199,289,293,294 and these have used ascites-derived TAMs rather than TAMs 
from tumour samples. These publications report that TAM gene expression is more 
similar to that of resident peritoneal macrophages than to monocytes. The most 
significant differences in gene expression between TAMs and resident macrophages 
were in genes regulating extracellular matrix (ECM) formation and remodelling199.  
 
In this chapter I will explore the effects of chemotherapy on TAMs by performing RNA-
sequencing of TAMs from human HGSOC omental metastases before treatment and 
following NACT. 
 
 Transcriptomic analysis of TAMs in HGSOC omental metastases 
CD14+ myeloid cells were obtained by fluorescent activated cell sorting (FACS) from 
human omental biopsy samples acquired at primary or interval cytoreductive surgery. 
Figure 5.1 shows the gating strategy employed from a representative biopsy sample. 
Within the FITC channel I stained for the lineage markers CD3, CD20, CD19, CD56, 
CD66b and Siglec 8. By gating for FITC- cells I was able to exclude cells expressing 
these markers. CD14+TAMs were defined as cells being CD45+HLA-DR+FITC-CD14+ 
and were sorted as a bulk population obtaining between 250,000-750,000 cells per 
sample. CD14+TAMs were chosen as the population to sequence to limit the analysis to 
TAMs and exclude CD14- myeloid cells, which would also be enriched for dendritic cells. 
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Figure 5.1 Multicolour flow cytometry gating strategy to sort TAMs for RNA-sequencing. 
Density plots from a representative patient sample showing the immuno-stained stromal vascular 
fraction from a human omental HGSOC metastasis. A Gating to exclude cellular debris, B, C 
sequential gating to exclude doublet cells, D sequential gating to exclude non-viable cells, E 
sequential gating for CD45+ cells, F sequential gating for FITC−HLA-DR+ cells. G Sequential 
gating for CD14+. CD14+TAMs sorted as a bulk population. SSC-A: forward scatter area, SSC-
W: side scatter width, FSC-A: forward scatter area, FSC-H: forward scatter height. 
 
Immediately following sorting, TAMs were lysed and the lysates were stored at -80°C. 
RNA was extracted using established protocols. Prior to RNA-sequencing, RNA 
concentration, purity and integrity were assessed. Table 5.1 shows the RNA 
concentration and RNA integrity number (RIN) values obtained. These values showed 
that the RNA was of sufficient quality and concentration for sequencing. TAM RNA from 
seven post-NACT samples and five pre-treatment samples was sequenced on the 
HiSeq4000 with 30-40 million reads per sample at the Welcome Trust Centre for Human 
Genetics. Raw reads were aligned to the reference genome GRCh37 (hg19). The 
sequence-aligned data were then analysed by Dr. Eleni Maniati (BCI Core Bioinformatics 
Service). 
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Table 5.1 RNA quality analysis. Table summarising the RNA concentration obtained from TAMs 
flow sorted from HGSOC. 260/80 and 260/230 absorbance ratios are shown as is the RNA 
integrity number (RIN). 
 
Only genes that achieved at least one read count per million reads (CPM) in at least 25% 
of the samples were kept. This led to 16,253 sufficiently quantified genes in total, 12,614 
of which were protein coding genes. Figure 5.2 demonstrates, as expected, a high 
expression of macrophage genes relative to lineage genes of other cell types. Sample 
SG0012 and SG0026 had a higher epithelial cell gene expression profile (EPCAM, 
PAX8, WT1) compared to other samples, suggesting a possible contamination of these 
samples with malignant cells. However, overall these data demonstrate good quality of 
TAM sorting, with minimal contamination of other cell types. 
 
 
Figure 5.2 Assessment of lineage genes expression in sorted myeloid populations. 
Log2RPKM expression of the indicated genes in the twelve sequenced samples. Data 
demonstrate a high abundance of macrophage lineage genes compared to genes characteristic 
of other cell lineages. Colour gradient indicates high (red) to low (blue) gene expression range. 
ND = Not detected. 
Sample ID RNA concentration (ng/ul) 260/280 absorbance ratio
260/230 
absorbance ratio RIN
SG0004 11.3 2 0.41 8.7
SG0005 27.3 2.24 0.31 8.6
SG0011 12.5 2 1.32 N/A
SG0012 29.3 2.02 0.99 10
SG0013 26.7 2.14 0.93 9.2
SG0020 43.5 1.96 1.56 8.4
SG0021 48.4 2.05 1.65 8.7
SG0024 57.5 2.02 1.37 9.3
SG0026 547.9 2.09 2.14 9.3
SG0027 48.7 1.93 0.66 8.4
SG0028 30.8 2.1 0.12 8.5
SG0029 73.9 1.77 1.29 9.3
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MARCO 8.17 8.46 4.34 5.06 2.87 7.09 6.53 6.35 6.90 3.97 7.07 7.07
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CD68 -2.97 -1.97 -0.31 -2.57 -1.84 -1.88 -1.63 -0.54 -1.25 -0.79 -0.46 -0.74
CD3E ND ND ND ND ND ND ND ND ND ND ND ND
CD3G ND ND ND ND ND ND ND ND ND ND ND ND
CD3D -0.70 -2.15 -3.69 -3.91 -0.80 -1.69 -3.05 -2.49 -2.24 -3.46 -0.52 -3.86
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Figure 5.3 Distribution of RNA species and classification of protein coding genes.  
A distribution of RNA species and B classification of protein coding genes. Data represent the 
twelve patients included in this analysis. 
 
Figure 5.3 shows the distribution of the RNA species and the classification of protein 
coding genes further confirming the quality of sequencing. Nucleic acid binding proteins 
were most abundant, other highly represented functional groups included receptors and 
signalling molecules. This is in keeping with TAM responding to multiple environmental 
stimuli in the TME of HGSOC. The coefficient of variation (square root of common 
dispersion) was 0.45 (Figure 5.4A). Although this is a large value, it is not atypical for 
human data generated from a small number of independent samples. Multidimensional 
scaling showed distances in terms of the biological co-efficiency of variation between 
samples, and provided an overview of the expressional differences between the samples 
(Figure 5.4B). 
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Figure 5.4 Assessment of biological variability within the data. A Scatter plot of tagwise 
dispersions against log2 counts per million. B Multidimensional scaling plot shows distances in 
terms expression differences between samples.  
 
Using protein coding genes, unsupervised clustering was performed by hierarchical 
cluster analysis. Only partial separation of the samples by chemotherapy status was 
observed (Figure 5.5). This could be explained by the low number of samples sequenced 
and the high degree of variability seen, especially in genes that were expressed at low 
levels (Figure 5.4).  
 
 
Figure 5.5 Hierarchical cluster analysis. Hierarchical cluster analysis performed on a Pearson’s 
correlation matrix of normalized read counts. Data represents five patients pre-chemotherapy and 
seven patients post NACT. 
 
Differential expression analysis was performed using a generalised linear model to 
subset genes with statistical significance (p-value < 0.05). There were 858 protein-coding 
genes with a statistically significant difference in HGSOC TAM post-NACT vs pre-
chemotherapy. Of these 81 were up regulated and 777 down regulated post-NACT. 
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Figure 5.6 shows a heat map of the differentially expressed protein coding genes across 
the twelve samples. Figure 5.7 shows a volcano plot of the up- and down regulated 
genes in the analysis.  
 
Figure 5.6 Heat map of differentially expressed protein coding genes. Data represents gene 
expression of five patients pre-chemotherapy (blue bar) and seven patients post neo-adjuvant 
chemotherapy (yellow bar). Color range indicates high (red) to low (blue) z-scores, which 
correspond to high and low expression levels respectively. 
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Figure 5.7 Volcano plot illustrating protein-coding genes that were differentially expressed 
in post vs pre-chemotherapy TAM. In red are statistically significant genes (p-value < 0.05). 
The names of upregulated genes with log2FC >0 p< 0.05 (FDR <0.25) and downregulated genes 
log2FC <-4 p< 0.05 (FDR <0.25) are also shown and marked in blue. 
 
 
 
Table 5.2 Top up regulated genes following chemotherapy treatment in TAM. Table 
summarising the 20 most up regulated genes with the highest fold change. logFC log10 fold 
change, logCPM log10 counts per million, LR log ratio, p-value <0.05. 
Gene name Description logFC logCPM LR
TREML4 triggering receptor expressed on myeloid cells-like 4 6.5695 1.0599 14.896
CCL24 chemokine (C-C motif) ligand 24 4.229 4.8958 18.035
RP11-219A15.1 Coiled-coil domain-containing protein 144A 3.4988 -0.092 5.7779
CCDC144A coiled-coil domain containing 144A 3.3941 2.3834 6.1131
ZFP57 ZFP57 zinc finger protein 2.8902 0.6245 3.5993
FABP4 fatty acid binding protein 4, adipocyte 2.4662 5.5147 6.353
LPL lipoprotein lipase 2.4057 6.499 15.631
NPIPB15 nuclear pore complex interacting protein family, member B15 2.3661 0.027 4.2559
CES1 carboxylesterase 1 2.301 3.102 7.9339
FOLR3 folate receptor 3 (gamma) 2.2521 1.6505 6.0196
DDX43 DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 2.068 -0.634 13.775
GFRA2 GDNF family receptor alpha 2 2.0522 4.317 10.758
LAMP5 lysosomal-associated membrane protein family, member 5 1.8166 1.2796 4.286
NID1 nidogen 1 1.805 4.1353 8.3106
CLDN5 claudin 5 1.7832 0.545 4.2667
LGALS2 lectin, galactoside-binding, soluble, 2 1.7202 5.9085 5.1636
CPAMD8 C3 and PZP-like, alpha-2-macroglobulin domain containing 8 1.72 2.8332 6.582
CCR2 chemokine (C-C motif) receptor 2 1.7008 7.3355 10.206
DHRS9 dehydrogenase/reductase (SDR family) member 9 1.6849 4.2561 8.5782
SCN4B sodium channel, voltage-gated, type IV, beta subunit 1.662 0.1742 9.1766
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Table 5.3 Top down regulated genes following chemotherapy treatment in TAM. Table 
summarising the 20 most down regulated genes with the highest fold change. logFC: log10 fold 
change, logCPM: log10 counts per million, LR: log ratio, p-value < 0.05. 
 
Table 5.2 and Table 5.3 summarise the top 20 up and down regulated genes following 
chemotherapy. The gene that showed the greatest fold change increase in expression 
was TREML4 (triggering receptor expressed on myeloid cells-like 4), a positive regulator 
of TLR7 signalling.  CLDN16 (claudin 16), a component of tight junctions, was the gene 
showing the greatest fold change decrease in expression after chemotherapy. 
 
Pathway analysis of the differentially expressed protein-coding genes was then 
performed using gene set enrichment analysis (GSEA) for gene ontology categories and 
canonical pathways (Figure 5.8). Amongst the top twenty significantly upregulated 
pathways in the post-NACT samples were activation of AKT/PI3K signaling, IL6 
signaling, IL8 signaling, activation of the inflammasome and IL1b signaling. Top 
significantly down regulated pathways in the post-NACT TAM were ECM formation and 
remodeling, ECM interactions and signaling and cell cycle and proliferation pathways. 
Gene name Description logFC logCPM LR
CLDN16 claudin 16 -6.109 3.0031 18.189
FGFR2 fibroblast growth factor receptor 2 -5.685 2.6003 35.576
ESRP1 epithelial splicing regulatory protein 1 -4.705 2.0191 20.91
DCDC2 doublecortin domain containing 2 -4.673 1.7523 17.255
ERBB4 v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 -4.631 1.595 21.135
FOLR1 folate receptor 1 (adult) -4.423 1.4843 14.233
C1orf186 chromosome 1 open reading frame 186 -4.226 2.2082 22.457
LPAR3 lysophosphatidic acid receptor 3 -4.201 2.0938 25.631
VTCN1 V-set domain containing T cell activation inhibitor 1 -4.182 2.1053 14.561
CLDN3 claudin 3 -4.168 1.856 15.254
KIAA1199 KIAA1199 -4.074 3.5179 27.579
NEBL nebulette -4.002 2.2437 18.951
WFDC2 WAP four-disulfide core domain 2 -3.985 1.7237 22.523
EMX2 empty spiracles homeobox 2 -3.969 -0.124 17.556
ERBB3 v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 -3.955 2.2127 15.169
ESPN espin -3.94 -0.202 27.394
THSD4 thrombospondin, type I, domain containing 4 -3.872 3.9842 19.492
CDH3 cadherin 3, type 1, P-cadherin (placental) -3.845 1.3482 30.389
CP ceruloplasmin (ferroxidase) -3.827 3.5801 22.288
BMP7 bone morphogenetic protein 7 -3.794 1.5583 6.0655
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Figure 5.8 GSEA analysis of protein-coding genes differentially expressed in post-NACT 
vs treatment naïve TAMs. A Barplot shows the top enriched pathways following chemotherapy 
exposure (p-value <0.05). B Enrichment plots are illustrated for the inflammasome and IL1b 
signaling (highlighted in red in A). Positive enrichment scores correspond to upregulation in post-
NACT samples, negative enrichment scores correspond to downregulation. 
 
 Comparing TAM chemotherapy-associated transcriptional reprogramming 
with a spectrum-model of macrophage activation 
Xue et al. describe a spectrum-model of macrophage activation based on analysis of 
macrophage transcriptomes following exposure to different stimuli295. In this paper 
human CD14+ monocyte-derived macrophages were stimulated in vitro with twenty-nine 
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discrete stimuli and RNA microarray analysis was performed. From this dataset forty-
nine co-expressed gene modules were defined by a weighted correlation network 
analysis (WGCNA). To understand better TAM transcriptional reprogramming in 
response to chemotherapy treatment, I related the differentially expressed genes 
between chemotherapy treated and untreated TAMs to the spectrum-model WGCNA 
modules from the Xue et al. paper295.  
 
Figure 5.9 shows the correlation of the WGCNA modules with genes differentially 
expressed in TAM upon chemotherapy exposure. The most significantly positively 
correlated modules were “MEGreen”, “MESienna3”, “MEPaleturquiose” and 
“MEDarkgrey”. GSEA was then performed within each of these modules. In support of 
the pathway analysis  performed previously, within these four modules pathways relating 
to IL1 response, TLR signalling, IFNg signalling, positive regulation of NFkB signalling, 
antigen presentation, apoptosis and programmed cell death were significantly 
upregulated (Table 5.4, Table 5.5, Table 5.6, Table 5.7). 
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Figure 5.9 Heat map showing correlation between WGCNA module and HGSOC TAM genes 
differentially expressed genes following chemotherapy. Heatmap summarising the 
correlation of module eigengene (ME) values with the differentially expressed genes in TAM 
following chemotherapy treatment of human HGSOC. Each module of the forty-nine modules has 
been ascribed a unique colour and colours name. Red indicates a positive correlation, blue 
indicates a negative correlation. Significant p-values are indicated. 
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Table 5.4 Enrichment analysis for Gene Ontology Biological Processes on the genes 
clustering in the Green WCGNA module. Table summarises the z-scores for pathways 
upregulated in post-NACT samples (adj. p<0.05). 
 
 
Table 5.5 Enrichment analysis for Gene Ontology Biological Processes on the genes 
clustering in the Sienna3 WCGNA module in post NACT samples. Table summarises the z-
score for upregulated pathways (adj. p<0.05). 
Chapter 5: Results 
 123 
 
 
Table 5.6 Enrichment analysis for Gene Ontology Biological Processes on the genes 
clustering in the Paleturquiose WCGNA module. Table summarises the z-score for 
upregulated pathways in post-NACT samples (adj. p<0.05). 
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Table 5.7 Enrichment analysis for Gene Ontology Biological Processes on the genes 
clustering in the Darkgrey WCGNA module. Table summarises the z-score for pathways 
upregulated in post-NACT samples (adj. p<0.05). 
 
I then examined which of the individual in vitro stimuli correlated most strongly with these 
four co-expressed gene modules. I observed that the gene profiles that are altered in 
macrophages upon chemotherapy significantly over-lapped with the gene changes that 
occur upon in vitro stimulation with IL4 and the fatty acids palmitic acid (PA) and stearic 
acid (SA) (Figure 5.10). 
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Figure 5.10 Correlation of WGCNA module with biological stimuli. Heatmap showing the 
correlation of module eigenvalues to biological stimulation conditions, for the four modules with 
the highest enrichment in differentially expressed genes following chemotherapy. 
 
In summary these data suggest chemotherapy treatment of HGSOC results in 
transcriptional reprogramming of TAMs. There was enhancement of TLR signalling, T 
cell and eosinophil chemotaxis, lipid metabolism, inflammasome and IL1b signalling and 
declines in ECM formation and remodelling pathways. Overall these changes are not 
consistent with a strict M1 (classically activated)-M2 (alternatively activated)-axis re-
polarisation as assessed by individual gene expression changes.  
 
 Discussion 
I conducted RNA-sequencing to characterise the transcriptome of CD14+TAMs sorted 
from HGSOC omental metastases from twelve patients, five pre-chemotherapy and 
seven following NACT. Unsupervised clustering analysis of protein coding genes 
showed pre and post-chemotherapy samples largely clustered in distinct groups with 
some interspersed samples (Figure 5.5). This partitioning suggests that chemotherapy 
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results in distinct changes in macrophage gene expression. The large degree of 
biological viability between samples (Figure 5.4) and the relatively small sample number 
from unmatched patients may underlie the lack of complete separation of samples by 
chemotherapy exposure. 
 
The top unregulated gene was TREML4, a gene implicated in the immune responses of 
dead or dying cells. TREML4 is a member of the TREM family of proteins that are 
important in fine-tuning immune responses296. The protein is known to be highly 
expressed on macrophages and DCs297. Treml4 binds nucleic acids, late apoptotic and 
necrotic cells297. Treml4 was specifically enriched in CD8a+ DC vs CD8a- DC, the former 
have particular roles in antigen presentation297. Ramirez-Ortiz et al. show that Treml4 
positively regulated macrophage activation, by amplifying the TLR7-mediated production 
of inflammatory cytokines, such as type I interferons298. Furthermore, Hemmi et al. show 
that Treml4 enhances the presentation of antigens to CD4+ and CD8+ T cell in vivo299. 
Targeting Treml4 with a HER2-anti-treml4 fusion protein resulted in presentation of 
HER2 to CD4+ and CD8+ T cells and engagement of anti-tumour immunity in a 
transplantable breast cancer model299. These data collectively suggest that this protein 
has important roles in engaging adaptive immunity through the recognition and 
presentation of antigens from dead or dying cells. Therefore, this result suggests that 
macrophages, following chemotherapy, may be important activating immune responses 
to dying malignant cells via TREML4. 
 
Also within the top ten upregulated genes post-chemotherapy were CCL24 (chemokine 
C-C motif ligand 24), FABP4 (fatty acid binding protein 4) and LPL (lipoprotein lipase). 
CCL24 is a known potent chemoattractant for resting T cells, eosinophils and 
neutrophils300. FABP4 is a known fatty acid binding protein with known roles in lipid 
transfer between adipocytes and tumour cells in omental metastasis301. LPL is essential 
in lipid metabolism. Upregulation of these genes may reflect switches in TAM metabolism 
as a result of normalisation of the fatty omental tissue post-chemotherapy. The most 
significantly down regulated gene was CLDN16, encoding CLDN16, a member of the 
claudin family of proteins, essential in the formation of tight junctions302. It is interesting 
that this was the most significantly downregulated gene as, to date, these proteins have 
no known roles within macrophages. Within the top ten down regulated genes was 
LPAR3 (lysophosphatidic acid receptor 3). Interestingly, lysophosphatidic acid, a 
bioactive fatty acid, has tumour promoting activity in HGSOC correlating with genes 
regulating cellular mobility and migration as well as cell communication and signalling in 
HGSOC ascites303. PDCD1 the gene encoding programmed cell death 1 (PD1) was also 
significantly down regulated in post-chemotherapy samples but was not in the top twenty 
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genes shown in Table 4.2. PD1 expression on macrophages inhibits phagocytosis304, 
suggesting a possible mechanism by which chemotherapy may mediate increased 
phagocytosis by TAM. 
 
Pathway analysis of the differentially expressed protein-coding genes was performed 
using GSEA for Gene Ontologies categories and canonical pathways. The most 
significantly enriched downregulated pathways were ECM deposition, remodeling and 
interaction along with cell cycle and proliferation pathways (Figure 5.8). Within the top 
significantly enriched pathways was activation of the inflammasome as well as IL1b, IL8 
and PI3K/AKT signaling pathways. TLR signaling was also upregulated in the pathway 
analysis (not shown in Figure 5.8), fitting with the observation of TREML4 being the top 
upregulated gene.  
 
Enrichment of the linked processes of TLR, inflammasome and IL1b signaling suggests 
that chemotherapy may result in TLR activation with downstream inflammasome 
assembly and IL1b production. As the majority of HGSOCs are sensitive to first-line 
chemotherapy, increased TAM exposure to apoptotic/dying cancer cells shortly following 
chemotherapy is likely. As the TLR family have evolutionary conserved roles in 
recognizing DAMPs and PAMPs of diverse origin305 upregulation of these pathways is in 
keeping with TAMs responding to dying cancer cells. These changes concomitant with 
highly significant decreases in ECM secretion, interaction and remodeling pathways 
which represent key functions of TAM in HGSOC and other cancers highlight radical 
TAM transcriptional re-programming following chemotherapy139,289. Overall these data 
suggest a skew away from classically described TAM functions towards an overall pro-
inflammatory and potentially anti-tumoural phenotype. 
 
Assessment of canonical macrophage activation makers demonstrated no significant 
changes in transcript expression across chemotherapy treated and untreated myeloid 
cells (MRC1 [CD206], CD163, HLA-DQ, CD80, CD86, iNOS). This suggested that the 
changes observed upon chemotherapy exposure were not captured by the M1 
(classically activated)-M2 (alternatively activated) paradigm.  This is in keeping with 
studies of ascites-derived TAM obtained from HGSOC which demonstrated a ‘mixed’ 
TAM phenotype as assessed by the expression of canonical macrophage activation 
markers198. A comparison between TAM and resident peritoneal macrophages showed 
that CD163 was upregulated but M1/classically activated markers (MHC, iNOS, TLR) 
were also upregulated.  
 
To further explore for changes in macrophage activation following chemotherapy 
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treatment I compared my data with a comprehensive transcriptome-based study of 
macrophage activation by Xue et al. To do this I determined which of the WGCNA 
modules described by Xue et al. most positively correlated with genes reflecting TAM 
chemotherapy exposure (Figure 5.9). Enrichment analysis within the four most 
correlated modules demonstrated pathways regulating TLR signalling, IL1b tissue 
response, programmed cell death and apoptosis (Table 5.4, Table 5.5, Table 5.6, Table 
5.7). This analysis serves to validate my results in a much larger, independent dataset.  
 
Finally I determined how biological stimuli interacted with the four modules most 
associated with TAM chemotherapy exposure. Interestingly in three of the four 
upregulated pathways the fatty acids palmitic and stearic acid were most correlated. 
Palmitic acid induces an inflammatory activation state in macrophages at physiological 
concentrations306. IL4 was correlated with the module “MEGreen”, however, this module 
was not highly associated with alternatively activated-stimuli (IL4, 1L-10) in the Xue et 
al. dataset overall. Indeed, the most highly correlated modules to M2-stimuli were 
“MERed”, “MEPlum”, and “MESaddlebrown”, whereas the most correlated modules to 
classically activated-stimuli (LPS, IFNg) were “MEOrangered4”, “MESteelblue” and 
“MEYellowgreen” – these modules were not significantly associated with transcriptional 
changes reflecting macrophage exposure to chemotherapy in my dataset. Although in 
this analysis I am comparing my data to a highly artificial system of macrophages 
exposed to single stimuli in vitro, the analysis does suggest changes in TAM 
transcriptional programs upon chemotherapy exposure distinct from the M1 (classically 
activated)-M2 (alternatively activated)  axis. This conclusion is supported by Cassetta et 
al. who demonstrate breast and endometrial cancer TAMs did not display enrichment for 
an M2-gene signature, which suggests TAM phenotypes cannot be categorised in this 
simplistic manner133. 
 
The limitations of the data presented in this chapter include the small number of samples 
and the fact that significantly different mRNA expression levels have not been validated 
by protein expression. Further validation with IHC and in situ hybridisation with RNA 
scope should be undertaken to complete this aspect of the project. 
 
These data lead me to conclude that chemotherapy treatment of HGSOC results in 
transcriptional reprogramming of TAMs, with features distinct from M1 (classically 
activated)-M2 (alternatively activated)-axis phenotypes and associated with a skew away 
from established pro-tumoural function, towards an antigen sensing, anti-tumour 
phenotype. This suggest that TAM chemotherapy exposure may foster overall 
antitumoral immunity in human HGSOC. 
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 Overall summary of human data (Chapters 3-5) 
• I found that NACT significantly decreased CD68+ densities within malignant cell 
areas of HGSOC omental biopsies.  
• Analysis of larger tissue sections revealed NACT promoted the formation of 
stromal macrophage ‘lakes’. 
• Stratifying patients by TAM density suggested enhanced survival in patients with 
high TAM density post-NACT.  
• FC analysis of treatment naïve and post-NACT HGSOC samples showed 
decreases in CD163+ and CX3CR1+ TAM, an increase in non-viable TAMs and 
an increase in DCs. 
• RNA-sequencing showed that NACT increased IL-1b, inflammasome and TLR 
pathways and decreased ECM, matrix remodelling and proliferation pathways in 
TAM. 
 
Taken together, I conclude that at a time point three-four weeks after NACT, TAM and 
DC populations are more likely to aid than inhibit host anti-tumour responses. 
 
In the next chapter I will ask if the effects of chemotherapy on myeloid cells can be 
reproduced in mouse models of HGSOC. I will use these models to gain further 
understanding of the effects of chemotherapy on TAMs and to provide a platform to 
explore the effects of TAM depletion in HGSOC. 
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6The effect of chemotherapy on the tumour microenvironment in murine HGSOC 
 Background 
HGSOC is characterised by ubiquitous TP53 mutations/deletions with frequent defects 
in genes regulating homologous recombination pathways7,20. A cardinal feature is 
widespread genome amplification and deletion7. 
 
In this thesis I have used three syngeneic injectable murine models that harbour many 
of the genetic features of human HGSOC: 60577, 30200 and HGS2. 60577 and 30200 
cell lines were established from tumours from genetic models generated by adenoviral 
transfection of the ovarian surface epithelium in FVB mice272. HGS2 was generated from 
tumours derived from a different genetic model273 that has been backcrossed to a Bl6 
background in our lab. 60577 and 30200 cell lines are Tp53-/-, Brca-1-/- and have 
inactivation of the pRb pathway. Both these cell lines, when injected intraperitoneally, 
produce tumours within the omentum, as well as miliary peritoneal deposits and large 
volume ascites when they reach an advanced stage. 60577 and 30200 models differ in 
latency, with 60577 tumours reaching an advanced stage in five-six weeks from cell 
injection, compared to eighteen-twenty weeks in the 30200 model. HGS2 is Tp53-/-, Pten-
/- and Brca-2-/-. This model produces metastasis to the omentum and other peritoneal 
sites reaching an advanced stage in around twelve weeks.   
 
Recently work in our lab has characterised the cellular, molecular, and biomechanical 
characteristics of these models and compared these data to patient biopsies (Maniati et 
al. submitted for publication). There were significant correlations in mRNA expression 
profiles, tissue modulus (a measure of material stiffness independent of sample 
dimension), host cell infiltrates, matrisome, vasculature and immune response pathways 
between the mouse and human TMEs showing that these models faithfully replicate 
features of human HGSOC. Although there were strong similarities between the models 
there were significant differences and potential therapeutic vulnerabilities.  Overall the 
analyses show that multiple models are needed to capture the diverse therapeutic 
response of human HGSOC. Hence, I studied three of the synegeneic models in this 
thesis with differing transcriptional profiles, natural histories and from two different mouse 
backgrounds. 
 
The models used here develop tumours in the murine omentum, as this is the site studied 
in patients in this thesis (Chapters 3-5) and in previous work in the lab113,114,307. In this 
chapter I will test the effects of carboplatin and paclitaxel chemotherapy on myeloid cell 
and lymphocyte cell number and phenotype in omental tumours and compare this to my 
findings in patients. 
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 In vitro sensitivity of the 60577, 30200 and HGS2 cell line to chemotherapy 
Before evaluating the effects of chemotherapy in vivo, I assessed the sensitivity of the 
60577, 30200 and HGS2 mouse cell lines272,273 to carboplatin and paclitaxel in vitro 
(Figure 6.1). IC50 values were similar between the three cell lines and were within the 
range described for human ovarian cancer cell lines308,309. 
 
Figure 6.1 The effects of carboplatin and paclitaxel chemotherapy on the 60577, 30200 and 
HGS2 cell lines in vitro. OD595 measurements presented as mean with error bars representing 
SEM, data normalised to media-only control. A carboplatin treatment, B paclitaxel treatment. 
30200 (green line), 60577 (red line) and HGS2 (blue) data combined from three separate 
experiments. IC50 values carboplatin: 60577=155µM, 30200=100µM HGS2=87µM; IC50 paclitaxel 
60577=31nM, 30200=12nM HGS2=7nM. 
 Summary of mouse experiments in this chapter 
In this chapter I present data from four mouse experiments conducted in three HGSOC 
models. Figure 6.2 describes the experimental outline for each mouse experiment. 
60577 and 30200 models were treated with carboplatin and paclitaxel. HGS2 was only 
treated with carboplatin. To reflect the clinical situation of treating patients with 
disseminated disease, mice were treated when tumours were established in the 
peritoneum. The experimental time points chosen were determined by detailed natural 
histories of the models conducted previously in the lab. 
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Figure 6.2 Schematic outline of all mouse experiments presented in this chapter. Box colour 
relates to murine model: 60577 model (black box), 30200 model (pink box), HGS2 model (blue 
box). A, B Time course experiment in 60577 model, mice were treated twenty-one days following 
cell injection with carboplatin, paclitaxel or vehicle, mice were culled at the time points indicated. 
C Time point experiment in the 30200 model, mice were treated 11.5 weeks following cell injection 
with carboplatin, paclitaxel or the combination of carboplatin and paclitaxel or vehicle. Mice were 
culled forty-eight hours after the final treatment. D Time point experiment in the HGS2 model, 
mice were treated eight weeks following cell injection with carboplatin or vehicle. Mice were culled 
six days after the final treatment. OD: once a day, BD: twice a day, OG: oral gavage. 
 
 Effects of chemotherapy on tumour growth and survival 
I wanted to determine the individual contribution of carboplatin and paclitaxel on survival 
and TAM phenotype. Therefore, in the majority of experiments in this thesis mice were 
exposed to single-agent treatment with either carboplatin or paclitaxel, rather than 
receiving these drugs in combination. Response to treatment was assessed by 
measuring omental weight and determining mouse survival. 
 
6.4.1 60577 model 
The mouse omentum is a discrete structure that can be identified and dissected in its 
entirety310,311. Therefore, I used omental weight as a surrogate measure of the degree of 
tumour infiltration within this structure. Furthermore, due to the miliary nature of 
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peritoneal disease dissemination, attempting to measure total tumour burden in these 
models would have been difficult and inaccurate. The carboplatin and paclitaxel time-
course experiments (Figure 6.2) allowed serial assessment of tumour (i.e. omental) 
weight through treatment in addition to the FC analysis. Figure 6.3 shows that 60577 
tumours were highly sensitive to carboplatin treatment. Omental weight decreased 
throughout the experiment in carboplatin treated mice, whereas control omenta 
increased in weight due to disease progression. The differences in omental weight 
reached statistical significance at a time point forty-eight hours after the second 
treatment of carboplatin. This is in clear contrast to the treatment of the 60577 model 
with paclitaxel (Figure 6.4), here there is no significant difference in omental weight at 
any time point in the study. 
 
 
Figure 6.3 The effect of carboplatin on omental weight in the 60577 model. Omental weight 
of tumours from mice culled at time points two days, seven days, nine days and fourteen days 
following completion of carboplatin treatment. Data relate to a single experiment, five mice per 
group, the mean for each group is shown. Error bars represent SEM. Dashed lines indicate 
treatment scheduling. Significant two-way ANOVA p-values are shown; **<0.01, ****< 0.0001. 
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Figure 6.4 The effects of paclitaxel on omental weight in the 60577 model. Omental weight 
of tumours from mice culled at time points two days, seven days, nine days and fourteen days 
following completion of paclitaxel treatment. Data relate to a single experiment, five mice per 
group, the mean for each group is shown. Error bars represent SEM. Dashed lines indicate 
treatment scheduling. 
 
In a further time point experiment in the 60577 model mice were treated with three doses 
of carboplatin, given at weekly intervals. Replicating features of treatment in patients, 
clinical signs of ascites resolved with carboplatin treatment. Mice proceeded to live 
without outward signs of disease for six weeks, resulting in significantly increased 
survival (Mantel-Cox log-rank p<0.0001) in carboplatin treated compared to vehicle-
treated mice (Figure 6.5A). At this time point mice were culled and the omenta examined. 
Microscopically, there were small foci of malignant cells indicating the beginnings of 
tumour regrowth. Omenta from carboplatin treated mice weighed significantly less then 
omenta from vehicle-treated controls reaching humane endpoint (44.7mg vs 9.2mg 
p<0.0001). Overall these data suggest that 60577 tumours are highly sensitive to 
carboplatin but not paclitaxel chemotherapy in vivo. Furthermore, the effects of 
carboplatin treatment were long lived, persisting up to a time point six weeks following 
treatment. 
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Figure 6.5 The effect of carboplatin treatment on the 60577 model. A Kaplan-Meier curves 
comparing mice treated with three once-weekly doses of carboplatin (red line) or 0.9% NaCl 
(black line). Dashed lines indicate treatment events and the time point when mice were culled. 
Log-rank (Mantel-Cox) p-value is shown. B Omental weight recorded for control mice succumbing 
to disease at endpoint and carboplatin treated mice culled six weeks post carboplatin treatment. 
Data relates to a single experiment, ten mice per group, the mean for each group is shown. Error 
bars represent SEM. Student’s t-test is shown to compare means between groups, ****<0.0001. 
 
 
6.4.2 30200 model 
I next assessed the effects of carboplatin, paclitaxel and combination treatment in the 
30200 model. Figure 6.6 shows the effects of treatment on the weight of omenta 
harvested forty-eight hours following three weekly treatments of chemotherapy. At this 
time point I observed a significant reduction (33.4mg vs 14.8mg p=0.043) in omental 
weight between carboplatin treated and paclitaxel treated mice. At this number of mice, 
there was a non-significant trend towards a reduction in omental weight in carboplatin 
and combination treated mice compared to vehicle-treated controls (Figure 6.6). 
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Figure 6.6 The effects of chemotherapy on 30200 tumour weight. Omental weight of tumours 
treated with carboplatin, paclitaxel, the combination of carboplatin and paclitaxel or vehicle from 
mice culled at a time point forty-eight hours following the last treatment. Data relates to a single 
experiment, five mice per group, the mean for each group is shown. Error bars represent SEM. 
Significant one-way ANOVA p-values are shown, *<0.05. 
 
Assessment of survival in the 30200 model was undertaken, comparing paclitaxel and 
combination treated tumours to vehicle-treated controls. Due to limitations of the number 
of mice available, I did not assess the effects of carboplatin alone in this experiment. 
Treatment with paclitaxel alone extended median survival, however, this was not 
significantly different compared to vehicle-treated controls (median survival of 143 vs 
126.5 days, Mantel-Cox log-rank p=0.19) (Figure 6.7). Treatment with the combination 
of paclitaxel and carboplatin significantly increased survival compared to control mice 
(median survival of 164 vs 126.5 days, Mantel-Cox log-rank p=0.012) (Figure 6.7), 
suggesting either increased sensitively of 30200 tumours to carboplatin or a synergistic 
action between these two drugs.  
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Figure 6.7 Effect of chemotherapy on survival in the 30200 model. Kaplan-Meier curves 
comparing mice treated with weekly paclitaxel i.p. injections (red line), carboplatin and paclitaxel 
combination treatment (blue line) or 0.9% NaCl (black line). Five mice per group. Log-rank 
(Mantel-Cox) p-values are indicated for survival differences between control and treated groups; 
ns denotes a non-significant p-value; *<0.05. 
 
6.4.3 HGS2 model 
I also used carboplatin to treat established HGS2 tumours. Mice again received three 
doses of carboplatin 20mg/kg administered weekly. Mice were culled at a time point one 
week after the completion of treatment. As seen in Figure 6.8B carboplatin treatment did 
not significantly affect tumour weight at this time point. However, carboplatin significantly 
increased survival compared to untreated controls (median survival of 105 vs 84 days, 
Mantel-Cox log-rank p=0.0027) (Figure 6.8A). Paclitaxel treatment was not tested in this 
model. 
 
 
Figure 6.8 The effects of carboplatin treatment on the HGS2 model. A Kaplan-Meier curves 
comparing mice treated with three once-weekly doses of carboplatin (red line) or 0.9% NaCl 
(black line). Dashed lines indicate treatment events. Log-rank (Mantel-Cox) p-value is shown. B 
Total tumour weight recorded for mice succumbing to disease at endpoint. Data relate to a single 
experiment, four vehicle-treated mice and five carboplatin treated mice, the mean for each group 
is shown. Error bars represent SEM. 
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In summary, all models used in this thesis were sensitive to carboplatin or the 
combination of carboplatin and paclitaxel given as three weekly doses. However, there 
were obvious differences in the response of the models. 60577 tumours were clearly the 
most sensitive to carboplatin treatment with extension of survival in excess of six weeks, 
whereas in HGS2 tumours the difference in median survival was three weeks.  
 
 Characterisation of murine TAMs by flow cytometry 
FC was used to assess the TAM populations of all three models. The gating strategy 
used is shown in Figure 6.9. Mouse TAMs initially were defined as CD45+Ly6C-Ly6G-
F4/80+CD11b+ cells. However, there were two clearly identifiable sub-populations 
varying in F4/80+ expression. I referred to these as F4/80high and F4/80dim cells (Figure 
6.9G). Characterisation of these populations demonstrated differences in canonical 
macrophage marker expression. The majority of F4/80dim cells were negative for MHC 
class II (Figure 6.9Ga) and CD206 in contrast to the F4/80high population (Figure 6.9Gb). 
Furthermore, the F4/80high and F4/80dim populations differed in their forward and side 
scatter parameters (Figure 6.9Ga, Gb). To determine if F4/80dim cells were TAMs or 
represented another cell population, I sorted F4/80high and F4/80dim populations from 
60577 tumours. H&E staining of the sorted populations showed that the F4/80dim gate 
contained a mixed population of cells, with nuclear features suggestive of eosinophils 
and myeloid cells (Figure 6.10A). The F4/80high gate contained only cells with a myeloid 
appearance (Figure 6.10B). Murine eosinophils have a ring-shaped nucleus312 and 
myeloid cells typically have a kidney shaped nucleus313. This result, in combination with 
the flow cytometry analysis of the different populations showed that the F4/80dim 
population contains a large proportion of eosinophils. 
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Figure 6.9 Multi-colour flow cytometry gating strategy to characterise murine TAM 
populations. Density plots from a representative immunostained murine HGSOC omental 
tumour. A Gating to exclude cellular debris, B, C sequential gating to exclude doublet cells, D 
sequential gating to exclude non-viable cells, E sequential gating for CD45+ cells, F sequential 
gating for Ly6C-Ly6G- cells G sequential gating for F4/80+CD11b+ cells showing F4/80high and 
F4/80dim population, Ga F4/80dim population showing MHC Class II and SSC-A parameters Gb 
F4/80high population showing MHC Class II and SSC-A parameters H Gating for eosinophils (SSC-
A high MHC Class II negative cells) and TAMs (MHC Class II+ cells) further assessment of TAM 
markers was made within this gate. SSC-A: side scatter area, SSC-W: side scatter width, FSC-
A: forward scatter area, FSC-H: forward scatter height. 
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Figure 6.10 F4/80dim and F4/80high CD11b+F4/80+ sub-populations contain different cell 
types. H&E staining of cytospun flow sorted F4/80dim and F4/80high cells, demonstrating 
differences in nuclear morphology and eosin uptake. Scale bar, 25μm 
 
Examining H&E stained sections of murine tumours at high magnification showed the 
presence of eosinophilic cells with typical nuclear features of eosinophils, further 
supporting these observations (Figure 6.11). 
 
 
Figure 6.11 Eosinophil population within 60577 HGSOC tumours. H&E staining of a 60577 
tumour viewed under x63 objective. Arrows indicate eosinophils identified by eosinophilic 
cytoplasmic granules and nuclear morphology. Scale bar, 25μm. 
 
To validate the flow cytometry findings, I stained tumour tissue sections with anti-F4/80 
and anti-CD206 antibodies. I observed F4/80+ eosinophils (Figure 6.12A) in tissue 
sections, as expected from the flow cytometry data these cells were CD206-negative 
(Figure 6.12B). This result validates the flow cytometry findings and has implications for 
F4/80 as a generally applicable pan-macrophage marker in these murine models.  
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Figure 6.12 Demonstration of eosinophils in a 60577 murine HGSOC tumour. A F4/80 B 
CD206 staining of the same area of a 60577 tumour section. Arrows indicate eosinophils based 
on nuclear morphology. Scale bar, 25μm. 
 
In further experiments, I found eosinophil populations in all three murine models. To 
ensure that TAMs are gated separately from the eosinophil population I have therefore 
defined TAMs by flow cytometry as CD45+Ly6C-Ly6G-F4/80+CD11b+MHC Class II+ cells 
(Figure 6.10H), this allowed clear separation of eosinophils from TAMs. Through this 
thesis I have ensured separation of eosinophils from the TAM population in all flow 
cytometry analyses performed. 
 
6.1 The effect of chemotherapy on TAM cell number in murine HGSOC 
6.1.1 60577 model 
To examine the effects of carboplatin chemotherapy in this model, mice were treated 
with carboplatin 20mg/kg intra-peritoneally (i.p.) commencing twenty-one days after 
60577 cell injection. Mice were injected once weekly for three weeks. Flow cytometry 
was used to assess the omental TME compared to vehicle-treated controls at time points 
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forty-eight hours and seven days following each dose of carboplatin (Figure 6.13A). 
 
I observed striking reductions in the TAM population within carboplatin treated tumours 
compared to vehicle controls, both when TAMs were quantified as a percentage of the 
CD45+ population (Figure 6.13A) and as cells/mg of tissue (Figure 6.13B). Expressing 
the data as cells/mg of tissue showed incremental decreases in TAM cell number in 
carboplatin treated tumours over the two-week experiment. This suggests evolving 
effects of carboplatin treatment. Interestingly, only forty-eight hours following the first 
dose of carboplatin, I observed a significant reduction in TAM density in carboplatin-
treated compared to control tumours. Two weeks after the start of treatment TAM cell 
number corresponded to that of the healthy omentum (Figure 6.13B). 
 
 
Figure 6.13 Effect of carboplatin on TAM density in the 60577 model. Flow cytometry data 
relating to the immunostained stromal vascular fractions derived from omental tumours treated 
with carboplatin (red circles), vehicle alone (black squares) or healthy omental controls (unfilled 
squares). A TAM frequency is expressed as a percentage of the CD45+ population and B as 
cells/mg of tissue. Data relate to a single experiment, five carboplatin treated mice, four-five 
vehicle-treated mice per time point and ten healthy omental controls; cells from healthy omental 
controls were combined and stained as five separate samples, the mean for each group is shown. 
Error bars represent SEM. Significant two-way ANOVA p-values are shown; **<0.01, ****<0.0001. 
Experiment performed twice. 
 
To further validate the results obtained by flow cytometry, I sought to confirm these 
findings by staining omental tissue sections with an anti-F4/80 antibody. There was a 
significant reduction of the percentage F4/80+ area in carboplatin treated compared to 
vehicle-treated controls at the day fourteen time point (Figure 6.14). As previously 
determined, F4/80 is not a specific marker for macrophages in these models, therefore I 
also stained for CD206, a marker predominantly expressed on macrophages and 
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immature dendritic cells314. There was also a significant reduction of CD206+ percentage 
area in carboplatin treated compared to vehicle controls at fourteen day time point 
(Figure 6.15, Figure 6.16). 
 
 
Figure 6.14 Quantification of F4/80 staining by Definiens® digital analysis in 60577 omental 
tumours. F4/80 staining expressed as percentage positive area of the biopsy. Data quantified 
relates to a single experiment, five carboplatin treated mice (red circles), four-five vehicle-treated 
mice (black squares), at a time points following two doses of carboplatin treatment, the mean for 
each group is shown. Error bars represent SEM. Significant two-way ANOVA p-value is shown; 
*<0.05. 
 
Figure 6.15 60577 omental tumour biopsies stained with an anti-CD206 antibody. 
Representative images from mice treated with carboplatin (bottom row) and vehicle controls (top 
row) fourteen days after the start of treatment. Scale bar: 100μm. 
Carboplatin 
Control 
Chapter 6: Results 
 145 
 
Figure 6.16 Quantification of CD206 staining by Definiens® digital analysis in 60577 
omental tumours. Data relates to a single experiment, five carboplatin treated mice, five vehicle-
treated mice, at a time point fourteen days following the start of treatment, the mean for each 
group is shown. Error bars represent SEM. Student’s t-test p-values is shown; *<0.05. 
 
Taken together these results show that carboplatin treatment depletes TAM from 60577 
model omental tumours. This process was rapid and resulted in densities of TAM similar 
to healthy omenta fourteen days following the start of treatment. 
 
Current standard first line chemotherapy for HGSOC is the combination of carboplatin 
and paclitaxel. Therefore an analogous experiment was conducted using paclitaxel at a 
dose of 10mg/kg i.p. (Figure 6.2B). Assessment of TAM density both as percentage of 
the CD45+ cell infiltrate and as cells/mg of tissue demonstrated no significant difference 
between paclitaxel treated and vehicle-treated control (Figure 6.17). These data show 
that carboplatin but not paclitaxel depleted TAM in this model. 
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Figure 6.17 Effect of paclitaxel on TAM density in the 60577 model. Flow cytometry data 
relating to the immunostained stromal vascular fractions derived from omental tumours treated 
with paclitaxel (red circles), vehicle alone (black squares) or healthy omental controls (unfilled 
squares). A TAM frequency is expressed as a percentage of the CD45+ population and B as 
cells/mg of tissue. Data relate to a single experiment, five paclitaxel treated mice, five vehicle-
treated mice per time point and ten healthy omental controls; cells from healthy omental controls 
were combined and stained as four separate samples, the mean for each group is shown. Error 
bars represent SEM. Student’s t-test p-value shown to compare means between normal omentum 
and control tumours at the start of treatment; ***p<0.001, p****<0.0001.  
 
6.1.2 30200 model 
To extend my assessment to the effects of chemotherapy on TAMs in murine HGSOC, 
I next treated 30200 tumour-bearing mice with either paclitaxel 10mg/kg i.p., carboplatin 
20mg/kg i.p., the combination of paclitaxel and carboplatin or vehicle alone. Assessment 
of TAM density after the third dose of chemotherapy demonstrated striking and 
significant reductions in TAM density in carboplatin and combination treated mice 
compared to vehicle-treated controls (Figure 6.18). Interestingly, and in support of my 
previous observations in the 60577 model, there were no differences in TAM density in 
tumours treated with paclitaxel alone compared to vehicle-treated controls (Figure 6.18). 
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Figure 6.18 Effect of chemotherapy on TAM frequency in the 30200 model. Flow cytometry 
data relating to the immunostained stromal vascular fractions derived from omental tumours 
treated with three once-weekly doses of carboplatin, paclitaxel, carboplatin + paclitaxel or vehicle 
alone. A TAM frequency is expressed as a percentage of the total CD45+ cell infiltrate. B TAM 
density expressed as cells/mg of tissue. Data relate to a single experiment, five mice per group, 
the mean for each group is shown. Error bars represent SEM. Significant one-way ANOVA p-
values are shown; *p <0.05, **p<0.01. 
 
6.1.3 HGS2 model 
Finally, I assessed the effects of carboplatin treatment in the HGS2 model. Mice were 
culled seven days after a third dose of carboplatin (Figure 6.2D). As seen in Figure 6.19 
the differences between carboplatin treated and vehicle controls at this time point, with 
this number of samples, was not statistically significant. However, in keeping with effects 
seen in the 60577 and 30200 models, there was a trend to a reduction (p=0.1) in TAM 
cell number after carboplatin treatment compared to vehicle-treated controls. 
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Figure 6.19 Effect of carboplatin on TAM density in the HGS2 model. Flow cytometry data 
relating to the immunostained stromal vascular fractions derived from omental tumours treated 
with carboplatin (red circles) or vehicle alone (grey diamonds). A TAM frequency is expressed as 
a percentage of the CD45+ population and B as cells/mg of tissue. Data relate to a single 
experiment. The mean for each group is shown. Error bars represent SEM. 
 
In summary, these data suggest that carboplatin treatment depletes macrophages from 
murine omental HGSOC tumours. This finding is in contrast to the effects of paclitaxel 
treatment. The results are also consistent with the reduction in TAM in the malignant cell 
areas post-NACT in human HGSOC. 
 
6.2 Examining the phenotype of TAM before and after chemotherapy 
6.2.1 60577 model 
Although the time points following chemotherapy assessed in murine and human 
tumours differed, the data overall showed a reduction of TAM following carboplatin 
treatment. To understand this further, I set out to determine in the mouse models if the 
reduction in TAM was due to loss of certain populations of TAM or a global loss of all 
TAM subtypes, using a range of markers (CD206, PDL1 and MHC Class II). CD206 and 
PDL1 were used as markers of an alternatively activated or immunosuppressive 
macrophage phenotype. Class II MHC was used as a marker of classical activation. 
 
Both CD206+ and PDL1+ TAMs were significantly decreased in carboplatin compared to 
vehicle-treated tumours as a percentage of the CD45+ population and as cells/mg of 
tissue (Figure 6.20). By day fourteen the number of PDL1+ and CD206+ TAMs 
approximated the numbers seen in normal omental tissue (Figure 6.20C, D).  
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Figure 6.20 Effect of carboplatin on CD206+TAM and PDL1+TAM density in the 60577 model. 
Flow cytometry data relating to immunostained stromal vascular fractions derived from omental 
tumours treated with carboplatin (red circles), vehicle alone (black squares) or healthy omental 
controls (unfilled squares). A CD206+TAM frequency is expressed as a percentage of the CD45+ 
population and B as cells/mg of tissue. C PDL1+TAM frequency is expressed as a percentage of 
the CD45+ population and D as cells/mg of tissue. Data relate to a single experiment, five 
carboplatin treated mice, four-five vehicle-treated mice per time point and ten healthy omental 
controls; cells from healthy omental controls were combined and stained as five seperate 
samples, the mean for each group is shown. Error bars represent SEM. Significant two-way 
ANOVA p-values are shown; **p <0.01, ****p <0.0001.  
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I next assessed the frequency of MHC Class II-high expressing TAMs (MHC Class II+) 
and CD86+TAM, both markers associated with a proinflammatory ‘anti-tumour’ TAM 
phenotype. Here again I observed significant decreases in the numbers of TAMs 
expressing both these markers as a percentage of the CD45+ population and as cells/mg 
of tissue (Figure 6.21).   
 
Figure 6.21 Effect of carboplatin on MHC Class II+TAM and CD86+TAM density in the 60577 
model. Flow cytometry data relating to the immunostained stromal vascular fractions derived 
from omental tumours treated with carboplatin (red circles), vehicle alone (black squares) or 
healthy omental controls (unfilled squares). A MHC Class II+TAM frequency is expressed as a 
percentage of the CD45+ population and B as cells/mg of tissue. C CD86+TAM frequency is 
expressed as a percentage of the CD45+ population and D as cells/mg of tissue. Data relate to a 
single experiment, five carboplatin treated mice, four-five vehicle-treated mice per time point and 
ten healthy omental controls; cells from healthy omental controls were combined and stained as 
five separate samples, the mean for each group is shown. Error bars represent SEM. Two-way 
ANOVA p-values are shown; *<0.01, **<0.01, ****<0.0001. 
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These data suggest that carboplatin treatment results in a rapid depletion of TAM 
expressing both pro- and anti-inflammatory markers. This may reflect a depletion of 
multiple TAM subpopulations, rather than depletion of a specific subpopulation of TAM 
defined by expression of a single marker. 
 
6.2.2 30200 model 
In agreement with my observations in the 60577 model, I observed significant reductions 
in CD206, PDL1 and MHC Class II-high expressing TAMs as a percentage of the total 
CD45+ cell infiltrate and as cells/mg of tissue (Figure 6.22) in the 30200 experiment. 
These data suggest that carboplatin either alone or in combination with paclitaxel 
depletes TAM expressing a broad range of macrophage markers. 
Chapter 6: Results 
 152 
 
Figure 6.22 Effect of chemotherapy on TAM populations in the 30200 model. Flow cytometry 
data relating to the immunostained stromal vascular fractions derived from omental tumours 
treated with three once-weekly doses of carboplatin, paclitaxel, carboplatin + paclitaxel or vehicle 
alone. A, C, E CD206+TAMs, PDL1+TAMs and MHC Class II+TAMs frequency is expressed as a 
percentage of the total CD45+ cell infiltrate, B, D, F CD206+TAMs, PDL1+TAMs and MHC Class 
II+TAM frequency is expressed as cells/mg of tissue. Data relate to a single experiment, five mice 
per group, the mean for each group is shown. Error bars represent SEM. Significant one-way 
ANOVA p-values are shown; *p <0.05, **p <0.01. 
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6.2.3 HGS2 model 
Finally, I preformed the same analysis in the HGS2 model. As described above, I did not 
find significant reductions in overall TAM density in this model. There were no significant 
differences in CD206+, PDL1+ (Figure 6.22) and MHC Class II-high (MHC Class II+) 
TAMs (Figure 6.23) as a percentage of the CD45+ cell infiltrate and as cells/mg of tissue 
following carboplatin treatment compared to vehicle-treated controls. There were 
however, non-significant reductions in all markers assessed, which, in the context of the 
changes seen in the previous two models would suggest a conserved effect across all 
three murine HGSOC models. 
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Figure 6.23 Effect of carboplatin on TAM density in the HGS2 model. Flow cytometry data 
relating to the immunostained stromal vascular fractions derived from omental tumours treated 
with carboplatin (red circles) or vehicle alone (grey diamonds). A, C CD206+TAM and PDL1+TAM 
frequency is expressed as a percentage of the CD45+ population and B, D as cells/mg of tissue. 
Data relates to a single experiment. The mean for each group is shown. Error bars represent 
SEM. 
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Figure 6.24 Effect of carboplatin on TAM density in the HGS2 model. Flow cytometry data 
relating to the immunostained stromal vascular fractions derived from omental tumours treated 
with carboplatin (red circles) or vehicle alone (grey diamonds). A MHC Class II+TAM frequency is 
expressed as a percentage of the CD45+ population and B as cells/mg of tissue. Data relates to 
a single experiment. The mean for each group is shown. Error bars represent SEM. 
 
Overall, these data demonstrate that carboplatin but not paclitaxel treatment results in 
reductions of TAM populations of murine HGSOC omental tumours. This supports my 
findings in human HGSOC, where I observed reductions in the density of TAMs within 
malignant cell areas following NACT compared to matched untreated samples. Within 
the murine models the reduction in TAM cell number is due to the loss of TAM that 
express markers associated with both an alternatively and classically activated 
phenotype. 
 
6.3 TAM phenotype after chemotherapy 
In human HGSOC I demonstrated changes in TAM phenotype following NACT as 
assessed by decreased surface expression of CD163 and trends to reductions in the 
scavenger receptors CD206 and CD209. I therefore wanted to assess the phenotype of 
the remaining TAM after carboplatin and paclitaxel treatment in murine tumours. TAM 
phenotype was assessed by comparing the expression of various activation markers by 
FC. This was under taken in two ways: by quantifying the percentage of the marker-
positive TAMs within the TAM population and by mean fluorescence intensity (MFI) of 
the various markers within the TAM population. This is in contrast to the data presented 
in section 6.6 which assessed for changes in the proportion of TAMs defined by a 
particular marker within the entire CD45+-immune cell microenvironment of HGSOC. 
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6.3.1 60577 model 
To characterise the effect of chemotherapy on TAM phenotype in 60577 tumours I 
assessed the expression of myeloid polarisation makers as a percentage of the TAM 
population and by mean florescence intensity (MFI) rather than the entire CD45+ 
population as described in 6.6. Interestingly, comparing carboplatin treated tumours with 
vehicle-treated controls I found significant reductions in the expression of CD206+ and 
PDL1+ both as the percentage of positive cells within the TAM population and by MFI 
(Figure 6.25A, B). The data showed significant differences between carboplatin treated 
and vehicle controls after the second dose of carboplatin (day 9).  
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Figure 6.25 Effect of carboplatin on TAM phenotype in the 60577 model. Flow cytometry data 
relating to the immunostained stromal vascular fractions derived from omental tumours treated 
with carboplatin (red circles), vehicle alone (black squares) or healthy omental controls (unfilled 
squares). A CD206+TAM frequency is expressed as a percentage of the total TAM population 
and B CD206 MFI. C PDL1+TAM frequency is expressed as a percentage of the total TAM 
population and D PDL1 MFI. Data relates to a single experiment, five carboplatin treated mice, 
four-five vehicle-treated mice per time point and ten healthy omental controls; cells from healthy 
omental controls were combined and stained as five seperate samples, the mean for each group 
is shown. Error bars represent SEM. Significant two-way ANOVA p-values are shown; *<0.05, 
**<0.01, ****<0.0001. 
 
Given the decreases in markers associated with an anti-inflammatory and 
immunosuppressive TAM phenotype, I assessed for possible reciprocal changes in pro-
inflammatory (classically activated) TAM markers.  I found significant reductions in both 
MHC Class II and CD86 expression in TAMs treated with carboplatin compared to 
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vehicle-treated tumours (Figure 6.26). 
 
Figure 6.26 Effect of carboplatin on TAM phenotype in the 60577 model. Flow cytometry data 
relating to the immunostained stromal vascular fractions derived from omental tumours treated 
with carboplatin (red circles), vehicle alone (black squares) or healthy omental controls (unfilled 
squares). A MHC Class II+TAM frequency is expressed as a percentage of the total TAM 
population and B MHC Class II MFI. C CD86+TAM frequency is expressed as a percentage of 
the total TAM population and D CD86 MFI. Data relates to a single experiment, five carboplatin 
treated mice, four-five vehicle-treated mice per time point and ten healthy omental controls; cells 
from healthy omental controls were combined and stained as five separate samples, the mean 
for each group is shown. Error bars represent SEM. Significant two-way ANOVA p-values are 
shown; *<0.05, ***<0.001, ****<0.0001. 
 
In summary these data show changes in macrophage activation markers in the 
remaining TAM population following carboplatin treatment compared to vehicle-treated 
controls. Assessing single markers within the entire TAM population, I observed 
significant reductions in both markers of classical and alternative macrophage activation. 
Overall, these data would support a change in phenotype distinct from the classical M1 
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(classically activated)/M2 (alternatively activated) paradigm after carboplatin treatment. 
 
I next assessed the effects of paclitaxel treatment on TAM phenotype in this model. 
Comparing between paclitaxel treated and control tumours I found a significant increase 
in CD206+TAM two weeks after treatment started (Figure 6.27). There was a significant 
reduction in PDL1+TAM in paclitaxel treated tumours forty-eight hours after treatment, 
however this was not seen at later time points. There were no significant changes in the 
expression of MHC Class II or CD86 expression.  
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Figure 6.27 Effect of paclitaxel on TAM phenotype in 60577 model. Flow cytometry data 
relating to the immunostained stromal vascular fractions derived from omental tumours treated 
with paclitaxel (red circles), vehicle alone (black squares) or healthy omental controls (unfilled 
squares). A CD206+TAM B PDL1+TAM C MHC Class II+TAM D CD86+TAM frequency is 
expressed as a percentage of the TAM population. Data relates to a single experiment, five 
paclitaxel treated mice, five vehicle-treated mice per time point and ten healthy omental controls; 
cells from healthy omental controls were combined and stained as four separate samples, the 
mean for each group is shown. Error bars represent SEM. 
These data would suggest that paclitaxel may increase CD206+ expression within TAMs 
possibly suggesting an increase in an anti-inflammatory phenotype. However, there were 
no concomitant changes in MHC Class II or CD86 expression to support a classical 
phenotype switch. These data are clearly different from the changes in TAM phenotype 
seen in response to carboplatin treatment. 
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6.3.2 30200 model 
I next assessed the effects of chemotherapy on TAM phenotype in 30200 tumours. I 
found a reduction in the expression of CD206+TAMs as a percentage of the TAM 
population and by MFI in carboplatin and combination (carboplatin + paclitaxel) treated 
tumours compared to paclitaxel and vehicle-treated tumours. The differences were 
statistically significant when comparing carboplatin vs paclitaxel and combination vs 
paclitaxel treated tumours (Figure 6.28A, B). There were no clear differences in PDL1 
expression on TAM assessed by MFI or as a percentage of positive cells. (Figure 6.28 
C, D).  
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Figure 6.28 Effect of chemotherapy on TAM phenotype in the 30200 model. Flow cytometry 
data relating to the immunostained stromal vascular fractions derived from omental tumours 
treated with three once-weekly doses of carboplatin, paclitaxel, carboplatin + paclitaxel or vehicle 
alone. A, C CD206+TAM, PDL1+TAM frequency is expressed as a percentage of the TAM 
population. B, D CD206, PDL1 MFI. Data relates to a single experiment, five mice per group, the 
mean for each group is shown. Error bars represent SEM. Significant one-way ANOVA p-values 
are shown; *p <0.05. 
 
Assessment of MHC Class II and CD86 TAM surface expression showed fewer clear 
changes than observed in the 60577 model. The percentage of MHC Class II-high TAM 
decreased after single agent carboplatin and paclitaxel treatment, however, this was not 
statistically significant. There was a significant reduction in the percentage MHC Class 
II-high TAMs in combination treated compared to vehicle-treated tumours (Figure 6.29A). 
However, MHC Class II MFI showed no difference between chemotherapy treated and 
control tumours (Figure 6.29B). CD86 decreased, though not significantly, both as the 
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percentage of positive cells and by MFI after carboplatin and combination treatment 
compared to vehicle-treated and paclitaxel treated tumours (Figure 6.29C, D). 
 
 
Figure 6.29 Effect of chemotherapy on TAM phenotype in the 30200 model. Flow cytometry 
data relating to the immunostained stromal vascular fractions derived from omental tumours 
treated with three once-weekly doses of carboplatin, paclitaxel, carboplatin + paclitaxel or vehicle 
alone. A, C MHC Class II+TAM, CD86+TAM frequency is expressed as a percentage of the TAM 
population, B, D MHC Class II, CD86 MFI. Data relates to a single experiment, five mice per 
group, the mean for each group is shown. Error bars represent SEM. Significant one-way ANOVA 
p-values are shown; *p <0.05. 
 
Overall, these data suggest that in the 30200 model carboplatin treatment, but not 
paclitaxel treatment, altered the phenotype of the TAMs remaining in the tumour 
compared to vehicle-treated controls. As seen in the 60577 model, I observed reduced 
expression of both CD206 and MHC Class II following carboplatin treatment. Reductions 
in alternatively activated markers seen in both these models mirrors changes in TAM 
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phenotype seen in human HGSOC post-NACT. 
 
6.3.3 HGS2 model 
Finally, I assessed for a change in phenotype with the TAM population (Figure 6.30) in 
the HGS2 model. Overall there were no significant differences in the expression of TAM 
activation markers between carboplatin treated and untreated tumours. However, in 
contrast to the experiments in the 30200 and 60577 models there was a trend to an 
increase in the alternatively activated markers CD206 and PDL1 (Figure 6.30). 
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Figure 6.30 Effect of carboplatin on TAM phenotype in the HGS2 model. Flow cytometry data 
relating to the immunostained stromal vascular fractions derived from omental tumours treated 
with carboplatin (red circles) or vehicle alone (grey diamonds). A CD206+TAM B PDL1+TAM C 
MHC Class II+TAM frequency is expressed as a percentage of the TAM population. Data relates 
to a single experiment. The mean for each group is shown. Error bars represent SEM. 
 
6.4 tSNE analysis of myeloid populations  
Dimensionality reduction using the tSNE (t-distributed stochastic neighbour embedding) 
algorithm allows visualisation of multidimensional data such as FC data in two 
dimensions. I used tSNE for two reasons i) to validate the manual gating applied to the 
FC data described previously and ii) to investigate subpopulations of macrophages 
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within healthy omentum, in murine HGSOC tumours and tumours treated with 
carboplatin.  
 
6.4.1 tSNE validation of manual TAM gating 
Data relating to the CD45+ population of all tumours in the 60677 carboplatin time-course 
experiment (Figure 6.2A) were concatenated and the tSNE algorithm was applied. This 
produced the tSNE plot shown in Figure 6.31A. I then applied the manual gating (Figure 
6.9) to the tSNE analysis (Figure 6.31B). The algorithm clustered TAMs as a discrete 
island. Analysing the TAM population through the experimental time-course shows the 
selective depletion of this population within carboplatin treated tumours compared to 
vehicle-treated controls (Figure 6.31D). 
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Figure 6.31 tSNE analysis of the 60577 model. A tSNE plot showing data relating to CD45+ 
population of all samples in the experiment. B Manual gating for TAMs (CD45+Ly6G-Ly6G-
CD11b+F4/80+MHC Class II+ cells) applied to data (blue overlay), manual gating for eosinophils 
is also shown (orange overlay). C tSNE plot showing data relating to CD45+ population of normal 
omentum. D tNSE plots showing data relating to CD45+ population for control (blue) and 
carboplatin treated tumours (red) at each of the four time points assessed. Dashed line overlay 
indicates TAM population. 
 
I performed a similar analysis for the 30200 experiment, which assessed both the effects 
of carboplatin and paclitaxel. Figure 6.32A shows the tSNE plot for the CD45+ population 
of all samples in the experiment. Applying the manual gating for TAMs, again showed 
these cells to cluster as a discrete island (Figure 6.32B). Carboplatin and the combination 
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of carboplatin and paclitaxel treatment depleted this population compared to paclitaxel 
single-agent or vehicle-treated tumours (Figure 6.32C). These data confirm the manual 
gating strategy and TAM depletion following carboplatin but not paclitaxel treatment. 
 
 
Figure 6.32 tSNE analysis of the 30200 model. A tSNE plot showing data relating to CD45+ 
population of all samples in the experiment, manual gating for TAMs (CD45+Ly6G-Ly6G-
CD11b+F4/80+MHC Class II+ cells) applied to data (red overlay). tSNE plot showing data relating 
to CD45+ population for B vehicle-treated, C carboplatin treated, D paclitaxel treated and E 
combination (carboplatin + paclitaxel) treated tumours. Dashed line overlay indicates the TAM 
population. 
 
6.4.2 tSNE analysis of TAM subpopulations 
The phenotype analyses presented so far have been limited by the assessment of 
individual markers assessed within the entire TAM population. tSNE allows for unbiased 
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clustering of the data, based on differences in fluorescence intensity of multiple markers 
at single-cell resolution. I applied this approach to define subpopulations within the TAM 
compartment (CD45+Ly6C-Ly6G-F4/80+CD11b+ cells) using data from all markers in the 
panel. It was possible to track these subpopulations within heathy omentum, untreated 
and carboplatin treated tumours over four times points during a two week treatment 
course. Given the previous findings of phenotype changes not clearly described by pro-
inflammatory and anti-inflammatory markers, I hoped assessment of multiple markers at 
single-cell resolution would provide a better understanding of the changes in TAM 
phenotype. 
 
Within the TAM cluster of the tSNE plot I defined 11 discrete nodes produced by the 
algorithm (Figure 6.33A). I named these nodes ‘modules’ 1-11. As can be seen in Figure 
6.33, each module contained cells with a different expression profile for the markers in 
the panel, e.g. module 1 cells were F4/80-high, CD206-high, whereas modules 9 and 10 
were F4/80-low yet obviously differed in MHC Class II, CD80 and CD86 expression. 
Figure 6.33B shows a heat map summarising the expression of all the myeloid markers 
within the panel across the eleven modules. These data show that within the entire TAM 
population, there is a great deal of complexity in the expression of a small number of 
myeloid surface markers. Such complexity was not captured by assessing individual 
marker expression within the entire TAM population. 
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Figure 6.33 tSNE analysis of TAM subpopulations in 60577 tumours. A Definition of 11 
modules based on tSNE clustering of data within TAM population, individual modules overlay the 
tSNE plot and have been assigned a unique colour. B Histograms for each module (colours as 
per A) showing fluorescence intensities for each marker are shown. C heatmap summarising MFI 
values for all markers assessed across all eleven modules. 
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I then assessed the eleven modules in the macrophage compartment of healthy 
omentum and in carboplatin and control tumours at four time points following carboplatin 
treatment in 60577 tumours (Figure 6.34). Within healthy omentum the predominant 
subpopulations of cells were represented by modules 8 and 10. These tissue-resident 
macrophages of the omentum were MHC Class II-low and differed in expression of F4/80 
with subtle differences in CD206 expression. Control tumours had striking changes in 
the TAM infiltrate compared to healthy omentum. Marked expansion of several other 
populations was seen, characterised by high MHC Class II and F4/80 expression. Thus, 
the repertoire of TAM subpopulations was more diverse in tumours compared to healthy 
tissue. Serial assessment of TAM subpopulations in control tumours, showed a gradual 
expansion of module 6, expressing intermediate levels of all markers in the panel. In 
advanced tumours, module 6 was the predominate population of TAM in 60577 omental 
tumours. 
 
With carboplatin treatment there was depletion of modules 4, 5 and 6. Following 
treatment, the most abundant population was module 8, which was also highly 
expressed in the healthy omentum. Therefore, carboplatin selectively depletes TAM 
populations that are recruited or expand in the tumour, whilst preserving some of the 
populations that are within healthy omentum. Interestingly and in keeping with my data 
so far, depleted TAMs expressed intermediate levels of CD206 and MHC Class II – this 
may explain the concomitant reduction of both of these markers observed when the TAM 
population is assessed globally. Following carboplatin treatment, the remaining TAM 
subpopulations more closely resemble the healthy omentum than untreated tumours. 
 
In summary, these data show a complex group of TAM subpopulations within murine 
HGSOC in the 60577 model. Comparing these subpopulations between non-diseased 
and diseased omenta show recruitment or expansion of TAM populations distinct from 
the tissue-resident macrophages of the heathy omentum. Carboplatin treatment 
restructured the TAM compartment. 
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Figure 6.34 Assessment of TAM subpopulations with carboplatin treatment in 60577 
tumours. tSNE plot with TAM modules overlaid for A normal omentum and B control and 
carboplatin treated tumours though the four time points assessed. C Bar plot showing the 
proportion of each module of the TAM population for normal omentum, vehicle-treated and 
carboplatin treated tumours at each of the four time points assessed. TP1: Time point 1 – two 
days after treatment started, TP2: Time point 2 – seven days after treatment started, TP3: Time 
point 3 – nine days after treatment started, TP4: Time point 4 – fourteen days after treatment 
started.   
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6.5 Increased TAM death post-chemotherapy 
6.5.1 Assessment of TAM viability 
The data presented above suggest carboplatin results in loss of TAMs from the TME of 
murine HGSOC. Two main processes may be responsible for this effect i) TAM 
recruitment may be reduced, ii) carboplatin treatment may result in increased TAM 
death. To investigate the possibility that TAMs are being killed by carboplatin treatment, 
I assessed non-viable TAMs as a percentage of the total TAM population. This 
demonstrated significantly more non-viable TAMs in carboplatin treated compared to 
control tumours (Figure 6.35) at all time points. This finding replicated an identical 
analysis within the human setting after NACT (Chapter 5; Figure 5.7). 
 
 
Figure 6.35 Assessment of non-viable TAMs at time points after carboplatin treatment in 
the 60577 model. Flow cytometry data relating to the immunostained stromal vascular fractions 
derived from omental tumours treated with carboplatin (red circles), vehicle alone (black squares) 
or healthy omental controls (unfilled squares). Non-viable TAM frequency is expressed as a 
percentage of the total TAM population. Data relate to a single experiment, five carboplatin treated 
mice, four-five vehicle-treated mice per time point and ten healthy omental controls; cells from 
healthy omental controls were combined and stained as five separate samples, the mean for each 
group is shown. Error bars represent SEM. Significant two-way ANOVA p-values are shown; 
***<0.001, ****<0.0001. 
 
This suggests that carboplatin treatment increases TAM death within the omental TME; 
this could be a mechanism for the depletion of TAM following carboplatin treatment. 
 
6.6 Effect of chemotherapy on lymphocyte populations  
Given the importance of myeloid-T cell interactions in mediating responses to 
chemotherapy in other cancer types222 I wished to characterise the effects of 
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chemotherapy on lymphocyte populations in the omental tumour microenvironment.  
Figure 6.36 shows the flow cytometry gating strategy.  
 
 
Figure 6.36 Multicolour flow cytometry gating strategy to characterise lymphocyte 
populations in mouse models. Density plots showing the immunostained stromal vascular 
fraction from a mouse omental tumour. A Gating to exclude cellular debris, B, C sequential gating 
to exclude doublet cells, D sequential gating to exclude non-viable cells, E sequential gating for 
CD45+ cells, F sequential gating for CD3− and CD3+ cells. G CD3+ cells gated for CD4+ and CD8+ 
cells, further assessment of activation markers was made within these gates. H CD3- cells gated 
for CD19+ cells. SSC-A: side scatter area, SSC-W: side scatter width, FSC-A: forward scatter 
area, FSC-H: forward scatter height. 
 
6.6.1 60577 model 
There was a significant increase in the CD3+, CD3+CD4+ populations expressed as a 
percentage of CD45+ cells (Figure 6.37A, C). However, there were no significant 
differences when these data were expressed as cells/mg of tissue (Figure 6.37B, D). 
This discrepancy is likely explained by the selective depletion of the TAM population, 
resulting in changes to the relative density of lymphocytes compared within the CD45+ 
population but not affecting the CD3+ and CD3+CD4+ cell number in the tissue overall. 
CD3+CD8+ cells decreased in the tissue overall as well as within the CD45+ population 
(Figure 6.37E, F). There were also decreases in the CD3-CD19+ B cell population 
expressed as a percentage of CD45+ cells (Figure 6.38A). 
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Figure 6.37 The effect of carboplatin treatment on T lymphocyte densities in 60577 
tumours. Flow cytometry data relating to the immunostained stromal vascular fractions derived 
from omental tumours treated with carboplatin (red circles), vehicle alone (black squares) or 
healthy omental controls (unfilled squares). A, C, E CD3+, CD3+CD4+, CD3+CD8+ frequency is 
expressed as a percentage of the CD45+ population and B, D, F as cells/mg of tissue. Data relates 
to a single experiment, five carboplatin treated mice, four-five vehicle-treated mice per time point 
and ten healthy omental controls; cells from healthy omental controls were combined and stained 
as five seperate samples, the mean for each group is shown. Error bars represent SEM. 
Significant two-way ANOVA p-values are shown; *<0.05, ***<0.001, ****<0.0001. 
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Figure 6.38 The effect of carboplatin treatment on B lymphocyte density in 60577 tumours. 
Flow cytometry data relating to the immunostained stromal vascular fractions derived from 
omental tumours treated with carboplatin (red circles), vehicle alone (black squares) or healthy 
omental controls (unfilled squares). A CD3-CD19+ frequency is expressed as a percentage of the 
CD45+ population and B as cells/mg of tissue. Data relate to a single experiment, five carboplatin 
treated mice, four-five vehicle-treated mice per time point and ten healthy omental controls; cells 
from healthy omental controls were combined and stained as five separate samples, the mean 
for each group is shown. Error bars represent SEM. Significant two-way ANOVA p-values are 
shown; *p <0.05. 
 
6.6.2 30200 model 
In support of my observations in the 60577 model CD3+ and CD3+CD4+ cells expressed 
as a percentage of the CD45+ cells increased in carboplatin and combination treated 
tumours compared to vehicle and paclitaxel treated tumours. There were significant 
differences in CD3+ and CD3+CD4+ cell number expressed as a percentage of CD45+ 
cell infiltrate between carboplatin and paclitaxel treated tumours (Figure 6.39A, C). 
However, as before, this difference was not seen when I expressed the data as cells/mg 
of tissue (Figure 6.39B, D). In contrast there was a significant decrease in the CD3+CD8+ 
population compared to vehicle and paclitaxel treated tumours expressed as cell/mg of 
tissue (Figure 6.39F). There were no significant differences in frequency of CD3-CD19+ 
B cells between the treatment groups (Figure 6.40). 
 
Overall these data would suggest relative changes in the cell number of CD3+ and 
CD3+CD4+ as a percentage of the CD45+ with a decrease in the CD3+CD8+ populations. 
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Figure 6.39 Effect of chemotherapy on T lymphocyte densities in the 30200 model. Flow 
cytometry data relating to the immunostained stromal vascular fractions derived from omental 
tumours treated with three once-weekly doses of carboplatin, paclitaxel, carboplatin + paclitaxel 
or vehicle alone. A, C, D CD3+, CD3+CD4+, CD3+CD8+ cell frequency is expressed as a 
percentage of the CD45+ population B, D, F CD3+, CD3+CD4+, CD3+CD8+ expressed as cells/mg 
of tissue. Data relates to a single experiment, five mice per group, the mean for each group is 
shown. Error bars represent SEM. Significant one-way ANOVA p-values are shown; *<0.05, 
**<0.01. 
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Figure 6.40 Effect of chemotherapy on B lymphocyte density in the 30200 model. Flow 
cytometry data relating to the immunostained stromal vascular fractions derived from omental 
tumours treated with three once-weekly doses of carboplatin, paclitaxel, carboplatin + paclitaxel 
or vehicle alone. CD19+ cell frequency expressed as A the percentage of CD45+ cells and B as 
cells/mg of tissue. Data relates to a single experiment, five mice per group, the mean for each 
group is shown. Error bars represent SEM. 
 
6.6.3 HGS2 model 
There were no significant differences in the densities of CD3+, CD3+CD4+, CD3+CD8+ 
(Figure 6.41) or CD3-CD19+ lymphocytes (Figure 6.42) between carboplatin treated and 
vehicle-treated tumours. 
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Figure 6.41 Effect of carboplatin on T lymphocyte density in the HGS2 model. Flow 
cytometry data relating to the immunostained stromal vascular fractions derived from omental 
tumours treated with carboplatin (red circles) or vehicle alone (grey diamonds). A CD3+, C 
CD3+CD4+, E CD3+CD8+ frequency is expressed as a percentage of the CD45+ population and 
B, D, F as cells/mg of tissue. Data relates to a single experiment. The mean for each group is 
shown. Error bars represent SEM. 
Chapter 6: Results 
 180 
 
Figure 6.42 Effect of carboplatin on B lymphocyte cell number in the HGS2 model. Flow 
cytometry data relating to the immunostained stromal vascular fractions derived from omental 
tumours treated with carboplatin (red circles) or vehicle alone (grey diamonds). A CD3-CD19+ 
frequency is expressed as a percentage of the CD45+ population and B as cells/mg of tissue. 
Data relates to a single experiment. The mean for each group is shown. Error bars represent 
SEM. 
 
6.7 Summary and comparision to human data (Chapters 3-5) 
The following bullet points summarise the key changes in immune cell infiltrate and 
phenotype with chemotherapy treatment in human and murine HGSOC. 
 
• In both human and murine HGSOC there was a decrease in TAM cell number. 
• In both murine and human HGSOC there was an increase in non-viable TAM 
following carboplatin treatment. 
• Macrophage surface expression of alternatively activated markers decreased 
following NACT in patients and following carboplatin in the 60577 model.  
• In the 30200 tumours there was a trend to a reduction in TAM expression of 
alternatively activated markers; in HGS2 tumours there was no difference in 
alternatively activated marker expression after carboplatin treatment.  
• The murine TAM response to paclitaxel was different to carboplatin, with 
increases in CD206 expression in 60577 and a trend to increase in 30200 and 
HGS2.  
 
Table 6.1 summarises the changes in immune cell density and phenotype observed in 
human and murine HGSOC omental metastases before and after chemotherapy that I 
have obtained in this thesis and from the published work of others in our lab.  
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Table 6.1 Table summarising mouse model and human experimental data. Difference 
between chemotherapy treated and untreated / vehicle-treated control HGSOC tumours; 
increases denoted by red shading, decreases denoted by blue shading, no data indicated by grey 
shading. Significant differences noted with dark shading, statistically non-significant trends noted 
with light shading. Human lymphocyte data from Böhm et al.113 and Montfort et al.114.  
 
 
  
Human 60577 30200 HGS2
Chemotherapy NACT Carboplatin Carboplatin Carboplatin
TAM frequency 
(IHC)
 decreased in malignant 
cell areas decreased decreased
Viable TAM 
frequency (FC) unchanged decreased decreased
unchanged - trend to 
decrease
Non-viable TAM 
frequency (FC) increased increased
DC populations cDCs increased
CD163 decreased
CD206 unchanged - trend to decrease decreased
unchanged - trend to 
decrease
unchanged - trend to 
increase
PDL1 decreased unchanged unchanged - trend to increase
CD209 unchanged - trend to decrease
CD86 decreased unchanged - trend to decrease
MHC Class II unchanged decreased unchanged - trend to decrease unchanged
CX3CR1 decreased
CD3+ unchanged - Böhm et al. increased
unchanged - trend to 
increase unchanged
CD3+CD4+ unchanged - Böhm et al. increased
unchanged - trend to 
increase unchanged
CD3+CD8+ unchanged - Böhm et al. decreased decreased unchanged
CD3-CD19+ unchanged - trend to increase Montfort et al. decreased
unchanged - trend to 
increase unchanged
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6.8 Discussion 
In this chapter I used three murine models that recapitulate the genetic and mutational 
profile of human HGOSC and tissue location (Maniati et al. submitted). The sensitivity of 
the murine cell lines to carboplatin and paclitaxel in vitro was within the ranges for human 
HGSOC cell lines reported in the literature, however these vary widely309. One large 
study assessed the sensitivity of a panel of thirty-six human ovarian cancer cell lines to 
single-agent chemotherapy, with IC50 values in the range 9-270µM for carboplatin and 
2-110nM for paclitaxel309. Furthermore, 60577 sensitivity to cisplatin has been tested 
with a reported IC50 value of 167µM272. When designing experiments to treat mice with 
chemotherapy I chose the dose of 20mg/kg for carboplatin and 10mg/kg for paclitaxel 
based on a literature review315. Carboplatin dosing in humans is based on the Cavert et 
al. formula316 and typical human doses of carboplatin are in the range 200-350mg/m2 
(based on the area under curve [AUC] 5 target). The standard human dose of paclitaxel 
is 175mg/m2. Using the surface area calculations as described by Freireich et al., a dose 
of 20mg/kg approximates 60mg/m2 and 10mg/kg approximates 30mg/m2 in mice317. 
Despite the carboplatin dose used to treat mice being lower than an equivalent human 
dose, tumours showed obvious responses. In initial experiments, paclitaxel was 
administered to mice at higher concentrations, however this was associated with toxicity 
(severe weight loss), necessitating dose reduction to 10mg/kg. 
 
Reflecting human HGSOC, the three BRCA deficient models tested in this thesis were 
sensitive to treatment with carboplatin or the combination of carboplatin with paclitaxel. 
Paclitaxel administered at a dose of 10mg/kg i.p., did not significantly increase survival 
compared to vehicle-treated controls. Histological assessment of paclitaxel treated 
tumours showed no discernible morphological changes compared to vehicle-treated 
tumours (data not shown). This suggests that the 60577 and 30200 models are not 
sensitive to paclitaxel in vivo, or that the dose of paclitaxel used was too low to produce 
a cytotoxic effect. 
 
The dose of carboplatin and paclitaxel chosen to treat mice is lower than the standard 
equivalent human dose. However, these drugs are administered intravenously to 
patients rather than i.p., as in the case of the mice. Intraperitoneal administration of 
chemotherapy in ovarian cancer (including the combination of cisplatin and paclitaxel) 
has been shown to improve survival52,53,318 in patients compared to conventional 
intravenous administration. Indeed, intraperitoneal administration of carboplatin 
increases the local concentration by 20-fold, whereas for paclitaxel it can achieve a 1000-
fold increase in concentration68. Therefore i.p. treatment is likely to be more effective at 
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lower doses than intravenous administration and provides some justification for using 
lower equivalent doses of chemotherapy in mice. In initial experiments (data not shown) 
I used a higher dose of paclitaxel (19 mg/kg), however, at this dose I observed significant 
weight loss in mice necessitating a dose reduction to 10mg/kg in further experiments. 
Toxicity may have been due to the ethanol / cremophor vehicle in which paclitaxel is 
formulated. This vehicle, necessary to solubilise this highly hydrophobic molecule, is a 
cause of toxicity when paclitaxel is administered to patients64. 
 
Carboplatin was highly effective when administered to tumour bearing mice at 20mg/kg 
i.p. and resulted in clinical resolution of ascites and significantly enhanced survival 
compared to vehicle-treated mice. These finding are reflected in the clinical data which 
shows the greater benefit from platinum-based chemotherapy compared to paclitaxel 
alone. A Phase 3 clinical trial showed significantly improved response rates and 
progression free survival to the combination of cisplatin (a first generation platinum drug) 
and paclitaxel or cisplatin alone compared to single-agent paclitaxel319. Furthermore, the 
combination of carboplatin and paclitaxel is non-inferior to treatment with cisplatin and 
paclitaxel320. 
 
Tumours from all three models had abundant TAM populations. A key difference 
consistently noted between mouse and human tumours was the degree of TAM 
infiltration; murine TAM populations represented 25-35% compared to 10-25% of CD45+ 
cells in human untreated HGSOC. Murine TAM expressed high levels of CD206 and 
PDL1, however there was also expression of CD86 and MHC Class II at high levels. 
These findings were in keeping with the expression of activation makers in human 
omental HGSOC TAM which also expressed CD163, CD206, and CD209 at high levels, 
yet were also MHC Class II high. It was encouraging that the TAM phenotype was 
comparable between mouse and human HGSOC. 
 
The reported effects of chemotherapy on the TME of other preclinical models are 
variable; with some studies showing TAM recruitment215–223 and others showing no 
change or depletion. Overall, in this series of experiments I show that carboplatin can 
deplete TAM; in contrast, paclitaxel did not affect TAM cell number. I found no evidence 
for TAM recruitment in any model in response to carboplatin or paclitaxel treatment.  
 
Next, I determined if carboplatin-associated TAM depletion was the result of loss of 
TAMs defined by a particular surface marker. In the 60577 and 30200 models I found 
significant reductions of TAM expressing both alternative/immunosuppressive (CD206, 
PDL1) and classical activation (MHC Class II, CD86) markers. This and my findings in 
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human tumours, suggestive of increased TAM cell death post-chemotherapy (Figure 
4.7), led me to examine if increased cell death could explain TAM depletion in murine 
tumours. Therefore, I quantified the percentage of non-viable TAM within the total TAM 
population. At all time points, there were significantly more non-viable TAM in carboplatin 
treated tumours compared to vehicle-treated controls (Figure 6.35). Therefore, I 
conclude that carboplatin may increase TAM cell death in both human and murine 
HGSOC. 
 
The concept of myeloid cell death in response to chemotherapy has not been reported 
in the context of carboplatin, yet has been reported following treatment with trabectedin. 
Trabectedin, also a DNA binding molecule, has been found to trigger the activation of 
caspase-8-mediated apoptosis selectively in monocytes212. In preclinical models, 
depletion of macrophages from the TME of tumours was found to be a key anti-tumour 
mechanism of this drug. This aspect of the thesis will be explored further in Chapter 9, 
where I will move into the in vitro setting to test the effects of carboplatin on 
macrophages. 
 
Within human samples I found a significant reduction in TAM density by CD68 
immunohistochemistry within malignant cell areas in a cohort of matched pre and post-
chemotherapy HGSOC samples (Figure 3.2). However, within the stroma and within the 
biopsy overall there were no significant differences in TAM density. Human samples 
were assessed at a time point three-four weeks following a dose of chemotherapy. In the 
mouse models I have assessed earlier time points.  A further factor that may account for 
the differences in the TAM response in human and murine tumours, is that murine 
tumours exhibited a less developed stroma compared to human samples. Therefore, it 
may be that the models recapitulate the malignant cell islands of human HGSOC most 
accurately. Further assessment of immune cell compartment of murine tumours pre and 
post-chemotherapy is needed and this is an objective of future work planned to extend 
this thesis (Chapter 10). 
 
Assessing the phenotype of TAM remaining in the TME, I found reductions in both MHC 
Class II and CD206 TAMs following carboplatin treatment in 60577 and 30200 tumours. 
Within the HGS2 model the changes in TAM phenotype where not significantly different 
between treated and untreated tumours. This suggests a change in TAM phenotype as 
the result of carboplatin treatment distinct from overall changes within the M1 (classically 
activated)/M2 (alternatively activated) model. Importantly there are similarities, 
comparing the changes in TAM phenotype in the murine models to the changes 
observed in human HGSOC samples. In patients I found a reduction of surface 
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expression of the CD163+ post-chemotherapy yet no changes in the MHC class II 
expression (Table 6.1). Therefore, the similarities observed between human and murine 
TAM responses are most likely as the result of the effects of carboplatin rather than 
paclitaxel. 
 
In the 60577 and 30200 models CD3+ and CD3+CD4+ cells increased as a percentage 
of the CD45+ population. These changes were not however reflected when the data were 
expressed as cells/mg of tissue. The reason for this discrepancy may be due to the 
changes in the F4/80 population, as described previously. CD8+ cells decreased both as 
a percentage of the CD45+ population and as cells/mg of tissue. Within the HGS2 model 
no changes were seen in the lymphocyte compartment. Although I have not studied the 
lymphocyte populations within the human HGSOC samples, previous work carried out 
in our lab has assessed the effects of NACT on T and B lymphocytes. NACT did not 
significantly affect the density of T cells, yet in good responders (CRS3), there was an 
enhanced Th1 response signature113. Furthermore, NACT promoted anti-tumour B cell 
reponses114. These findings have been further supported by work in the laboratory of 
Brad Nelson who also assessed TILs in the omentum of matched HGSOC samples. This 
detailed IHC-based assessment showed significant increases in CD3+, CD8+ and CD20+ 
cells and near-significant trends to increased CD4+ lymphocytes following NACT118. 
Comparing the responses observed within the murine models with these data and those 
provided by others115 suggest that these models may also replicate aspects of the human 
lymphocyte response to chemotherapy. Study of the lymphocyte populations in murine 
HGSOC in response to chemotherapy by IHC is planned in future work building on the 
data presented in this thesis. 
 
TAM exist as a spectrum of activation states defined by changes in not one but hundreds 
of genes120. Therefore, assessing the expression of a single surface proteins will not 
detect phenotypic complexity. To explore my data in more detail I applied the tSNE 
algorithm to allow assessment of all the markers in the flow cytometry panel at single-
cell resolution. tSNE was applied to murine FC data. The design of the antibody panel 
prevented the use of tSNE to assess TAM subpopulations in human samples. tSNE was 
not part of mainstream FC analysis when the project was started and as such the design 
of the panel did not take the use of this approach into consideration. 
 
tSNE confirmed TAM depletion and validated the manual gating strategy applied to the 
murine FC data. Within the TAM population tSNE defined subpopulations (modules 1-
11) in healthy omentum, control and carboplatin treated tumours. Through a time-course 
experiment it was possible to observe re-structuring of TAM subpopulations through 
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disease progression and in response to treatment. Using this approach, clear differences 
in TAM subpopulations were found between healthy, untreated and carboplatin treated 
tumours. Within healthy omentum tissue-resident macrophages were F4/80-low, CD11b-
low, MHC Class II low (modules 8 and 10). This observation is supported by elegant 
studies in murine pancreatic cancer, where tissue-resident macrophages were defined 
by low expression of MHC Class II139. Within tumours, TAM phenotypes were more 
complex then tissue-resident macrophages, with the addition of populations not 
appreciated in the healthy omentum. Expansion of subpopulations co-expressing high 
levels of F4/80 and MHC Class II (modules 1-3) were seen, suggesting these cells are 
recruited or expand within the tissue. Additionally, through two weeks of tumour 
progression there was expansion of F4/80-intermediate, MHC-intermediate, CD206-
intermediate TAMs (modules 4-6). These are the dominate TAM populations in 
advanced tumours. Interestingly, with carboplatin treatment these subpopulations are 
selectively depleted. This provides an explanation for the reduction in both MHC Class 
II and CD206 markers found within the whole TAM population as assessed by 
conventional FC analysis (Figure 6.25, Figure 6.26).  
 
Compared to untreated tumours, carboplatin treated tumours were enriched for MHC-
low F4/80-low (module 8 and 10) TAM, regarded as the tissue resident population of 
healthy omentum. However, in contrast to healthy omentum there is also expansion of 
F4/80-high, MHC Class II-high cells (modules 1-3). These populations are opposed in 
terms of phenotype markers. It is tempting to consider that these cells may be 
functionally distinct. In Chapter 8 I will target TAM following chemotherapy in this model, 
this may help to gain an understanding of the roles of these cells in the post-
chemotherapy TME. 
 
Building on the data presented in this chapter, in Chapter 7 I generate a murine model 
of HGSOC relapse and characterise the phenotype of the TAM population in these 
tumours. 
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Chapter 7 
TAMs at relapse in murine HGSOC 
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7Effects of chemotherapy on survival and relapse in murine HGSOC models  
 Background 
Despite three-quarters of HGSOC patients responding to first line chemotherapy, the 
five-year survival rate is 40%, a figure that has not changed for thirty years29. In patients 
who present with stage III or IV disease, the five-year survival drops to 20% and 4% 
respectively4.  A majority of patients relapse within eighteen months of primary treatment 
with increasingly chemo-resistant disease. Strategies to prevent tumour regrowth after 
chemotherapy are crucial to improving outcome4. 
 
In chapter 6 I described the effects of carboplatin and paclitaxel treatment on tumour 
growth and mouse survival in the pre-clinical models of HGSOC. Here I describe a 
continuation of these experiments which have resulted in the generation of a murine 
model that replicates the relapse of HGSOC. This relapse model, or others like it, offer 
the potential to learn more about the TME of relapsed HGSOC and provides a clinically 
relevant platform to test therapeutic interventions. 
 
In all the murine survival experiments presented in this thesis a human endpoint was 
used to determine when tumour-bearing mice were culled. Survival endpoint was based 
on ‘moderate’ severity as per the Home Office Project License. The survival endpoint for 
mice was defined as a change in general health, specifically 15% body weight loss over 
72 hours or 20% over any time period, or inability to ambulate, or hunched posture, or 
difficulty breathing or signs of hypothermia as well as signs of ascites or palpable 
tumours exceeding an estimated size of 1cm diameter. In survival experiments 
assessment of mice was made twice daily by the same individual to limit inter-observer 
variability. Furthermore, in the majority of cases survival determinations were made by a 
trained animal technician who was not directly involved in the experimental design. 
 
 Generating a relapse model of HGSOC 
The 60577 model appeared to most closely mimic human platinum sensitive disease, 
with clinical resolution of ascites and a significantly extended treatment free interval of 
at least six weeks (Figure 6.5A). Therefore, I followed a cohort of five carboplatin treated 
mice long-term to see if they relapsed. Mice continued to live with no signs of disease 
until four months following the last treatment when the first mouse of the cohort started 
to show abdominal distension secondary to ascites development. Subsequently, all mice 
demonstrated evidence of disease and were culled at a humane end point. Figure 7.1A 
shows mouse survival for this experiment, carboplatin treated mice had a median 
survival of 190 days vs 40 days for control mice (log-rank p=0.0005). This experiment 
was repeated as shown in Figure 7.1B, the median survival of carboplatin-treated mice 
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was 142 days vs 35 days for control mice (log-rank p=0.0023). 
 
Figure 7.1 Effect of chemotherapy on survival in the 60577 model. Kaplan-Meier curves 
comparing mice treated with three once-weekly carboplatin i.p. injections (red line) or 0.9% NaCl 
(black line). Dashed lines indicate carboplatin treatments. Control and treated mice were in 
separate experiments. A, B show data derived from two independent experiments. Data relate to 
seven vehicle-treated control mice and ten carboplatin treated mice. Log-rank (Mantel-Cox) p-
value is shown. 
 
Mice typically showed clinical signs of disease relapse approximately fourteen days prior 
to reaching the humane end point. At autopsy, mice had clear evidence of significant 
tumour burden including macroscopically identifiable omental tumours and large volume 
ascites. This is in contrast to mice culled at six weeks following chemotherapy, which 
showed no macroscopic evidence of disease or ascites. Figure 7.2 shows the omental 
weights of mice reaching a humane end point due to relapse compared to vehicle-treated 
tumours, omental weight was significantly increased in relapsed disease (0.16g vs 0.04g 
p = 0.01). 
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Figure 7.2 Omental weight of relapsed 60577 tumours. Omental weight of tumours from mice 
culled at end point following tumour relapse after carboplatin treatment. Data relate to ten vehicle-
treated control mice and five carboplatin treated mice. Endpoint controls were in a separate 
experiment, the mean for each group is shown. Student’s t-test p-value is shown; *<0.05. 
 
 Characterising TAM populations in relapsed tumours 
I performed multicolour flow cytometry on the relapsed omental tumours. I compared the 
relapsed tumours to vehicle-treated tumours resected at a humane end point. TAM 
density as a percentage of the CD45+ population was comparable between these groups 
(Figure 7.3). TAM phenotype at relapse closely resembled the surface marker 
expression profile of vehicle-treated tumours at end point (Figure 7.4A, B, C). There was, 
however, a statistically significant increase in CD206+ TAM as a percentage of the TAM 
population at relapse compared to vehicle-treated tumours at end point (67.5% vs 
28.7%, p = 0.0016), (Figure 7.4A).  
 
Figure 7.3 TAM cell number in relapsed 60577 tumours. Flow cytometry data relating to the 
immunostained stromal vascular fractions derived from relapsed omental tumours treated with 
carboplatin or vehicle. Data relate to five mice in the relapse group and 10 vehicle-treated mice 
sacrificed at a humane end point. Endpoint controls were in a separate experiment, the mean for 
each group is shown. Error bars represent SEM. 
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Figure 7.4 TAM surface marker expression in relapsed 60577 tumours. Flow cytometry data 
relating to the immunostained stromal vascular fractions derived from relapsed omental tumours 
treated with carboplatin or vehicle controls. A frequency of CD206+TAMs expressed as a 
percentage of the TAM population. B frequency of MHC Class 2+TAMs expressed as a 
percentage of the TAM population C frequency of PDL1+TAMs expressed as a percentage of the 
TAM population. Data relate to five mice in the relapse group and ten mice in the vehicle-treated 
control group, sacrificed at a humane end point. Endpoint vehicle-treated control tumours were in 
a separate experiment, the mean for each group is shown. Error bars represent SEM. Significant 
one-way ANOVA with Turkey’s correction p-values are shown; *<0.05, **<0.01. 
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Lymphocyte populations were also assessed (Figure 7.5). I observed no difference in 
lymphocyte cell number in relapsed tumours compared to vehicle-treated tumours at end 
point. 
 
Figure 7.5 Lymphocyte cell number in relapsed 60577 tumours. Flow cytometry data relating 
to the immunostained stromal vascular fractions derived from relapsed omental tumours treated 
with carboplatin or vehicle controls. A frequency of CD3+CD4+ expressed as a percentage of the 
CD45+ population. B frequency of CD3+CD8+ expressed as a percentage of the CD45+ population. 
C frequency of CD3- CD19+ expressed as a percentage of the CD45+ population. Data relate to 
five mice in the relapse group and ten mice in the vehicle-treated control group, sacrificed at a 
humane end point. Endpoint controls were in a separate experiment, the mean for each group is 
shown. Error bars represent SEM. 
 
Therefore relapsed tumours, following a long treatment-free interval, had a TME that was 
very similar, in terms of myeloid and lymphocyte cell number, to vehicle-treated tumours. 
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 Discussion 
To explore the possibility of HGSOC relapse following carboplatin treatment, a cohort of 
mice were followed up long-term. Four-six months following the last dose of 
chemotherapy all mice developed signs of tumour progression and developed ascites. 
Median survival following carboplatin treatment was determined in two separate 
experiments and ranged from 142 – 190 days vs 35 – 40 days for vehicle-treated mice.  
 
I then characterised the immune infiltrate in the relapsed tumours. Interestingly, there 
were no differences in TAM or lymphocyte cell number in vehicle-treated tumours and 
tumours at relapse. Comparing this to the data relating to early time points following 
carboplatin treatment (Chapter 6) suggests re-accumulation of both TAM and 
lymphocyte populations as tumours re-grow in the omentum. TAM surface expression of 
CD206 was significantly increased in relapse tumours compared to vehicle-treated 
controls. All other surface markers assessed were not significantly different between the 
experimental groups. Therefore, I conclude that an immunosuppressive TAM phenotype 
is re-established at relapse. Kreuzinger et al. defined an immune transcriptomic 
signature in matched relapsed and primary human HGSOC tumours, finding that in some 
relapsed tumours this signature was concordant with the primary tumours, whereas 
others were discordant92. Thus, this mouse model of relapse may recapitulate the human 
setting of concordant TMEs within relapse and primary disease.  
 
The results obtained so far lead to the hypothesis that preventing the re-accumulation of 
TAM after chemotherapy may delay or prevent HGSOC relapse. In the next chapter I will 
target TAM, using small molecule inhibitors of colony stimulating factor receptor 1 (CSF-
1R), both as single agents and in combination with chemotherapy. I will ask the question: 
‘Can targeting TAM following chemotherapy prevent relapse of HGSOC?’. 
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8Targeting TAM by CSF-1R inhibition in HGSO 
 Background 
The CSF-1-CSF-1R axis is a survival and differentiation pathway for cells of the myeloid 
lineage and therefore represents a key strategy for targeting TAMs138. As described in 
Chapter 1, numerous CSF-1R-targeting approaches have been developed and have 
shown promise in a range of pre-clinical models237. Multiple clinical trials are currently in 
progress testing TAM-targeting agents in combination with conventional treatment 
modalities and immunotherapies135,237. 
 
In Chapters 6 and 7 I have shown that carboplatin can deplete TAMs in murine HGSOC 
and that TAM populations repopulate relapsed tumours. This led me to hypothesise that 
targeting TAM following chemotherapy could delay relapse. To test this hypothesis I 
have used orally bioavailable CSF-1R inhibitors (CSF-1Ri) administered to tumour-
bearing mice with established tumours and also following chemotherapy. The murine 
model of HGSOC relapse (described Chapter 7) provides an appropriate system to test 
this approach. 
 
 CSF-1Ri treatment of murine models of HGSOC 
In this thesis I have used two small molecule inhibitors of CSF-1R; AZD7507, provided 
by AstraZeneca and BLZ945 developed by Novartis, which was obtained commercially. 
AZD7507 and BLZ945 are both selective and potent inhibitors of CSF-1R kinase activity. 
The reported biochemical IC50 values are 3nM for AZD7507 and 1nM BLZ945; both have 
negligible activity against other kinases215,251. 
 
8.2.1 AZD7507 treatment of the 60577 model 
To examine the effect CSF-1Ri in the 60577 model, AZD7507 was administered orally 
to mice for twelve days twice daily, commencing twenty-one days after 60577 cell 
injection. At this time point tumours have formed within the omentum, therefore this 
recapitulates the clinical situation of treating established tumours. CSF-1Ri and vehicle-
treated controls were culled twelve hours following the last dose of AZD7507 and the 
tumour microenvironment was assessed by FC. Figure 8.1 show a schematic outline of 
the experimental approach. 
  
Chapter 8: Results 
 196 
 
 
Figure 8.1 Schematic outline of an experiment assessing the effect of AZD7507 treatment 
on the 60577 model. Significant experimental time points and treatment scheduling is shown. 
AZD7507 dosing based on Candido et al.251 BD: twice a day, OG: oral gavage. 
 
An effective AZD5707 dose, resulting in TAM depletion and increased survival of KPC-
tumour bearing mice, has been defined in our lab251. I therefore decided to use the same 
dosing schedule in my experiments. As expected, TAMs (CD45+Ly6C-Ly6G-
CD11b+F4/80+ cells) were significantly decreased by AZD7507 treatment in the 
omentum both when expressed as a percentage of the CD45+ cell population and as 
cells/mg of tissue (Figure 8.2). However, the depletion observed was not complete, in 
keeping with the findings of others140,251. 
 
 
Figure 8.2 The effect of AZD7507 treatment on TAM density. Flow cytometry data relating to 
the immunostained stromal vascular fractions derived from 60577 omental tumours treated with 
AZD7507 (red circles) or vehicle alone (black squares). A TAM (CD45+Ly6C-Ly6G-CD11b+F4/80+ 
cell) frequency is expressed as a percentage of the CD45+ population and B as cells/mg. Data 
relate to a single experiment with ten AZD7507 treated mice and four vehicle-treated mice, the 
mean for each group is shown. Error bars represent SEM. Student’s t-test p-values; *<0.05, 
**<0.01. 
 
To assess if the observed TAM depletion was due to loss of a specific TAM population 
defined by classically (MHC Class II) or alternatively activated (CD206) surface markers, 
I assessed these markers as a percentage of the CD45+ tumour infiltrate and as cells/mg 
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of tissue. TAMs expressing both of these markers were significantly decreased by 
AZD7507 treatment compared to vehicle-treated controls (Figure 8.3).  
 
Figure 8.3 The effect of AZD7507 treatment on MHC Class II+ and CD206+ TAM density. Flow 
cytometry of immunostained stromal vascular fractions derived from omental tumours treated with 
AZD7507 (red circles) or vehicle alone (black squares). A CD206+TAM frequency is expressed 
as a percentage of the CD45+ population and B as cells/mg. C MHC Class II+TAM frequency is 
expressed as a percentage of the CD45+ population and D as cells/mg. Data relate to a single 
experiment, ten AZD7507 treated mice and four vehicle-treated mice, the mean for each group is 
shown. Error bars represent SEM. Student’s t-test p-values; *<0.05, **<0.01. 
Several studies have suggested that as well as depleting TAMs, CSF-1Ri may affect 
TAM phenotype215,216. To assess for a change in TAM phenotype following AZD7507 
treatment I measured CD206 and MHC Class II-high (MHC Class II+) expression as the 
percentage of positive cells within the TAM population and by MFI. Figure 8.4 A and B 
show no significant differences in CD206 expression between the AZD7507 and vehicle-
treated groups. However, there was a significant decrease in MHC Class II expression 
both expressed as percentage of positive cells and by MFI (Figure 8.4 C and D). This 
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implies a change of overall TAM phenotype in the remaining cells. 
 
 
Figure 8.4 The effect of AZD7507 treatment on TAM phenotype. Flow cytometry data of the 
immunostained stromal vascular fractions derived from omental tumours treated with AZD7507 
(red circles) or vehicle alone (black squares). A CD206+TAM as a percentage of the TAM 
population and B as MFI. C MHC Class II+TAM as a percentage of the TAM population and D as 
MFI. Data relate to a single experiment, ten AZD7507 treated mice and four vehicle-treated mice, 
the mean for each group is shown. Error bars represent SEM. Student’s t-test p-values are shown; 
**<0.01, ****<0.001. 
 
TAM depletion may result in changes to other cell types in the TME222,239,251. As seen in 
Figure 8.5 I was unable to detect any change in the total CD3+, or CD8+ T lymphocyte 
populations. I did observe a significant decrease in the CD4+ population following 
AZD7507 treatment as a percentage of the CD45+ population, however, this was not 
significant when assessed as cells/mg of tissue (Figure 8.5). There was also a significant 
decrease in CD19+ B lymphocytes following AZD7507 treatment compared to vehicle-
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treated tumours (Figure 8.6). 
 
 
Figure 8.5 The effect of AZD7507 treatment on T lymphocyte populations. Flow cytometry 
of immunostained stromal vascular fractions derived from 60577 omental tumours treated with 
AZD7507 (red circles) or vehicle alone (black squares). A CD3+ C CD3+CD4+ E CD3+CD8+ as a 
percentage of the CD45+ population and B CD3+, D CD3+CD4+, F CD3+CD8+ as cells/mg of 
tissue. Data relate to a single experiment, ten AZD7507 treated mice and four vehicle-treated 
mice, the mean for each group is shown. Error bars represent SEM. Student’s t-test p-values are 
shown; ***<0.001. 
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Figure 8.6 The effect of AZD7507 treatment on B lymphocyte populations. Flow cytometry 
data relating to the immunostained stromal vascular fractions derived from omental tumours 
treated with carboplatin (red circles) or vehicle alone (black squares). A CD19+ cells as a 
percentage of the CD45+ population and B as cells/mg of tissue. Data relate to a single 
experiment, ten AZD7507 treated mice and four vehicle-treated mice, the mean for each group is 
shown. Error bars represent SEM. Student’s t-test p-values; *<0.05, **<0.01. 
 
In this initial experiment the original plan had been to treat mice for fourteen days, 
however, as several of the AZD7507 treated mice developed large volume ascites and 
reached a humane end point before this time point, the experiment was terminated after 
twelve days of treatment. This suggests that AZD7507 may not improve survival in this 
model. Mouse post-mortem findings demonstrated well developed tumours and large 
volume ascites in all AZD7507 treated mice as well as vehicle controls. Assessment of 
the omental weight in AZD7507-treated mice showed no statistical difference in tumour 
weight, again suggesting that AZD7507 did not alter tumour growth in this model (Figure 
8.7).  
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Figure 8.7 The effect of AZD7507 treatment on tumour weight in the 60577 model. Omental 
weight from mice treated with AZD7507 (red circles) or vehicle alone (black squares). Data relate 
to a single experiment, ten AZD7507 treated mice and four vehicle-treated mice, the mean for 
each group is shown. Error bars represent SEM. 
 
To formally assess the effects of AZD7507 treatment on survival in the 60577 model I 
performed a second experiment. Mice were either pre-treated with AZD7507 for forty-
eight hours prior to cell injection, or AZD7507 was started, in mice bearing established 
tumours, twenty-one days following cell injection. Mice in each group were continuously 
treated with AZD7507 or vehicle alone until a humane endpoint was reached. There was 
no difference in survival between AZD7507-treated and vehicle-treated controls when 
the treatment was started immediately prior to tumour cell injection nor after twenty-one 
days (Figure 8.8A). Furthermore, there was no difference in the mean omental weight 
between AZD7507-treated and vehicle-treated controls under either treatment regimen 
(Figure 8.8B). Therefore, in this model, global TAM depletion with CSF-1Ri did not affect 
murine HGSOC survival when administered in the context of an established tumour or 
before tumour development. Given that the phenotype of TAMs change following 
chemotherapy it will be important to assess the effects of TAM depletion following 
chemotherapy. Later in this Chapter I will assess the effects of CSF-1Ri-mediated TAM 
depletion at different time points following chemotherapy. 
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Figure 8.8 The effect of AZD7507 treatment on survival and tumour weight in the 60577 
model. A Kaplan Meier curves showing survival of mice treated with AZD7507 started forty-eight 
hours before 60577 cell injection (red dashed line), AZD7507 started twenty-one days after 60577 
cell injection (red line), vehicle-treated mice started forty-eight hours before 60577 cell injection 
(back dashed line) and vehicle-treated mice started twenty-one days after 60577 cell injection 
(black line). B Omental weight from mice treated with AZD7507 (red circles) or vehicle control 
(black squares). Data relate to a single experiment, four-seven mice per group, the mean for each 
group is shown. Error bars represent SEM. 
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8.2.2 BLZ945 treatment of the 60577 model 
I next assessed the effects of BLZ945 in the 60577 murine model. BLZ945 was obtained 
commercially. Due to high cost of this compound, initially I only obtained enough drug to 
treat four mice for four days. BLZ945 treated tumours were compared to vehicle-treated 
tumours at a time point 12 hours following the last treatment. Figure 8.9 shows a 
schematic outline for this experiment. BLZ945 has not been previously used in the lab, 
in view of the expense of this compound, I used doses that have proved effective in the 
treatment of tumour-bearing mice described in the literature215,321. 
 
 
Figure 8.9 Schematic outline of an experiment assessing the effect of BLZ945 on the 60577 
model. Significant experimental time points and treatment scheduling is shown. OD: once a day, 
OG: oral gavage. 
 
After four days of treatment with BLZ945, there was a significant decrease in the TAM 
density in BLZ945 treated tumours compared to vehicle-treated controls (Figure 8.10).  
 
Figure 8.10 The effect of BLZ945 treatment on TAM cell number. Flow cytometry data relating 
to the immunostained stromal vascular fractions derived from omental tumours treated with 
BLZ945 (red circles) or vehicle alone (black squares). A TAM frequency is expressed as a 
percentage of the CD45+ population and B as cells/mg. Data relate to a single experiment, four 
BLZ945 treated mice and three vehicle-treated mice, the mean for each group is shown. Error 
bars represent SEM. Student’s t-test p-values are shown; ***<0.001. 
 
As seen previously in experiments using AZD7507, FC analysis showed there was a 
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significant reduction in TAMs expressing the surface markers CD206, MHC Class II as 
well as PDL1 (Figure 8.11) both when quantified as cells/mg of tissue and as a 
percentage of the CD45+ immune cell infiltrate. 
 
Figure 8.11 The effect of BLZ945 treatment on MHC Class II+ and CD206+ TAM cell number. 
Flow cytometry data relating to the immunostained stromal vascular fractions derived from 
omental tumours treated with BLZ945 (red circles) or vehicle alone (black squares). A 
CD206+TAM frequency is expressed as a percentage of the CD45+ population and B as cells/mg. 
C MHC Class II+TAM frequency is expressed as a percentage of the CD45+ population and D as 
cells/mg. E PDL1+TAM frequency is expressed as a percentage of the CD45+ population and F 
as cells/mg. Data relate to a single experiment, four BLZ945 treated mice and three vehicle-
treated mice, the mean for each group is shown. Error bars represent SEM. Student’s t-test p-
values are shown; *<0.05, **<0.01. 
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I next looked for any change in TAM phenotype after BLZ945 treatment. Interestingly, as 
observed with AZD7507 treatment of this model, I found significant reductions in MHC 
Class II expression with no changes in CD206 expression (Figure 8.12). 
 
Figure 8.12 The effect of BLZ945 treatment on TAM phenotype. Flow cytometry data relating 
to the immunostained stromal vascular fractions derived from omental tumours treated with 
BLZ945 (red circles) or vehicle alone (black squares). A CD206+TAM percentage of the TAM 
population and B as MFI. C MHC ClassII+TAM percentage of the TAM population and D as MFI. 
Data relates to a single experiment, four BLZ945 treated mice and three vehicle-treated mice, the 
mean for each group is shown. Error bars represent SEM. Student’s t-test p-values are shown; 
*<0.05. 
 
Assessments of the lymphocyte populations showed significant decreases in the CD3+ 
and CD3+CD4+ populations (Figure 8.13) but no significant changes in CD3+CD8+ cell 
number (Figure 8.13). As seen with AZD7507 treatment, there was a significant 
decrease in CD19+ cells in BLZ945 treated compared to vehicle-treated tumours (Figure 
8.14). 
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Figure 8.13 The effect of BLZ945 treatment on T lymphocyte populations. Flow cytometry 
data relating to the immunostained stromal vascular fractions derived from omental tumours 
treated with BLZ945 (red circles) or vehicle alone (black squares). A CD3+ C CD3+CD4+ E 
CD3+CD8+ as a percentage of the CD45+ population and B CD3+, D CD3+CD4+, F CD3+CD8+ as 
cells/mg of tissue. Data relate to a single experiment, four BLZ945 treated mice and three vehicle-
treated mice, the mean for each group is shown. Error bars represent SEM. Student’s t-test p-
values; **<0.01. 
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Figure 8.14 The effect of BLZ945 treatment on the B lymphocyte population. Flow cytometry 
data relating to the immunostained stromal vascular fractions derived from omental tumours 
treated with BLZ945 (red circles) or vehicle alone (black squares). A CD19+ cells as a percentage 
of the CD45+ population and B as cells/mg of tissue. Data relate to a single experiment, four 
BLZ945 treated mice and three vehicle-treated mice, the mean for each group is shown. Error 
bars represent SEM. Student’s t-test p-values are shown; *<0.05, **<0.01. 
There were no significant differences in omental weight between BLZ945 treated and 
vehicle controls (Figure 8.15), as might be expected after only four days on treatment. 
 
 
Figure 8.15 The effect of BLZ945 treatment on tumour weight in the 60577 model. Fresh 
omental weight from mice treated with BLZ945 (red circles) or vehicle alone (black squares). Data 
relates to a single experiment, four BLZ945 treated mice and three vehicle-treated mice, the mean 
for each group is shown. Error bars represent SEM. 
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8.2.3 Summary: CSF-1Ri treatment of 60577 tumours 
Overall these data show no reduction in tumour size or survival benefit of CSF-1Ri TAM 
depletion in the 60577 model. However, both AZD7507 and BLZ945 reduced the density 
of TAMs in 60577 tumours. Surface expression of MHC Class II on TAM was significantly 
reduced whereas CD206 expression remained unchanged and highly expressed. CSF-
1Ri treatment also resulted in changes to tumour infiltrating lymphocyte populations with 
significant reductions of CD4+ T cells and CD19+ B cells following treatment with either 
inhibitor. At post mortem there were no obvious macroscopic changes in the amount or 
sites of peritoneal dissemination in CSF-1Ri-treated mice compared to vehicle-treated 
controls. 
 
 CSF-1Ri treatment of HGSOC relapse 
An overarching aim of this thesis is to determine if there is any value in targeting TAMs 
in metastatic HGSOC. Treating 60577 tumours with AZD7507 alone did not change 
survival or tumour size. Therefore, targeting TAM before chemotherapy may not be 
helpful. The findings presented in Chapters 3 and 6 suggest that TAMs were depleted in 
human and mouse HGSOC following carboplatin treatment. Therefore CSF-1Ri 
treatment co-administered with chemotherapy may not further modify the TME. I decided 
instead to test the effect of CSF-1Ri following carboplatin chemotherapy. I hypothesised 
that the period following chemotherapy may represent a ‘window of opportunity’ to target 
TAMs, preventing TAM re-accumulation, with the aim of delaying HGSOC relapse. The 
relapse 60577 model of HGSOC provided a suitable system to test this hypothesis. 
 
8.3.1 Effect of CSF-1Ri on survival to relapse 
To assess the effects of CSF-1Ri on tumour regrowth post-chemotherapy, mice were 
treated with three once-weekly doses of carboplatin, then following an interval of ten 
weeks from the last dose of carboplatin, they were treated with AZD7507 for three weeks. 
This corresponded with the first mouse reaching a humane end point due to recurrent 
disease. I chose to start treatment at ten weeks following carboplatin because in previous 
experiments in the 60577 relapse model mice had started to reach endpoint at 
approximately thirteen weeks following completion of carboplatin treatment (Chapter 7). 
Figure 8.16 shows a schematic representation of this experiment. 
  
Chapter 8: Results 
 209 
 
Figure 8.16 Schematic outline of an experiment assessing the effects of AZD7507 on 
HGSOC relapse. Significant experimental time points and treatment scheduling are shown. BD: 
twice a day, OG: oral gavage. 
 
The main objective of this experiment was to study the effect of AZD7507 compared to 
vehicle-treated mice on overall survival.  As shown in Figure 8.17 there was no significant 
difference in survival between AZD7507 and vehicle-treated controls. All mice in the 
experiment developed recurrent disease with evidence of omental tumours and large 
volume ascites at endpoint. 
 
 
Figure 8.17 The effect of AZD7507 treatment on survival to relapse. Kaplan Meier curves 
showing AZD7507 treated mice (red line) and vehicle-treated controls (blue line). Carboplatin 
tretaments are indicated (dashed lines), the period of AZD7507 or vehicle tretament is indicated 
(red shading). Data from a single experiment are shown. Log-rank (Mantel-Cox) test p-value is 
shown; ns=non-significant. 
 
Given that TAM reaccumulate in relapsing tumours (see Chapter 7), I next asked if 
initiating CSF-1Ri treatment sooner than ten weeks following chemotherapy would 
change outcome. Therefore, I treated mice with either AZD7507 or BLZ945 starting four 
weeks after carboplatin treatment. This time point was chosen as previous studies 
showed only small foci of malignant cells in the omentum at a time point six weeks 
following carboplatin treatment. Therefore, I assumed that TAM would not have 
reaccumulated in the omentum at this earlier time point. Figure 8.18 shows the schematic 
outline of this experiment. 
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Figure 8.18 Schematic outline of experiment assessing the effect of AZD7507 and BLZ945 
on HGSOC relapse. Significant experimental time points and treatment scheduling are shown. 
OD: once a day, BD: twice a day, OG: oral gavage. 
 
Contrary to expectations, when treatment was started four weeks after completion of 
carboplatin, administration of either AZD7507 or BLZ945 significantly reduced time to 
relapse and survival compared to vehicle only treated controls (Figure 8.19). The median 
survival in AZD7507-treated mice was 126 days vs 149 days for vehicle-treated controls 
p=0.001; BLZ945-treated mice median survival was 135 days vs 150 days for vehicle-
treated controls p=0.016. 
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Figure 8.19 The effects of AZD7507 and BLZ945 tretament on survival to relapse in the 
60577 model commensed four weeks following carboplatin treatment. Kaplan Meier curves 
showing A AZD7507 or B BLZ945 treated mice (red line), vehicle-treated controls (blue line) and 
mice not treated with chemotherapy (black line). Carboplatin or vehicle tretaments are indicated 
(dashed lines), the period of AZD7507 or vehicle tretament is indicated (red shading). Data from 
a single experiment is shown. Log-rank (Mantel-Cox) test p-value is shown; *<0.05, ***<0.001. 
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To further explore this result an experiment was performed in which mice were treated 
with AZD7507 for 12 weeks starting immediately after completion of carboplatin 
treatment. Again, mice treated with AZD7507 starting immediately after chemotherapy 
had a shortened overall survival compared to vehicle-treated controls (Figure 8.20). This 
experiment was performed with the assistance of Dr. Chiara Berlato, Barts Cancer 
Institute. Analysis of flow cytometry data relating to this experiment is ongoing. 
 
 
Figure 8.20 The effects of AZD7507 tretament on survival to relapse in the 60577 model 
commensed immedialy following carboplatin tretament. Kaplan Meier curves showing 
AZD7507 treated mice (red line) and vehicle-treated controls (blue line). Carboplatin tretaments 
are indicated (dashed lines), the period of AZD7507 or vehicle tretament is indicated (red 
shading). Data from a single experiment are shown. Log-rank (Mantel-Cox) test p-value is shown; 
*<0.05. 
 
Overall this series of experiments suggest that TAM populations are modified by 
carboplatin treatment to take on roles which limit tumour growth. Therefore, depletion of 
TAMs soon after, or immediately following the completion of carboplatin treatment 
explains the detrimental effects of CSF-1Ri on murine survival. 
 
8.3.2 Assessment of TAM density in CSF-1Ri treated tumours by 
immunohistochemistry 
To confirm TAM depletion in the relapse model secondary to AZD7507 and BLZ945 
treatment, I measured F4/80 expression by IHC within omental tumours in the survival 
experiments (Figure 8.21). This confirmed significant reductions in F4/80+ infiltrate in 
BLZ945 treated mice compared to vehicle controls. The data relating to AZD7507 treated 
vs vehicle controls were not statistically significant (p=0.08), although the difference 
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between means was very similar to BLZ945 treated tumours. This is likely due to small 
numbers in the AZD7507 control group. 
 
Figure 8.21 Validation of TAM depletion with CSF-1Ri in relapsed HGSOC. Quantification of 
F4/80 staining by Definiens® digital analysis in relapsed tumours. A AZD7507 (red circles) and 
vehicle-treated controls (black squares). B BLZ945 (red circles) and vehicle-treated controls 
(black squares). F4/80 staining expressed as percentage positive area of the biopsy. Data 
quantified relate to a single experiment, the mean for each group is shown. Error bars represent 
SEM. Student’s t-test p-values are shown; *<0.05. 
 
These results add further weight to the interim conclusions from both the human and 
murine studies in the previous chapters. I hypothesise that after chemotherapy TAM may 
contribute to a microenvironment that attempts to limit tumour growth and development. 
Partial depletion of these TAM may be detrimental.  
 
 Discussion 
In this chapter I report a series of experiments that were conducted to assess the value 
of targeting TAM with CSF-1Ri in metastatic HGSOC. Treatment of the 60577 model 
with CSF-1Ri as a single-agent did not alter survival (Figure 8.8). Furthermore, there 
were no differences in tumour weight after twelve days of AZD7507 treatment compared 
to vehicle-treated controls (Figure 8.7). I next treated tumour-bearing mice after 
chemotherapy with both AZD7507 and BLZ945. Counter to expectations, starting either 
CSF-1Ri four weeks after carboplatin treatment significantly decreased overall survival 
(Figure 8.19). Furthermore, starting AZD7507 treatment immediately following 
carboplatin treatment also significantly decreased overall survival compared to vehicle 
treatment controls (Figure 8.20). Therefore, CSF-1Ri treatment following carboplatin 
seems to be harmful. This surprising result shows that chronic CSF-1Ri treatment may 
deplete or repolarise populations of TAMs which restrain tumour progression.  
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Alternatively, chronic CSF-1Ri-mediated TAM depletion may induce compensatory 
changes in the TME with recruitment of other tumour promoting cells e.g. granulocytes; 
or the changes observed in lymphocyte cell number may be responsible. CSF-1Ri 
resulted in overall reductions in CD4+ T cells and CD19+ B cells. Tumour infiltrating 
lymphocytes are the cell type most robustly associated with a good prognosis in ovarian 
cancer34. Furthermore, work in our lab has shown B cells in HGSOC are associated with 
an antitumoral immune landscape114. Therefore, although CSF-1Ri treatment 
significantly reduced TAM density, the changes observed in the lymphocyte populations 
could also explain reductions in overall survival in mice treated with CSF-1Ri post-
chemotherapy. 
 
AZD7507 and BLZ945 treatment resulted in reduction of TAM cell density (Figure 8.2, 
Figure 8.10), showing that effective doses of these compounds were being used. 
However, higher concentrations may have resulted in further depletion. This could be 
tested in future experiments. The remaining TAMs showed reduced expression of MHC 
Class II with preserved high CD206 expression. Therefore, in addition to TAM depletion 
CSF-1Ri treatment may have altered the overall phenotype of the remaining 
macrophage population, towards an alternatively activated state. This finding agrees with 
Mitchem et al. who showed specific depletion of MHC Class II-high TAM by CSF-1Ri; in 
this study the depleted cells also expressed high levels of F4/80 and were able to 
phagocytose tumour cells. Therefore, in this model CSF-1Ri treatment may have skewed 
TAM towards a tumour promoting phenotype. Furthermore, in several systems MHC 
Class II-low macrophages have been associated with poor prognosis and a profibrotic 
phenotype139,322. 
 
Human studies in a number of cancers types support my data, which have shown that 
following chemotherapy high TAM density was associated with improved survival181,188. 
Di Caro et al. showed that chemotherapy modified the association of TAM density with 
clinical outcome in PDAC; prior to chemotherapy TAM were immunosuppressive and 
high TAM density associated with poor outcome, following chemotherapy TAM density 
predicted improved survival. Taken together, these data show that chemotherapy may 
directly or indirectly change macrophage function towards antitumoral functions.  
 
Initiating CSF-1Ri treatment at a later time point, ten weeks compared to immediately 
after or four weeks post-carboplatin, was not associated with differences in survival to 
relapse (Figure 8.17). Hence it is possible that the ‘positive’ effects of carboplatin on 
TAMs may exist for a relatively short period of time following the completion of treatment. 
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Therefore, the ideal time to intervene with TAM-modifying therapy may be immediately 
post-chemotherapy with the aim of further stimulating the anti-tumour activities of TAM 
rather than depleting them with a CSF-1Ri. It can be envisaged that a brief period of 
CSF-1Ri treatment just before chemotherapy, rather than a long-term treatment, as in 
my experiments, may alter the interaction of the TAM population with chemotherapy. It 
may be that such an approach would reduce TAM-mediated immunosupression which 
may enhance the ‘immuno-stimulatory’ effects of chemotherapy. 
 
In both the patient biopsies and mouse models I found evidence for direct, or indirect, in 
vivo cytotoxic activity of carboplatin on TAMs. In the final chapter I have investigated this 
further using in vitro models.
  216 
 
 
 
 
 
 
 
 
 
Chapter 9 
Carboplatin activates inflammatory cell death in 
macrophages
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9Carboplatin activates inflammatory cell death in macrophages 
9.1 Introduction 
In the data presented so far in this thesis I have described the effects of NACT or on 
TAMs in human and murine HGSOC. These data show that chemotherapy results in: i) 
a change in TAM phenotype with down regulation of CD206 and scavenger receptors, 
ii) upregulation of inflammasome, TLR and IL1b signalling pathways (so far only in 
human TAM) iii) significant reductions in TAM and iv) increases in non-viable TAM. I 
conclude that carboplatin may induce TAM cell death as well as promote an inflammatory 
TAM phenotype. A unifying mechanism linking these latter two processes could be the 
activation of pyroptosis. This led me to ask the question – ‘can carboplatin induce 
pyroptosis in macrophages?’. 
 
Pyroptosis is an inflammatory form of cell death characterised by cell membrane lysis 
and the release of the proinflammatory cytokines IL1b and IL-18323,324. This process is 
mediated by the activation of pro-inflammatory caspases (capase-1/11 in the mouse and 
caspase-1/4/5 in humans) which occurs following the assembly of specific multiprotein 
signalling platforms called inflammasomes. In the canonical pathway, inflammasome 
assembly, with resultant cleavage and activation of caspase-1 mediates cleavage of the 
repressor domain from the pore forming domain (PFD) of gasdermin D (GSDMD)323,325. 
This results in the assembly of gasdermin pores in the cell membrane causing the cell 
to swell and lyse326. This event facilitates the release of the inflammatory cytokines. Non-
canonical activation of pyroptosis can also occur via gasdermin D cleavage by caspases-
4/5/11. In humans gasdermin D is one of six gasdermin family members323. Several other 
gasdermins form pores upon cleavage of the PFD. One of these, gasdermin E (DFNA5) 
is activated by cleaved caspase-3327. Therefore, caspase-3 has recently been shown to 
activate pyroptosis via this alternative pathway. 
 
In view of the data summarised above, I assessed the effects of carboplatin treatment 
on macrophage viability, phenotype, inflammasome assembly and activation of 
pyroptosis using human monocyte derived macrophages. 
 
9.2 Assessments of the effect of chemotherapy on human HGSOC cell lines in 
vitro 
To define relevant in vitro concentrations of carboplatin to use in experiments on 
macrophages, I first tested the sensitivity of three human HGSOC cell lines (AOCS1, 
G164 and G33) to carboplatin (Figure 9.1). All three cell lines had a similar response to 
carboplatin with IC50 of  55.56µM (AOCS), 123.8µM (G164), 189.6µM (G33); these are 
within the ranges reported for the sensitivity of other ovarian cancer cell lines to 
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carboplatin309. Furthermore, IC50 carboplatin values were similar to those of the murine 
HGSOC cell lines (86.1µM -155.4µM) (Figure 6.1). 
 
Figure 9.1 Testing the sensitivity of human HGSOC cell lines to carboplatin. G33 (red line), 
G164 (blue line) and AOCS1 (green line) cells were cultured in media containing varying 
concentrations of carboplatin for forty-eight hours. Cells were then fixed and stained with crystal 
violet. Crystal violet staining was quantified by spectrophotometry. OD595 measurements 
presented as the mean with error bars representing SEM from three experiments, normalised to 
media-only control for carboplatin. IC50 values: G33=203.1µM, G164=98.63µM and 
AOCS1=45.1µM. 
 
9.3 The effects of chemotherapy on macrophages in vitro 
Next I tested the effects of chemotherapy on human macrophages (Figure 9.2 and Figure 
9.3). Macrophages were differentiated from CD14+ human monocytes by culture in the 
presence of h-MSCF (CSF-1) for seven days and then polarised in vitro to either 
M1/classically activated or M2/alternatively activated phenotypes with LPS/IFNg or IL-
4/IL-10 respectively. The cells were then treated with carboplatin at different 
concentrations for forty-eight hours, cell viability and phenotype were assessed by flow 
cytometry. Macrophages were killed by carboplatin at concentrations in the range 50-
200µM. This is within the range of IC50 value for the human HGSOC cell lines tested 
(Figure 9.1). The IC50 was lower for M1/classically activated macrophages (93µM) than 
M2 (203µM) polarised macrophages. 
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Figure 9.2 Assessing the effects of carboplatin on macrophage viability in vitro. Human 
CD14+ monocytes derived from leucocyte cones were differentiated in media containing h-MCSF 
for seven days prior to being polarised to M1/classically activated (blue line) and M2/alternatively 
activated (red line) phenotypes with LPS/IFNg and IL-4/IL-10 respectively, M0 (green line) cells 
received no additional stimulation. Cells were cultured in media containing varying concentrations 
of carboplatin for forty-eight hours. Data represent viable cells expressed as the percentage of 
single cells, normalized to the media only control for each stimulation condition. Data relate to a 
single experiment. IC50 values: M0=201.7µM, M1=93.5µM and M2=203.3µM.  
 
I then assessed a range of phenotype markers in viable macrophages after carboplatin 
treatment. The surface expression of CD206, CD163 and PDL1 on M2-polarised 
macrophages decreased with increasing concentrations of carboplatin compared to 
untreated cells (Figure 9.3). HLA-DR surface expression also decreased, although only 
at higher carboplatin concentrations than those that caused changes in other markers 
(Figure 9.3). These data suggest a change in macrophage phenotype from an 
alternatively to a classically activated phenotype by carboplatin treatment. Furthermore, 
these data recapitulate the findings in mouse and human HGSOC tumours where 
carboplatin decreased both CD206 and CD163 on TAMs. 
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Figure 9.3 Assessing the effects of carboplatin chemotherapy on macrophage phenotype 
in vitro. Human CD14+ monocytes derived from leucocyte cones were differentiated in media 
containing h-MCSF for seven days prior to being polarised to an M2 phenotype with IL-4/IL-10. 
Cells were cultured in media containing varying concentrations of carboplatin for forty-eight hours. 
Flow cytometry was performed to assess expression of cell surface markers. Data represent MFI 
of A CD206, B CD163 and C PDL1 and D HLA-DR in viable macrophages. Data relate to a single 
experiment. 
In summary, these preliminary data show a direct effect of carboplatin on macrophages 
in culture, independent of the presence of malignant cells and their responses to 
carboplatin treatment. Carboplatin seems to kill macrophages at concentrations similar 
to the IC50 of carboplatin on human HGSOC cell lines in vitro. This experiment was 
repeated using macrophages polarised with conditioned media from human HGSOC cell 
lines rather than using IL-4/IL-10 as shown above. This experiment (data not shown) 
supported the data presented here, however, further replicates of these experiments are 
needed and will be undertaken in planned future work. 
 
9.4 Assessment of cell death markers in human HGSOC 
These data, coupled with my findings of increased non-viable TAM following 
chemotherapy in both mouse and human tumours (Figure 4.7, Figure 6.35), led me to 
look for evidence of TAM death in human HGSOC sections. I performed dual-colour IHC 
for CD68 and Pax-8 on human HGSOC biopsies and in consecutive sections I stained 
for cleaved caspase-3 as a marker of apoptosis. Interestingly, there was clear overlap of 
the cleaved caspase-3 and CD68 staining patterns. The areas of most obvious overlap 
were within post-chemotherapy ‘macrophage lakes’ described in Chapter 3 (Figure 9.4). 
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Figure 9.4 CD68, Pax-8 and cleaved caspase-3 evaluated in HGSOC omental metastases 
pre and post-chemotherapy. Representative staining of four HGSOC omental biopsies A pre 
chemotherapy and B post-chemotherapy. For each sample consecutive sections have been 
stained. Left column: CD68 (brown), Pax-8 (purple) green counterstaining. Right column: Cleaved 
caspase-3 (brown), blue counterstaining. Scale bar: 50µm. 
 
Despite the fact that cleaved caspase-3 is frequently regarded as a marker of apoptosis, 
assessment of cell and nuclear morphology suggested that the cleaved caspase-3+ cells 
were not apoptotic. Also, the distribution of the staining would be highly unusual for 
apoptosis which usually shows positivity within individual cells rather than in large 
clusters of cells as seen in Figure 9.4. To further explore this finding, I performed a 
TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labelling) assay on 
sections containing cleaved caspase-3+ macrophage lakes. This technique recognises 
fragmented DNA within the nucleus, a classical feature of apoptosis. In keeping with the 
morphological appearances of these cells, they did not appear to be TUNEL positive 
suggesting that they were not undergoing apoptosis (Figure 9.5). 
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Figure 9.5 TUNEL staining within ‘macrophage lakes’ post-chemotherapy. Representative 
example of staining result. A positive control, tissue incubated with DNAase for 20mins prior to 
TUNEL staining. B Post-chemotherapy HGSOC biopsy showing area within a ‘macrophage lake’ 
shown at x20 magnification. C as B x40. Scale bar: 100µm, 50µm. 
 
The data presented so far show that carboplatin can kill TAM and that post-NACT TAM 
express high levels of cleaved of caspase-3 compared to untreated tumours. In Chapter 
4 I showed that the top upregulated pathways in post-NACT human TAM were 
‘inflammasome’ and ‘IL1b signalling’, hence I hypothesised that TAM may be undergoing 
inflammatory forms of cell death such as pyroptosis in tumours. 
 
It has recently been established that caspase-3 cleavage can activate pyroptosis by the 
cleavage of gasdermin E327. However, canonical activation of pyroptosis is via 
inflammasome assembly, resulting in caspase-1 mediated cleavage of gasdermin D. To 
test if there was an activation of the inflammasome in macrophages as the result of 
carboplatin stimulation, I performed a proximity ligation assay (PLA)328 to test for the 
interaction of NLRP3 (NOD-, LRR- and pyrin domain-containing 3) and ASC (apoptosis-
associated speck-like protein containing a CARD) in macrophages treated with 250µM 
and 500µM carboplatin (Figure 9.6 and Figure 9.7). There was a significant increase in 
the number of PLA signals/cell in macrophages treated with 250µM and 500µM 
carboplatin compared to untreated cells (Figure 9.7). These data show that carboplatin 
treatment results in formation of the NLRP3 inflammasome complex and support the 
pathway analysis of the TAM RNA-sequencing data as described above.  
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Figure 9.6 PLA assay. Image shows representative examples of PLA assay performed on M2-
differentiated macrophages. A media only control, B LPS/nigericin treated cells (positive control), 
C cells treated with carboplatin 250µM and D cell treated with carboplatin 500µM for twenty-four 
hours. Green specks indicate NLRP3 inflammasome complexes. Scale bar: 25µM. 
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Figure 9.7 Quantification of PLA signals. Quantification of PLA signal per cell in untreated 
controls, positive control (LPS/nigericin treated cells), and carboplatin treated macrophages at 
concentrations of 250µM and 500µM applied for twenty-four hours. Data relate to a single 
experiment, PLA signals quantified in twenty-five – thirty-five cells per group, the mean for each 
group is shown. Error bars represent SEM. One-way ANOVA p-values are shown; ****<0.0001. 
 
To assess inflammasome activation in human HGSOC omental metastases, I conducted 
immunofluorescent staining for CD68 and NLRP3 in biopsy samples obtained from 
untreated tumours and after NACT. I found increased expression of NLRP3 in CD68 
positive cells (Figure 9.8) further supporting the concept of inflammasome activation 
post-chemotherapy. 
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Figure 9.8 Assessment of NLRP3 expression in human HGSOC omental metastases. 
Immunofluorescent staining of HGSOC omental metastases from a patient A treated with interval 
cytoreductive surgery and B treated by primary cytoreductive surgery. Top-left: nuclei stained 
blue with DAPI, top-right: CD68 staining (green), bottom-left: NLRP3 staining (red) and bottom-
right: merged view. Scale bar: 10um. 
 
As I found increased cleaved caspase-3 in TAM after chemotherapy, I wished to further 
explore the possibility of caspase-3 cleavage after chemotherapy in macrophages. Given 
that cleaved caspase-3 is able to activate pyroptosis via the cleavage of DFNA5, I also 
measured cleavage of DFNA5 in the cells using western blot of macrophage lysates. 
Figure 9.9 shows carboplatin induced cleavage of caspase-3 and DFNA5 in M2 polarised 
macrophages in vitro. This provides evidence of non-canonical activation of pyroptosis 
in macrophages in response to carboplatin treatment. 
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Figure 9.9  Cleavage of DFNA5 and caspase-3 with carboplatin treatment of M2 monocyte-
derived macrophages. Monocytes were cultured for seven days with h-MCSF. The differentiated 
macrophages were stimulated with IL4/IL-10 additional three days. Cell were incubated with 
varying concentrations of carboplatin for twenty-four hours or LPS/nigericin as a positive control. 
Data relate to a single experiment. 
 
As pyroptosis is associated with proinflammatory cytokine release, especially IL1b and 
IL-18, I measured cytokine secretion in macrophages cultured with and without 
carboplatin using an MSD V-Plex assay.  As can be seen in Figure 9.10, carboplatin 
treatment of macrophages increased the secretion of multiple cytokines, including IL1b. 
Uncontrolled cytokine release adds further support for inflammatory cell death in TAMs 
following carboplatin treatment. 
 
In conclusion, I have found evidence that carboplatin triggers the cleavage and activation 
of gasdermin E, leading to NLRP3 inflammasome assembly, pyroptosis and release of 
pro-inflammatory cytokines. 
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Figure 9.10 Macrophage cytokine secretion following carboplatin treatment. Monocytes 
were cultured for seven days with h-MCSF. The differentiated macrophages were stimulated with 
IL4/IL-10 additional three days. Cell were incubated with varying concentrations of carboplatin for 
twenty-four hours or left untreated. Ten cytokines (A-J) were measured by performing an MSD 
V-Plex assay. Data relate to a single experiment. 
  
Chapter 9: Results 
 228 
 Discussion 
I this chapter I report a preliminary series of experiments on macrophages differentiated 
from CD14+ human monocytes. It is well described that these cells can be successfully 
polarised to M1/classically activated or M2/alternatively activated states in vitro with the 
cytokines IFN/LPS and IL-4/IL-10 respectively120. I assessed the effects of carboplatin 
treatment on cell death and macrophage phenotype in vitro. Interestingly, I found 
significant increases in macrophage cell death with carboplatin treatment. This effect 
was noted at concentrations of carboplatin approximating the IC50 concentration for three 
HGSOC cell lines. These findings substantiate my findings of increased cell death within 
the TAM population of both human and mouse HGSOC after carboplatin treatment. 
Furthermore, these data show a direct effect of carboplatin on macrophages. 
 
As described previously, the sensitivity of cell lines to carboplatin reported in the literature 
varies widely. The IC50 values obtained for three human HGSOC cell lines are within the 
range described in the literature309, although direct comparison is limited by different 
assays and culture conditions329. A source of variability in my data is that two different 
methods were used to assess cell viability in macrophages and in malignant cells. 
Macrophages were assessed via flow cytometry, and malignant cells were assessed by 
crystal violet staining of adherent cells. Therefore, this limits comparisons between the 
concentrations of carboplatin used to treat malignant cells and macrophages. This work 
will be extended and repeated (see Future plans, Chapter 10). However, I conclude that 
carboplatin does affect macrophages directly and can change cell phenotype and induce 
death at concentrations approximating those that produce responses in human HGSOC 
cell lines in vitro. 
 
Given these findings, I wanted to measure cell death in human HGSOC biopsies. I found 
post-chemotherapy TAM to express high levels of cleaved caspase-3 (Figure 9.4). 
Cleaved caspase-3 is a common marker for apoptosis, yet the morphology of the cells, 
the nuclear features and the distribution of the staining were not typical of this mode of 
cell death. Furthermore, the TUNEL assay was negative in sections that contained high 
cleaved caspase-3 positivity (Figure 9.5) suggesting that cleaved caspase-3+, CD68+ 
cells were not apoptotic. There are no other markers that can be used to reliably assess 
cell death in fixed paraffin embedded tissue. Therefore, I was not able to conclusively 
determine if there was an increase in TAM cell death in tissue sections. However, 
cleaved caspase-3 activates pyroptosis, via cleavage of gasdermin E. This fitted well 
with the pathways analysis of human TAM post-NACT showing inflammasome 
activation.  
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To explore the possibility that carboplatin can induce inflammasome activation in 
macrophages, I performed the PLA assay for the NLRP3/ASC complex in cultured 
M2/alternatively-differetiated macrophages. This showed NLRP3 inflammasome 
assembly in carboplatin treated macrophages. However, only two concentrations of 
carboplatin were used (250µM and 500µM). I sought to confirm these in vitro findings in 
human tissue samples by co-staining tissues for NLP3 and CD68. Qualitative 
assessment of this staining suggested an upregulation of NLRP3 expression following 
chemotherapy. These data support the RNA-sequencing data and suggest 
inflammasome activation in macrophage following carboplatin treatment. 
 
To explore a role for cleaved caspase-3 in activating pyroptosis, I measured cleavage of 
caspase-3 and gasdermin E in macrophage lysates by western blot. I found cleavage of 
caspase-3 and gasdermin E at carboplatin concentrations of 250-500µM. Furthermore, 
an MSD assay showed a strong increase in the secretion of multiple cytokines in 
carboplatin treated compared to untreated cells. This further supports carboplatin 
activated pyroptosis in macrophages. 
 
The data presented in the chapter are preliminary but my interim conclusion is that some 
macrophages treated with carboplatin die as the result of activation of pyroptosis. This 
would explain macrophage depletion and phenotype changes described previously in 
this thesis. 
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10 Summary of findings, discussion and future plans 
 
HGSOC has a poor survival; this is due to the failure of chemotherapy, administered in 
combination with radical cytoreductive surgery, to control this disease. Frequently 
patients will respond well to chemotherapy and undergo surgical clearance of all 
macroscopic disease, yet still relapse within a short time frame. Survival has not been 
meaningfully impacted in the last twenty years; this highlights the need for new 
therapeutic strategies to combat HGSOC. Immunotherapies have shown success in 
treating a subset of cancers, in some cases with dramatic and durable responses. 
Extending the use of immunotherapies more widely is a current challenge facing this 
area of science. An in depth understanding of the tumour microenvironment of HGSOC 
and how this evolves under the effects of therapy is essential in the design of effective 
immunotherapies for this disease. 
 
 Summary of findings 
Figure 10.1 is a graphical summary of the significant finding presented in this thesis. I 
will now discuss how the key points of my thesis relate to aspects of macrophage biology 
and immunotherapy design in HGSOC.
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Figure 10.1 Graphical summary and current working hypothesis. Chemotherapy results in a transient restructuring of the TAM populations favouring an anti-
tumoural TME. TAM depletion and increased antigen sensing may underlie the changes observed. ‘Chronic’ CSF-1Ri treatment from 0-4 weeks post-chemotherapy 
reduced overall survival, suggesting an overall tumour-limiting TAM phenotype soon after chemotherapy in contrast to CSF-1Ri before chemotherapy or at relapse.
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 The HGSOC TME post-chemotherapy 
Historically, research into the mechanisms of action of chemotherapy has focused on 
the malignant cells. However, in addition to targeting malignant cells, chemotherapy 
frequently activates anti-tumour or pro-tumour immune pathways and networks within 
the wider TME208. Understanding the mechanisms underlying these differential effects is 
important and may identify strategies to boost chemotherapy response and prevent 
relapse. 
 
I have focused on the myeloid compartment of the HGSOC TME and the data in this 
thesis show changes in myeloid cell density, location and phenotype in response to first-
line chemotherapy. Overall my data suggest that chemotherapy, most notably 
carboplatin, drives anti-tumour functions in TAMs and increases DC density. There are 
multiple lines of evidence to support this within both human and murine tumours. By FC 
I found reductions in TAM alternatively activated surface marker expression and 
transcriptomic assessment of human TAM showed enrichment of the pathway terms 
‘inflammasome’, ‘IL1b signalling’ and ‘TLR signalling’, suggesting inflammatory 
macrophage activation.  
 
Targeting TAMs in vivo using CSF-1Ri in mouse HGSOC models resulted in partial TAM 
depletion. There was no effect on survival when CSF-1Ri was administered as a single 
agent during all stages of tumour development or to mice bearing established tumours. 
In contrast, CSF-1Ri treatment immediately after chemotherapy or four weeks after 
chemotherapy resulted in a significantly worse survival compared to vehicle-treated 
controls. Treating mice at a time point ten weeks following the end of chemotherapy did 
not result in changes to murine survival. These data suggest dynamic changes in TAM 
phenotype and function in HGSOC through primary chemotherapy and beyond. 
 
These data fit with the findings of others showing that NACT can promote anti-tumour 
responses within other cell types within the TME of HGSOC, e.g. CD3+ and CD8+ T cell 
recruitment330. Furthermore, in haematological malignancies203, PDAC188 and CRC181, 
chemotherapy alters TAM phenotype and in this context, high TAM densities post-
chemotherapy predict improved patient outcome. For example, following chemotherapy 
Di Caro et al. show that high density of TAMs associates with extended survival, yet the 
converse was true before chemotherapy188. 
 
The roles of TAMs in HGSOC are not clear. This study contributes data from high-fidelity 
murine models to suggest that TAM depletion may not impact ovarian cancer growth and 
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progression (Figure 8.8). Moughon et al. depleted TAMs in the ID8 HGSOC model248 
using the CSF-1Ri GW2580. GW2580 treatment decreased alternatively activated 
macrophage density in ascites and reduced ascites volume secondary but survival 
differences were not reported248. Data assessing of the role of TAM in the context of 
human ovarian cancer is limited. Lan et al. showed that patients with tumours richly 
infiltrated with CD163+ TAMs to have significantly reduced progression-free and overall 
survival194. TAM CD206/CD68 ratio predicts worse PFS193, and, correspondingly, a high 
M1 (classically activated)/M2 (alternatively activated) ratio associated with improved 
survival195. Furthermore, Zhang et al. showed a high intra-tumoural, as opposed to 
stromal or whole tissue, M1 (classically activated)/M2 (alternatively activated) phenotypic 
ratio was associated with improved survival196 suggesting localisation as well as 
phenotype to be clinically relevant. However, it should be noted that these studies are 
predominantly in mixed cohorts of ovarian cancer subtypes and the effects of 
chemotherapy on macrophage phenotype was not considered. Therefore, although 
these data are limited to small studies assessing TAM phenotype using a limited range 
of markers and in mixed cohorts of ‘ovarian cancer’ patients, they suggest that the TAM 
phenotype may be important in determining patient outcome. 
 
TAMs do not function in isolation but in concert with a range of other cells within the 
TME. Although this has not been assessed in this work, understanding the networks that 
TAMs form with other cell types is likely to provide further insight into the effects of 
immunity on tumour growth and the response of HGSOC to treatment. Understanding 
changes to the TME under the influence of treatment is important as it may provide 
insights into the design of immunotherapeutic strategies for HGSOC. 
 
 TAM diversity and chemotherapy 
I have explored the effects of chemotherapy on TAM by considering changes in TAM 
phenotype, in the bulk population (by RNA-seq and FC) and at single-cell resolution (via 
tNSE analysis of FC data). TAM exist as a spectrum of phenotypes in tumour 
microenvironments331, tSNE analysis supports this view. I was able to define multiple 
TAM subpopulations using a relatively small number of macrophage activation markers. 
Gaining an appreciation of TAM subpopulations through resolving marker expression at 
single-cell level with tSNE provided a greater understanding of TAM heterogeneity that 
was not appreciated when comparing the changes of single markers within the bulk TAM 
population. For example, using this approach I observed that populations expressing 
markers at intermediate levels decreased, which correlates with my changes assessing 
the TAM population globally.  Interestingly, tSNE shows that chemotherapy altered the 
relative proportions of TAM subpopulations in murine HGSOC. Tracking TAM 
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subpopulations though chemotherapy treatment showed, that although there was overall 
TAM depletion, the proportion of TAM subpopulations expressing markers 
representative of different functional states also changed.  
 
These data, taken together with CSF-1Ri treatment of the post-chemotherapy TME, 
suggests that chemotherapy sculpts the relative proportions of anti-tumoural vs pro-
tumoral TAM. Further single-cell approaches will greatly help in the understanding of 
TAM biology where the complexity of myeloid cell phenotypes will greatly exceed that 
seen simplistic in vitro systems. Single-cell RNA-sequencing (scRNA-seq) and CyTOF 
will be important in further defining TAM diversity in HGSOC. Application of tNSE to 
human FC data has been hampered by the configuration of the panel of antibodies used. 
However, use of these techniques represents a natural extension of this project. 
Furthermore, tSNE assessment of the myeloid populations depleted by CSF-1Ri will be 
undertaken in murine tumours. 
 
 How does chemotherapy affect TAMs? 
The data presented in this thesis suggest TAMs can be affected by chemotherapy either 
directly or as a result of the effects on the malignant cells.  
 
Given the in vitro and in vivo sensitivity of human and the murine HGSOC to carboplatin, 
the microenvironment that TAMs find themselves in will change rapidly and given the 
plasticity of this cell type it is not surprising that differences in TAM phenotype and 
functions are appreciated. Immunogenic cell death is well characterised in response to 
many cytotoxic drugs332. In this process malignant cells responding to chemotherapy 
emit signals either as the result of membrane lysis releasing intracellular molecules or 
by upregulation of surface proteins. These signals, known as DAMPs include ATP, 
HMGB1 and calreticulin332. I found the most significantly upregulated gene in 
macrophages after chemotherapy exposure was TREML4. This molecule is highly 
expressed on macrophages and dendritic cells and is able to bind dead and apoptotic 
cells297. Furthermore, treml4 can facilitate the presentation of tumour antigens to CD4+ 
and CD8+ T cells, resulting in enhanced antitumor immunity. This suggests that TAMs 
are responding to and interacting with dead/dying tumour cells in the HGSOC 
microenvironment i.e. that there is immunogenic cell death in the TME of HGSOC. 
Furthermore, the increase in DCs seen post-chemotherapy further supports the concept 
of chemotherapy mediating engagement of anti-tumour immunity in response to tumour 
antigens. 
 
It is important to model the diversity of human HGSOC treatment response. In this thesis 
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I attempt to capture this diversity by studying three murine models that differ in their 
transcriptomic profiles (Maniati et al. manuscript submitted). These models also differ in 
their responses to carboplatin; 60577 was the most sensitive and HGS2 the least 
sensitive. Interestingly, TAM response to chemotherapy associated with the response of 
malignant cells to chemotherapy. 60577 showed significant TAM responses to 
carboplatin, both in phenotype and cell number, in contrast to HGS2, which showed non-
significant changes. Furthermore, the TAM response to carboplatin compared to 
paclitaxel, to which murine tumours were not sensitive to as single-agent therapy, were 
very different. Alternatively activated marker expression was increased in paclitaxel 
treated tumours, compared to decreases following carboplatin treatment. Although more 
data are needed, these observations point to TAM response being linked to malignant 
cell response. 
 
In patients with HGSOC ‘good’ responses to chemotherapy are associated with dense 
fibro-inflammatory infiltrates in combination with malignant cell destruction280. I show that 
macrophages ‘lakes’ form in response to chemotherapy, the association of these with 
nests of residual malignant cells suggests a response to dead/dying malignant cells. 
Further support for chemotherapy response determining HGSOC TME immune 
activation comes from findings in our lab where tumours that responded well (CRS3) 
compared to those that did not (CRS2) were significantly enriched a Th1 T cell 
signiture113. 
 
Using scRNA-seq and CyTOF approaches, Gubin et al. show the evolution of the TME 
of murine T3 sarcoma tumours in response to successful immune-checkpoint therapy331. 
They demonstrate significant TME restructuring, with depletion of CX3CR1+TAM 
subpopulations and increases in subpopulations characterised by iNOS expression, a 
marker of classical macrophage activation331. These changes were associated with 
reduction of Treg and increase in effector T cell responses331. These changes reflect 
changes I have documented in the HGSOC TME in response to chemotherapy. This 
could suggest of the tantalising concept of a common response of the TME driven by a 
good response in malignant cells, irrespective of treatment modality. 
 
I also provided data to suggest a direct mechanism of action of carboplatin on 
macrophages. I conducted studies on human macrophages in isolation from other cell 
types, to assess for any direct effects of chemotherapy. Surprisingly, I found evidence 
that carboplatin is able to directly target macrophages and resulted in cell death and 
phenotype changes in the absence of tumour cells. The concentration and time of 
exposure are important variables to consider in the generalisability of these results to in 
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vivo conditions. However, these initial studies are supported by work showing that 
trabectedin, which is also a drug that binds DNA (analogous to carboplatin) resulted in 
death of monocytes via caspase-8 dependant apoptosis212. Clearly both direct and 
indirect mechanisms could be operational in the TME, and the importance of each 
mechanism may differ in different contexts. 
 
 Targeting TAM in the context of chemotherapy in HGSOC 
Despite chemotherapy engaging antitumoral immunity and frequently having dramatic 
effects of the malignant cells, chemotherapy rarely cures HGSOC. This suggests a 
partial and or transient immune activation and that combining chemotherapy with 
approaches to extend antitumor immunity long term could be valuable. 
 
My experiments in murine models suggest that depleting TAM after chemotherapy is not 
a useful strategy in HGSOC and furthermore, following chemotherapy may actually be 
harmful. This would suggest that strategies to promote the positive effects of 
chemotherapy long term in the TME could be of benefit in the tumour and others. There 
are multiple approaches that have shown success in activating macrophages to anti-
tumoural phenotypes in mice. These include the use of TLR agonists, CD40 agonists, 
PI3Kg inhibitors138. Future work is proposed to assess the effects of TAM activating 
agents as a therapeutic approach in the treatment of HGSOC. 
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 Overall summary 
Chemotherapy promotes an anti-tumour TAM phenotype distinct from M1 (classically 
activated)-M2 (alternatively activated)-axis changes. TAM depletion with CSF-1Ri is not 
a beneficial strategy in this disease. Re-programming of TAM before and/or during 
chemotherapy, or intervening following chemotherapy to maintain a positive TAM 
phenotype, may represent more successful ways to harness the potential of TAM-based 
immunotherapy in HGSOC. 
 
 Future work 
10.7.1 Limitations of current work 
Chapters 3-5 
The small number of human samples that were obtained during the course of the project 
has limited the analyses. Transcriptomic data were obtained only for bulk TAM 
populations; sc-RNA would have provided a powerful tool to extend the data presented.  
 
The human matched post-NACT samples were contained in TMAs. Due to small core 
size these may have not accurately captured the stromal response. I did not have access 
to larger HGSOC sections matched pre and post-NACT, which would have allowed for 
more comprehensive assessment of both the malignant cell areas and the stromal 
response. When assessing the effects of TAM density on survival the small sample 
number is especially limiting. In addition, it has not been possible to perform multivariate 
analysis to control for other possible confounding variables. 
 
Within the transcriptomic data I have not been able to validate the RNA findings at protein 
level. There are a range of molecules of interest that should be validated at protein level 
by IHC or by RNA scope analysis. 
 
Chapters 6-8 
The murine models recapitulate many of the features of human HGSOC; however, there 
were differences. The stromal areas of the tumours did not appear to be as well 
developed in mice compared the appearance in human samples. Given that I see 
differences in the appearance of stromal macrophages in human samples pre and post-
NACT this is a potential limitation. 
 
It has not been possible to characterise the TAM response of all models to both 
carboplatin and paclitaxel. HGS2 has not been characterised in response to paclitaxel 
and the response of the 30200 model to carboplatin as a single-agent has not been 
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assessed, although experiments are underway. Furthermore, it has not been possible to 
fully characterise the responses of the TME to chronic CSF-1Ri treatment in the relapse 
model, although this will be undertaken (see below). 
 
In this study I have not been able to explore the possible mechanisms by which TAM 
may become anti-tumoral post-chemotherapy. For example, it could be envisaged that 
TAM be able to directly phagocytose and kill tumour cells following chemotherapy 
exposure. In vitro experiments will be conducted to assess the effects of chemotherapy 
on TAM-mediated tumour cell killing. 
 
Chapter 9 
The data presented in this chapter are preliminary and will need to be repeated and 
extended. Although the data produced so far suggest possible activation of the 
inflammasome and cleavage of gasdermin E these were only seen at concentrations of 
carboplatin of 250µM applied to cells for twenty-four hours. This is a high concentration 
of the drug and lower concentrations will need to be assessed.  
 
Furthermore, I have not performed any experiments to assess the effects of carboplatin 
on macrophages in the presence of malignant cells. Co-culture experiments with human 
HGSOC cell lines and or in 3-D in vitro models are needed to further extend these data. 
 
To address some of the shortcomings described above and to extend the work presented 
in this thesis, I propose the following experiments: 
 
• tSNE on human samples pre and post-NACT 
• scRNA-seq on human myeloid cells from HGSOC (this will be undertaken in the 
lab as a distinct project) 
• Further quantification and validation of RNA-seq data by IHC 
• Further analysis of murine tumour immune population pre and post-
chemotherapy by IHC 
• Analysis of murine tumour immune populations by IHC following CSF-1Ri 
treatment both as a single-agent and when administered after chemotherapy 
• Extend relapse experiments into 30200 / HGS2 models 
• Assess the effects of carboplatin on macrophages in 2D/3D co-culture systems 
with malignant cells 
• Look for evidence of inflammasome assembly using PLA assay in human 
HGSOC sections 
• Look for further evidence of pyroptosis in human and mouse tumours pre and 
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post NACT/carboplatin 
• In vivo experiments to test the effects of therapeutics that promote anti-tumour 
macrophage activities following carboplatin treatment 
• In vitro experiments to assess the effects of chemotherapy on macrophage 
effector function, including tumour cell killing assays 
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